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Thesis Summary 
At present, the prime candidate for augmentation of bone defects are autologous bone 
grafts (ABGs), owing to their ability to emulate the physiological signalling environment to 
induce bone marrow-derived, mesenchymal stem cells (BMMSCs) to differentiate into 
functional osteoblasts. However, the uses of ABGs are negated due to patient 
complications. Dentine matrix has recently become increasingly recognised as possessing 
bioactive nature and has demonstrated the ability to augment bone repair in vivo. 
However, the constituents of dentine that confer efficacy for bone formation are poorly 
understood. The aim of this study was to determine the potential for demineralised 
dentine matrix (DDM) to induce biological responses of BMMSCs and elucidate the key 
mediators required for bioactivity. 
Isolation of a sub-population of BMMSCs yielded a population of cells with enhanced 
expansive capacity in vitro, with maintained mesenchymal stem cell marker expression. 
Application of DDM to BMMSCs significantly reduced cell expansion (0.1-10μg/mL), 
reduced apoptotic activity (10μg/mL) and enhanced migration (0.1μg/mL). Importantly, 
DDM at 10μg/mL directed osteogenesis of BMMSC by enhancing RunX2 gene expression 
after 5 days and deposition of a mineralised matrix after 28 days. 
Western blot and enzyme-linked immunosorbent assay (ELISA) analyses of DDM identified 
a plethora of growth factors associated with directing osteogenesis of BMMSCs, including; 
transforming growth factor-β1 (TGF-β1), bone morphogenetic protein-2 (BMP-2) and 
vascular epidermal growth factor (VEGF). Fractionation of DDM by heparin-affinity, to 
concentrate growth factors, resulted in diminished potential of DDM to enhance RunX2 
expression and mineral deposition of BMMSCs. Depletion of decorin from DDM had no 
effect on osteogenic potential, however, depletion of biglycan attenuated RunX2 
expression and mineral deposition. Substrates composed of silk-fibroin/gelatin (SF/G) at 
ratios of 75:25 supported attachment and expansion of BMMSCs with no discernible 
changes in morphology, compared to cells cultured on plastic. Addition of DDM to SF/G 
substrates resulted in enhanced BMMSC expansion (20μg/mL) and evidence of mineralised 
matrix deposition (5-20μg/mL), compared to un-loaded SF/G substrates. 
In conclusion, DDM possesses bioactive potential towards BMMSCs, which is attributable 
to a range of synergistically acting growth factors along with additional matrix constituents. 
The ability of DDM to stimulate osteogenesis demonstrates potential for future 
developments in the field of tissue engineering of bone.  
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Chapter 1 - General Introduction 
1.1 Background Introduction 
Adult mesenchymal stem cells (MSCs) have been well characterised over recent 
years and are indispensable constituents in the process of tissue repair and 
regeneration. Bone is a highly dynamic tissue possessing its own niche of MSCs that 
enable efficient tissue regeneration in response to tightly regulated biological 
signals, with growth factors being well characterised in this process. However, 
these signalling events are disrupted in conditions, such as osteoporosis, diabetes 
and in implant dentistry, where altered biological signalling induces resorption and 
thus complicates implant placement. 
Currently, the ‘gold standard’ method for enhancing bone regeneration is to use an 
autologous bone graft (ABG), most commonly obtained from the posterior ileac 
crest. However, donor site morbidity and reduced effectiveness in patients with 
systemic compromising complications, such as diabetes and osteoporosis, has 
prompted the search for alternatives. ABGs owe their effectiveness to regenerate 
tissue as they contain physiological concentrations of bioactive growth factors 
embedded in an extracellular matrix (ECM), to stimulate resident bone marrow-
derived, mesenchymal stem cells (BMMSCs) to differentiate down the osteogenic 
lineage and secrete reparative bone. Bone allografts are alternatives used to 
alleviate the complications experienced by ABGs, however, these pose a risk of 
disease transmission and subsequent sterilisation to improve their safety 
diminishes the grafts osteoinductivity. The use of growth factors clinically to 
enhance bone repair, notably bone morphogenetic proteins (BMPs), BMP-2 and 
BMP-7, are regarded as largely ineffective due limited efficacy and cost 
considerations as a result of the supra-physiological doses required.  
Mounting evidence indicates that the ECM of mineralised tissue plays critical roles 
in supporting the activity of growth factors towards cells. Present knowledge 
indicates that matrix proteins serve to sequester growth factors and modulate their 
biological activity. Notably, the matrix proteins biglycan and decorin have been 
shown to bind avidly to growth factors, such as transforming growth factor-β1  
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(TGF-β1) (Yamaguchi et al, 1990), in addition to enhancing the signalling response of 
BMP-4 (Chen et al, 2004) and BMP-2 (Mochida et al, 2006), both of which possess 
roles in differentiation of MSCs to osteoblasts. There are additional reports that 
signify the importance of extracellular matrix components in orchestrating cell 
signalling events that enable optimal tissue repair to occur (Berendsen et al, 2011).  
In vivo, dentine is reported to possess bioactive characteristics for augmentation of 
bone repair. Notably, dentine has been demonstrated to enhance the repair of 
bone in diabetic rabbits (Gomes et al, 2008) and in the tooth sockets of rats (Reis-
Filho et al, 2012; de Oliveira et al, 2013).  Recent proteomic studies relating to 
human dentine have indicated that dentine contains 147 and 289 protein 
components, respectively (Chun et al 2011, Jágr et al 2012). Although the presence 
of numerous growth factors has been confirmed in dentine, a large proportion of 
the remaining components remain elusive as to their specific purpose within the 
matrix. 
The aims of this Thesis were to assess the bioactive potential for dentine matrix to 
drive differentiation of BMMSCs towards the osteoblastic lineage. Optimal 
concentrations of growth factors present within dentine matrix that enhance 
osteogenic differentiation were assessed and their roles in bioactivity of dentine 
determined. Additionally, the significance of biglycan and decorin in the bioactivity 
of dentine was tested. Ultimately, the research undertaken within this Thesis aimed 
to improve knowledge of the pertinent constituents of dentine ECM to lead to the 
development of bioactive scaffolds for use in clinical bone repair. 
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1.2 Stem Cells 
1.2.1 Stem Cell Overview 
In recent years, the term ‘stem cell’ has obtained increasing recognition and is 
discussed widely among literature in relation to to cell therapy and tissue 
engineering. A stem cell can be described as possessing two properties; the ability 
to self-renew and to be able to differentiate into a specialised cell with a 
determined function (Romito and Cobellis, 2015). Stem cells are widely regarded as 
indispensable entities for the development, maintenance and repair of tissues and 
organs throughout life (Weissman, 2000; Pekovic and Hutchinson, 2008). The 
potency of a stem cell can be described as one of four definitions. Totipotent stem 
cells possess the ability to differentiate into any cell within the body; pluripotent 
stem cells can differentiate into phenotypes from different germ layers; 
multipotent stem cells are capable of differentiation into phenotypes from the 
same germ layer; unipotent stem cells only possess the capacity to differentiate 
into one type of cell (Larijani et al, 2012). Broadly, stem cells are divided into two 
groups; embryonic stem cells (ESCs) and adult stem cells.  
1.2.2 Embryonic Stem Cells (ESCs) 
Human ESCs were initially isolated in humans from the inner cell mass of 
blastocysts (Thomson et al, 1998) and possess the ability to indefinitely self-
replicate and remain in an undifferentiated state. ECS by definition are termed 
pluripotent, as they are able to differentiate into cells from all three germ layers in 
vitro and in vivo (De Paepe et al, 2014). Such sought properties of ESCs 
demonstrate ideal characteristics for use in tissue engineering and regenerative 
medicine. However, intense ethical issues relating to ESC isolation and processing 
negates their use as a suitable candidate for use within these fields and thus 
alternative options are sought (Behr et al, 2010). 
Telomeres are sequences of DNA rich in guanine repeats and protect eukaryotic 
chromosomes against degradation (Blackburn, 2001). During cell replication, 
telomeres progressively shorten which ultimately results in incomplete 
chromosomal replication, chromosomal senescence and loss of cell viability (Collins 
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and Mitchell, 2002). Telomerase reverse transcriptase (TERT), encoded by the TERT 
gene, prevents chromosomal senescence by replenishing telomeres (Blasco, 2005). 
ESCs express TERT and possess high telomerase activity, which decreases following 
differentiation of ESCs (Saretzki et al, 2008). However, telomerase activity is 
reported to be very low or absent in adult stem cells (Flores et al, 2006). 
ESCs possess characteristic markers to determine their phenotype. Oct4 is a 
homeodomain transcription factor (Wu and Schöler, 2014). Oct4 knock-out (KO) in 
embryos results in loss of pluripotency of the inner cell mass (Nichols et al, 1998). In 
addition, forced expression of Oct4 generates induced pluripotent stem cells from 
neural stem cells (Kim et al, 2009). Nanog is a divergent homeodomian protein 
additionally associated as a marker of ESCs, as it is expressed in pluripotent cells, 
however, its expression is absent in differentiated cells (Chambers et al, 2003). 
Nanog expression is also regarded as critical for pluripotency of ESCs as deficiency 
results in differentiation towards the extra-embryonic endoderm lineage (Mitsui et 
al, 2003). Although ESCs are not the focus of this Thesis, the expression of ESC 
markers, such as Oct4 and Nanog, have been identified in adult stem cells and are 
postulated to possess functional roles in determining the differentiation potential 
(Riekstina et al, 2009). 
1.2.3 Mesenchymal Stem Cells (MSCs) 
The original notion of osteogenic precursor cells was proposed by Friedenstein et al 
in 1968, when cells from the bone marrow of mice could differentiate into bone in 
vitro. A couple of years later, a sub-set of cells from the bone marrow were 
identified noted to possess clonogeneic behaviour, which were initially referred to 
as colony forming unit-fibroblastic (CFU-F) (Friedenstein et al, 1970) and 
subsequently were identified in human bone marrow (Castro-Malaspina et al, 
1980). The term mesenchymal stem cell was coined in 1991, where the CFU-F cells 
from bone marrow were demonstrated to possess differentiation potential towards 
cells of bone and cartilage lineage (Caplan, 1991). Since their initial discovery, MSCs 
have been identified within many tissues of the body including, but not limited to 
bone marrow, adipose tissue, dental pulp, articular cartilage and liver tissue (Huang 
et al, 2011). MSCs are reported to reside in a specialised microenvironment, 
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referred to as a niche, which additionally contains ECM and signalling molecules 
associated with the MSC in question (Spradling et al, 2001). However, the precise 
milieu and composition of the niche varies between different MSCs. The role of the 
niche is to provide the optimal environment for the balance of quiescent and active 
cells to be achieved, thus maintaining a constant supply of slowly dividing cells 
(Chen et al, 2011). Upon activation, due to tissue requirement, disease state or 
trauma, MSCs are able to exit the niche and proliferate and differentiate to produce 
specialised cells that can contribute to the repair of the compromised tissue. 
Generally, it is accepted that stem cells lie predominantly dormant in tissues and 
that only a select few are active for participation in tissue homeostasis (Kindler, 
2005). Stem cells undergo two types of division, as outlined in Figure 1.1. 
Asymmetric division occurs when a mother cell divides into an identical daughter 
cell and a daughter “transit” cell, which has lost its indefinite proliferative capability 
(Potten and Loeffler, 1990). Asymmetric cell division serves as a purpose to allow 
self-renewal of the mother stem cell in addition to producing a more differentiated 
cell, therefore contributing to cell maintenance. Symmetric cell division is classed as 
a mother cell dividing into two duplicate daughter cells, which possess identical 
characteristics. Such division contributes to self-renewal and subsequent expansion 
of the stem cell population (Tajbakhsh et al, 2009). Stem cell expansion occurs to 
maintain a sufficiently large pool of undifferentiated cells available for 
differentiation into lineage specific cells to participate in wound repair (Egger et al, 
2011). 
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Figure 1.1 - Schematic image outlining asymmetric division (a) and symmetric division (b) of 
stem cells. Image adapted from Knoblich (2001). 
 
The process of asymmetric cell division resultantly gives rise to the existence of a 
highly heterologous population of cells. Heterogeneity of MSCs has been noted in 
literature reports via observations of clonal populations of MSCs, with three 
observed phenotypes noted; spindle-shaped, star-shaped and large/flat cells 
(Muraglia et al, 2000; Xiao et al, 2010). Extended in vitro culture of clonal 
populations of BMMSCs results in the sequential loss of adipogenic and subsequent 
chondrogenic differentiation potential, therefore leading to cells with the potency 
to differentiate towards the osteogenic lineage (Digirolao et al, 1999; Muraglia et 
al, 2000). Heterogeneous BMMSCs are thus postulated to consist of highly 
proliferative, non-committed cells along with cells characterised by low 
proliferative capability and lineage restriction (Chan et al, 2004; Phinney, 2012) 
(Figure 1.2). 
 
 
 
 
 
) 
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As a means of MSC standardisation, the International Society for Cellular Therapy 
(ISCT) recommended the minimal criteria for human MSC identification. Firstly, 
MSCs are plastic adherent in standard culture conditions. Secondly, fluorescence-
activated cell sorting (FACS) analysis indicates the presence of cell surface markers 
CD105, CD73 and CD90. The absence of CD34 (hematopoietic progenitor), CD45 
(pan-leukocyte), CD14 and CD11b (monocyte and macrophage), CD79a and CD19 
(B-cell); and HLA-DR (post MSC stimulation) markers, are also definitive of MSCs. 
Finally, in addition to the other criteria, MSCs must also be able to undergo in vitro 
differentiation into osteoblasts, adipocytes and chondrocytes, determined by 
Alizarin red/von Kossa, Oil Red O and Alcian blue/collagen type II 
immunohistochemical staining, respectively (Dominici et al, 2006). 
Although the current definition of an MSC is to fulfil all three requirements outlined 
by Dominici et al (2006), the expression of cell surface markers is often solely used 
to characterise MSC populations. However, evidence suggests that the expressions 
of markers associated with MSCs are not faithfully associated with this cell type. 
Figure 1.2 - Schematic diagram representing the heterogeneous nature of MSC 
populations in relation to lineage commitment hierarchy. Clonal progenitors sequentially 
lose tri-potent differentiation potential through bi-potency down to uni-potent cells. 
Adapted from Phinney (2012). 
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The markers, CD90 and CD105, have been shown to demonstrate positive 
expression in skin-derived fibroblasts (Alt et al, 2011). Furthermore, endothelial 
cells obtained from the umbilical vein are reported to co-express CD105 and CD73 
(Narravula et al, 2000). The notion that MSCs should be CD34 negative has also 
provoked controversy, as CD34 expressing cells from the bone marrow have been 
demonstrated to differentiate into chondrocytes, adipocytes and osteoblasts 
(Kaiser et al, 2007). As a result of the reported discrepancies in the markers used to 
identify MSCs, additional markers have been investigated to aid in the 
determination of MSC populations.  
CD146 (Melanoma Cell Adhesion Molecule; MCAM) has been identified in MSCs 
derived from bone marrow (Shi and Gronthos, 2003) and its expression in clonally-
derived BMMSCs, is around 2-fold higher in multi-potent clones, compared to uni-
potent clones (Russell et al, 2010). As mentioned previously, ECS markers are also 
implicated to be expressed in MSC populations, notably Oct4 and Nanog. Although 
Oct4 and Nanog expression is negative in osteoblasts, their expression is present in 
MSCs prior to differentiation (Arpornmakelong et al, 2009).  
Despite the efforts to determine markers that strictly identify MSCs, no definitive 
marker has of yet been identified (Feng-Juan et al, 2014). Therefore, identifying 
MSCs in vitro can be challenging, especially when considering the reported 
heterogeneity in differentiation potential (Chan et al, 2004; Phinney, 2012). A 
method to isolate a more homologous population of MSCs from an otherwise 
heterogeneous population is via adhesion to fibronectin, through interactions with 
α5β1 integrins on the cell surface (Wu et al, 1993). MSCs expressing α5β1 integrins 
on their surface are correlated with greater proliferative capacity and enhanced 
colony forming efficiency (Jones and Watt, 1993; Jones et al, 1995). Consequently, 
primitive cells have been preferentially selected from heterogeneous populations 
via adhesion to fibronectin (Jones et al, 1995; Dowthwaite et al, 2004; Waddington 
et al, 2009). 
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1.3 Regulation of Osteogenic Differentiation 
1.3.1 Osteoblastic Differentiation of MSCs 
The differentiation of MSCs into osteoblasts, the cells responsible for the synthesis 
of bone, is a complex process involving the interplay of various signalling molecules, 
transcription factors and transcribed proteins. The transcription factor RunX2 (runt-
related transcription factor-2, also known as core-binding factor subunit α, Cbfa1), 
is widely regarded as the master gene required for osteogenic differentiation. In 
mice, RunX2 deficiency has been shown to result in the inability to form osteoblasts 
(Otto et al, 1997). In humans, a non-sense mutation of the RunX2 gene that is 
transcribed to a truncated RunX2 protein results in the autosomal dominant bone 
disorder cleidocranial dysplasia (Zhang et al, 2000). Activated RunX2 binds to 
promoters of osteoblast-associated genes, including osteopontin (OPN), type I 
collagen, bone sialoprotein (BSP) and osteocalcin (OC) (Ducy et al, 1997; Kern et al, 
2001). 
There are numerous literature reports demonstrating that RunX2 mRNA expression 
is up-regulated during differentiation of MSCs (Tsuji et al, 1998; Banjeree et al, 
2001; Gu et al, 2012), however, there is contradictory evidence relating to RunX2 
expression and differentiation of human MSCs to osteoblasts. It has been noted 
that human MSCs constitutively express RunX2 mRNA, although a correlation 
between RunX2 expression and the generation of an osteoblast phenotype do not 
demonstrate a positive correlation (Ven den Bos, 1998). In addition, induction of 
osteoblast differentiation in human MSCs by dexamethasone is reported to 
increase OC expression with no changes in RunX2 expression observed (Shui et al, 
2003). Phosphorylation of RunX2 protein and increased DNA binding is postulated 
to induce osteogenic differentiation without altering RunX2 mRNA expression levels 
(Prince et al, 2001; Shui et al, 2003). On the contrary, two isoforms of RunX2 mRNA 
are reported to exist; type I demonstrates constitutive expression in non-osseous 
mesenchymal tissues and osteoblast progenitors, however, type II RunX2 is 
reported to increase expression during osteoblast differentiation (Banerjee et al, 
2001; Sudhakar et al, 2001). Consequently, the activation of RunX2 is proposed to 
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undergo regulation on several levels, including transcription, translation and 
protein activation. 
The expression and activation of RunX2 is regulated by additional transcription 
factors. Msx2 is a homeobox protein, which prevents osteogenic differentiation and 
switches cells to a state of proliferation (Dodig et al, 1999). Msx2 represses the OC 
promoter in rats (Newberry et al, 1997) and is postulated to prevent osteoblast 
differentiation by repressing the transcription of RunX2 (Shirakabe et al, 2001). Dlx5 
is another homeobox protein which regulates RunX2 and acts antagonistically to 
Msx2. Dlx5 overexpression stimulates the promoter region of type II RunX2 isoform, 
whereas Msx2 acts to suppress the promoter (Lee et al, 2005). Dlx5 alleviates the 
suppressive action of Msx2 and thus promotes osteoblast differentiation (Shirakabe 
et al, 2001). 
The transcription factor, Taz, induces increased activation of the OC promoter via 
RunX2, whereas this increase is not observed in a dominant negative phenotype of 
Taz (Cui et al, 2003). Taz co-activates the expression of RunX2 dependent genes 
whilst simultaneously inhibiting adipogenesis by suppressing PPAR-ϒ related gene 
expression, thus suggesting Taz acts determine the fate of multipotent MSCs (Hong 
et al, 2005). 
Osterix (Osx) is a transcription factor that acts downstream of RunX2, as Osx-null 
mice do not form bone despite expression of RunX2, in addition to lack of OSx 
expression in RunX2 null mice. Osx null pre-osteoblasts also express chondrocyte 
marker genes, Sox9, Sox5 and collagen type II (Nakashima et al, 2002). Osx 
expression is also inducible by BMP-2 in RunX2 deficient MSCs (Matsubara et al, 
2008). Expression of Osx stimulates osteoblast maturation by increasing expression 
of mature osteoblast markers, including OC, BSP and type I collagen (Komori, 2006; 
Choi et al, 2011). 
Figure 1.3 summarises the key transcription factors associated with osteoblast 
differentiation from MSCs. 
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Figure 1.3 - Schematic diagram of the main transcription factors that govern osteogenic 
differentiation of MSCs. TAZ inhibits adipogenic differentiation potential of MSCs and 
commits cells to the osteogenic lineage. Activation of RunX2 is required for differentiation 
of committed osteoprogenitors to pre-osteoblasts and subsequently activates Osx, which 
induces maturation to osteoblasts. Adapted from Hughes et al, (2006).
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1.3.2 Signalling Factors Associated with Osteogenic Differentiation 
1.3.2.1  Transforming growth factor-β (TGF- β) 
Transforming growth factor-β (TGF-β) proteins belong to a super gene family 
comprised of five closely related molecules, in addition to homologous cousins, 
which include BMPs (Allori et al, 2008). Three isoforms of TGF-β (TGF-β1 – TGF-β3) 
are present in mammals and are highly homologous, exerting their effects through 
type I and type II serine-threonine kinase receptors (TBRI and TBRII, respectively). 
TGF-β binds to a tetrameric receptor comples consisting of two of each TBRI and 
TBRII receptors, after which TBRII phosphorylates TBRI. In Smad-dependent TGF-β 
signalling, activated TBRs induce phosphorylation of Smad proteins 2 and 3. 
Subsequently, a complex with Smad4 is formed which translocates to the cell 
nucleus to regulate target gene expression (Nakao et al, 1997; Chen et al, 2012; 
Huang et al, 2012a). 
All three isoforms of TGF-β are expressed at sites of intramembranous and 
endochondral ossification (Horner et al, 1998). Sub-periosteal injections of TGF-β1 
and TGF-β2 motivate endochondral ossification, along with TGF-β2 stimulating 
expression of TGF-β1 (Joyce et al, 1990). TGF-β1 is a potent stimulator of 
proliferation (Zhang et al, 2015a) and migration (Tang et al, 2009) of BMMSCs in 
vitro. TGF-β1 does not induce osteoblastic differentiation of BMMSCs (Katagiri et al, 
1994); on the contrary, TGF-β1 is noted to repress expression of RunX2 (Kang et al, 
2005), in addition to exerting inhibitory activities against osteogenesis at later 
stages of differentiation (Maeda et al, 2004). It is, however, postulated that TGF-β1 
induces proliferation BMMSCs and osteoblastic precursors to increase the numbers 
of available cells available to participate in osteogenic differentiation (Centrella et 
al, 1994; Rodrigues et al, 2010). 
1.3.2.2  Bone Morphogenetic Proteins (BMPs) 
BMPs were initially identified as components of organic bone matrix; and were able 
to induce formation of ectopic bone, by Urist (1965). Since their initial discovery, 
over twenty members have been identified and represent the largest sub-group of 
the TGF-β superfamily (Kawabata et al, 1998; Wang et al, 2014). Constituting such a 
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wide array of signalling molecules, BMPs exert various processes on cells including 
proliferation (Stewart et al, 2010), apoptosis (Zou et al, 1996; Lagna et al, 2006); 
and differentiation (Kobayashi et al, 2005; Luther et al, 2011). BMPs bind to BMP 
receptor II (BMPR-II) on the cell surface, which in turn reacts with BMP receptor I 
(BMPR-I). Activated BMP receptors in turn phosphorylate and activate Smad 
proteins 1, 5 and 8, which form complexes with Smad4 and translocate to the 
nucleus and interact with the transcription factors RunX2, Osx Dlx5 and Msx-2 to 
regulate osteogenic differentiation (Canalis, 2009; Lin and Hankerson, 2011; 
Rahman et al, 2015). BMPs are also able to induce osteogenesis independently of 
Smads, via activation of the mitogen-activated protein kinase (MAPK) signalling 
cascade, where induction of the MAPK pathway results in phosphorylation and 
activation of RunX2 (Greenblatt et al, 2013). Of the BMPs, BMP-2, BMP-4 and BMP-
7 are reported to have potent activity in influencing osteogenic differentiation of 
rodent cells (Hughes et al, 1995; Franceschi et al, 2000; Hassan et al, 2006), in 
addition to promoting osteogenesis of human MSCs (Gori et al, 1999; Lavery et al, 
2008; Shen et al, 2010). 
1.3.2.3 Wnt 
Wnt (Wingless) is a signalling cascade that consists of around twenty cysteine-rich 
glycoproteins, which can act in a canonical or non-canonical manner. In canonical 
signalling, Wnt ligands bind to transmembrane receptor Frizzled (Fzd) and co-
receptor low-density lipoprotein-receptor-related protein 5/6 (LRP5/6). Binding of 
Wnt ligands to these receptors causes intracellular accumulation of β-catenin, 
which can enter the nucleus and interact with the transcription factor T-cell 
factor/lymphoid enhancer factor, permitting the activation of transcription of 
target genes (Lin and Hankerson, 2011; Wanger et al, 2011). β-catenin protein 
levels are acknowledged to be up-regulated in osteoblast precursors, whereas β-
catenin inactivation results in the chondrocytic differentiation of cells (Day et al, 
2005). Loss of function mutations in LRP5 causes osteoporosis-pseudoglioma 
syndrome (Levasseur et al, 2005). Conversely, gain of function mutations in LRP5 
result in increased bone density, accompanied by elevation of markers of bone 
formation, including OC (Boyden et al, 2002). Recombinant BMP-2 induces up-
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regulation of the Wnt ligands, Wnt-7a, Wnt-10b, Wnt-11 and Wnt-13, in addition to 
LRP-6 receptor. Inactivation of the β-catenin gene results in significantly reduced 
chondrogenic differentiation of mesenchymal cells, following BMP-2 administration 
(Chen et al, 2007). In addition, expression of canonical Wnt proteins has been 
shown to result in up to a 5-fold increase of RunX2 promoter activity (Gaur et al, 
2005).  
1.3.2.4  Fibroblast Growth Factors (FGFs) 
Fibroblast growth factors (FGFs) refer to a family of at least twenty-three highly 
conserved, monomeric peptides (Wiedłocha and Sørensen, 2004), which act 
through four related tyrosine kinase receptors (FGFR1-FGFR4) (Huang et al, 2007). 
Studies show that inactivated FGFR2 causes skeletal dwarfism accompanied with 
reduced bone mineral density (BMD) compared to controls, accompanied with 
decreased osteoblast proliferation (Yu et al, 2003). Haploinsuffiency of FGF-2 leads 
to decreased BMD compared to wild type, which is rescued with the application of 
exogenous FGF2. Reduced mRNA secretion of RunX2 also correlates with FGF2 +/- 
and FGF -/- (Naganawa et al, 2006), suggesting crosstalk between RunX2 and FGF 
signalling. This relationship was supported by Naganawa et al (2008), who 
demonstrated that FGF2 -/- osteoblasts experienced reduced BMP-2 induced 
nuclear accumulation of phosphorylated Smad 1/5/8, along with diminished co-
localisation to RunX2. Furthermore, FGF2-/- BMMSCs experience reduced β-catenin 
accumulation, which is rescued following application of exogenous FGF-2 (Fei et al, 
2011). FGFR3 KO also causes a reduction in bone mineralisation and lack of 
trabecular connectivity (Valverde-Franco et al, 2004). 
1.3.2.5  Vascular Epidermal Growth Factor (VEGF) 
Vascular epidermal growth factor (VEGF) is a family of seven closely related growth 
factors that exert biological signalling effects through three tyrosine kinase 
receptors (VEGFR1 – VEGRF3) (Roy et al, 2006). VEGF is critical for embryological 
development, with heterozygous loss of a VEGF allele in ESCs resulting in impaired 
angiogenesis and severe developmental abnormalities (Ferrara et al, 1996). VEGF 
plays critical roles in the development of bone as VEGF suppression almost 
completely subdues blood vessel penetration into the epiphyseal growth plate, 
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affiliated with hindered trabecular bone formation and enlargement of the 
hypertrophic chondrocyte zone (Gerber et al, 1999). Exogenous VEGF 
administration enhances angiogenesis and callus maturation, whereas neutralising 
VEGF decreases angiogenesis and callus mineralisation (Street et al, 2002). VEGF is 
regulated by the hypoxic inducible factor 1 (HIF-1) pathway, where an oxygen-
related subunit, HIF-1α, accumulates and dimerises under low oxygen tension, 
mediating changes in hypoxia-inducible genes (Dai et al, 2007). Overexpression HIF-
1α in osteoblasts results in raised levels of VEGF, accompanied with the 
development of highly vascularised and dense bones (Wang et al, 2007). VEGF 
mRNA transcription is up-regulated in fibroblasts overexpressing RunX2 (Zelzer et 
al, 2001), contributing to the importance of angiogenesis in endochondral bone 
formation.   
1.3.2.6  Insulin-like Growth Factor (IGFs) 
Insulin-like growth factors (IGFs) are a family of two polypeptides (IGF-I and IGF-II) 
that act through two tyrosine kinase IGF receptors (IGFR-I and IGFR-II), which elicit 
cellular proliferation and growth. Osteoblasts express both IGF-I and IGF-II, 
although the former is noted to be more potent (Allori et al, 2008; Arvidson et al, 
2011). IGF has been shown to influence bone formation by acting on differentiated 
cells, where application of IGF to mature osteoblasts increases collagen type I 
expression. However, IGF does not alter gene expression of RunX2, alkaline 
phosphatase (ALP), type I collagen or OC in human BMMSCs (Thomas et al, 1999).  
IGF-1 has also been demonstrated to enhance phosphorylation and stabilisation of 
β-catenin (Playford et al, 2000). 
1.3.2.7 Platelet-Derived Growth Factor (PDGFs) 
Platelet-derived growth factors (PDGFs) are a family of growth factors consisting of 
3 isoforms; homodimers composed of polypeptide chains PDGF-A (PDGF-AA) and 
PDGF-B (PDGF-BB); and a heterodimer (PDGF-AB) (Heldin and Westermark, 1999). 
PDGF signals primarily through PDGF receptor α (PDGFRα), whereas PDGF-BB 
predominantly signals via PDGF receptor β (PDGFRβ) and signals mainly through the 
MAPK pathway (Donovan et al, 2013). Deletion of PDGFRβ in MSCs induced to 
differentiate to osteoblasts results in enhanced RunX2 and OC expression 
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(Tokunaga et al, 2008). PDGF-BB receptor inhibition in human MSCs is reported to 
decrease proliferation, however, possess no influence on osteogenic differentiation 
(Kumar et al, 2010). In addition to enhancing proliferation of MSCs, PDGF acts as a 
chemotactic agent for human MSCs (Fiedler et al, 2002). 
1.4  Extracellular Matrix (ECM) Components Associated with Mineralised 
Tissues 
1.4.1 Small, Leucine-Rich Proteoglycans (SLRPs) 
Small leucine-rich proteoglycans (SLRPs) were originally identified as proteoglycans 
consisting of protein cores of around 36-45 kDa. As their names suggest, the 
protein cores contain tandem leucine-rich repeats and undergoes translational 
modification to possess covalently bound glycosaminoglycan (GAG) chains of 
varying composition and length (Iozzo and Murdoch, 1996; Iozzo and Schaeffer, 
2010; Nikitovic et al, 2012). The SLRP family currently encompasses eighteen genes 
which are further classified into five sub-families, based on chromosomal 
organisation, N-terminal cysteine-rich clusters and functional similarities (McEwan 
et al, 2006; Schaeffer and Iozzo, 2008; Iozzo et al, 2011). 
Following synthesis, SLRPs are secreted into the pericellular matrix where they can 
bind to ECM constituents or remain free within the matrix, although the association 
of SLRPs with other matrix constituents is regarded as a strictly pre-determined 
process (Henry et al, 2001; Gruber et al, 2002; Vanderploeg et al, 2012). Members 
of the SLRP family have been identified as being able to promiscuously interact with 
a plethora of factors within the ECM, including TGF-β1 (Hildebrand et al, 1994), 
BMP-4 (Chen et al, 2004), PDGF (Nili et al, 2003) and IGF-1 (Schönherr et al, 2005). 
Additionally, some SLRPs are implicated as being able to bind to matrix collagens 
(Scott, 1996; Reed and Iozzo, 2002; Zhang et al, 2006). 
1.4.2 Biglycan and Decorin 
Biglycan and decorin are members of the class I sub-family of SLRPs. Biglycan 
consists of a 45 kDa protein core containing tissue-specific GAG chains composed of 
either dermatan sulphate (DS) or chondroitin sulphate (CS), which are covalently 
attached at the N-terminus of the core protein (Choi et al, 1989; Roughley and 
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White, 1989; Bianco et al, 1990). Non-glycosylated forms of biglycan have been 
discovered, however, in articular cartilage (Roughley et al, 1993) and intervertebral 
discs (Johnstone et al, 1993). Structurally similar to biglycan, decorin consists of a 
core protein of around 42 kDa containing a single GAG chain of either DS or CS, 
covalently linked to a serine residue near the N-terminus of the protein (Krusius and 
Ruoslahti, 1986; Mann et al, 1990). Schematic structures of biglycan and decorin 
are outlined in Figure 1.4. Human biglycan and decorin are encoded on 
chromosomes X and twelve, respectively (McBride et al, 1990). Initial 
determination for the roles of biglycan in bone development were speculated when 
patients suffering from Turner’s syndrome (females devoid of a second X 
chromosome), were observed to be shorter in stature and possess low levels of 
biglycan, contrary to patients possessing supernumerary X chromosomes that 
presented with increased limb length and higher biglycan levels. Subsequent in vivo 
investigations into the targeted deletion of the biglycan gene in mice resulted in 
delayed and decreased bone growth compared to wild-type animals, accompanied 
with the inability to achieve peak bone mass attributable to diminished osteoblast 
numbers (Xu et al, 1998). In vivo KO of decorin in mouse models does not incur the 
osteopenic phenotype as displayed in biglycan KO models, however, dual KO of 
both biglycan and decorin results in a marked osteopenic phenotype (Corsi et al, 
2002). BMMSCs derived from biglycan and decorin dual KO mice are additionally 
noted to result in over-activation of the TGF-β signalling pathway due to 
unregulated sequestration. Consequently, osteoprogenitors undergo apoptosis and 
result in decreased bone formation (Bi et al, 2005).  In vitro, the depletion of 
decorin and biglycan from dentine via immunoprecipitation results in a 47-fold 
reduction in binding affinity of TGF-β1, thus indicating a role for sequestration and 
protection of biological activity within dentine (Baker et al, 2009). 
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Figure 1.4 - Schematic diagram of the structure of the SLRPs biglycan and decorin. Core 
proteins contain leucine-rich repeats flanked either side by disulphide bonds. DS and/or CS 
GAG chains are covalently linked to the core protein at the amino terminus end. Image 
adapted from Embery et al, (2001). 
 
1.4.3  Roles for Biglycan and Decorin in Mineralised Tissues 
The importance of SLRPs in mineralisation can be determined as a result of their 
presence within mineralised tissues. Within mineralised matrices, biglycan and 
decorin are predominantly substituted with CS GAGs, however, in soft connective 
tissues they are usually associated with DS GAGs (Fisher et al, 1989; Bratt et al, 
1992). 
Regarding mineralisation, CS GAGs are reported to possess around a 5-fold greater 
binding capacity for calcium than DS GAGs (Embery et al, 1998). In bone, both 
biglycan and decorin are also identified with decorin being localised in the 
pericellular matrix, whereas biglycan demonstrates a more homogeneous 
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distribution throughout the matrix (Ingram et al¸1993). During osteogenic 
differentiation of alveolar bone-derived cells, biglycan is expressed during cell 
proliferation and again at the onset of mineralisation, whereas decorin expression 
remains consistent. DS represent up to around 70% of total sulphated GAGs during 
proliferation, whereas CS constitutes 100% of GAGs during mineralisation 
(Waddington et al, 2003a). This observation correlates largely with that seen in 
dentine, where biglycan and decorin substituted with GAGs are present. However, a 
shift in profile from DS-substituted SLRPs in pre-dentine to predominantly CS-
substituted SLRPs in the pre-dentine/dentine interface to completely CS-substituted 
SLRPs in calcified dentine is noted, therefore suggesting differential functions in 
directing mineralisation (Waddington et al, 2003b). 
1.4.4 Biglycan and Decorin in the Modulation of Cell Signalling Events 
Mounting evidence is also for ECM components modulating cell signalling events. 
Biglycan has been affiliated with enhancing osteogenic responses to BMP-4, with 
biglycan deficiency demonstrating attenuated RunX2 expression, which was 
restored following reintroduction of biglycan (Chen et al, 2004). Treatment of 
murine C2C12 myoblasts with BMP-2 induces lineage conversion into osteoblasts, 
accompanied with increased synthesis of decorin. Moreover, BMP-2 signalling was 
diminished in decorin null myoblasts, suggesting the existence of a feedback 
mechanism (Gutierrez et al, 2006). More recently, enhancement of the canonical 
Wnt signalling pathway via biglycan has been established, by interacting with Wnt 
ligand Wnt3a in addition to LRP6 via its core protein. Furthermore, biglycan 
deficiency results in lessened Wnt3a retention and blunts Wnt-induced LRP6 
phosphorylation (Berendsen et al, 2011). Consequently, both biglycan and decorin 
are postulated to possess modulatory activity in cell signalling events. 
1.5 Bone Repair 
1.5.1 Fracture Healing of Bone 
Bone tissue has a high regenerative potential in vivo and although not fully 
elucidated, the process of endogenous bone repair has been characterised as a 
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complex process consisting of a tightly regulated interplay between various 
signalling mechanisms and cell types.  
When a bone fracture occurs, bone architecture in addition to the local blood 
vessels become damaged, leading to activation of the clotting cascade and the 
development of a haematoma to aid in stabilisation of the damaged tissue (Kolar et 
al, 2010). The haematoma is considered to play a critical role in the bone repair 
process, as haematoma transplanted into the sub-periosteum, in addition to in 
muscle, produces new bone tissue after 4 days (Mizuno et al, 1990). The arrival of 
neutrophils at a fracture site occurs around 24 h after injury, where their primary 
function is to prevent infection by removing debris from the wound (Simpson and 
Ross, 1972). However, they also function as a secretor of mediators, including 
interleukin-6 (IL-6) and chemokine (C-C motif) ligand-2 (CCL-2) to recruit monocytes 
and macrophages (Hurst et al, 2001; Xing et al, 2010). Recruited macrophages 
further secrete a plethora of chemotactic mediators including tumour necrosis 
factor-α (TNF-α), interleukin-1β (IL-1β), IL-6 and CCL2 to recruit locally residing 
MSCs and osteoprogenitor cells to the site of injury (Einhorn et al, 1995; Kon et al, 
2001; Bielby et al, 2007). The presence of platelets within the fracture haematoma 
provides an abundant source of growth factors, such as PDGF, TGF-β1, VEGF and 
IGF-1 (Eppley et al, 2004; Van Dan Dolder et al, 2006).  
Penetration of newly formed blood vessels into the haematoma permits the 
infiltration of MSCs and osteoprogenitor cells that initiate the reparative phase 
(Dimitriou et al, 2005; Marsell et al, 2009). Repair of fractured bone tissue occurs 
predominantly via indirect healing, by mechanisms known as endochondral 
ossification and intramembranous ossification (Gerstenfeld et al, 2006). 
Endochondral ossification mainly occurs adjacently to the fracture site periosteum, 
where mechanical stability is low and is driven by low oxygen tension (Dimitriou et 
al, 2005). Initially, highly proliferative mesenchymal-derived cells are present within 
the fracture callus as soon as 3 days post-fracture; and undergo chondrogenesis 
from around 7-21 days post-fracture to produce a soft callus (Iwaki et al, 1997), 
characterised by increased expression of Sox9 and type II collagen (Einhorn, 1998). 
Chondrocytes proliferate rapidly for around 10-14 days, after which they undergo 
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apoptosis (Lee et al, 1998; Gibson, 1998). The cartilaginous matrix enhances 
mechanical stability of the fracture repair site (Claes et al, 1997), which promotes 
vascularisation of the callus (Claes et al, 2002), subsequent re-establishment of 
oxygen tension, pH and nutrient supply permitted by the budding of endothelial 
cells from nearby capillaries to generate new blood vessels, induced by VEGF, PDGF 
and FGF (Ai-Aql et al, 2008). Vascularisation provides a route of entry for MSCs 
which differentiate into osteogenic cells and replace the soft callus with woven 
bone, which subsequently remodels to become regenerated bone (Dimitriou et al, 
2005; Marsell et al, 2009). 
Concomitantly, the process of intramembranous ossification occurs at the fracture 
periphery, where committed osteoprogenitor and undifferentiated MSCs from the 
periosteum form bone directly without a cartilaginous intermediate (Einhorn, 1998; 
Carano and Filvaroff, 2003). Intramembranous ossification is dependent on the up-
regulation of expression of RunX2 and Osx in MSCs to differentiate into osteoblasts 
(Takarada et al, 2016); and is driven by the presence of various growth factors, such 
as TGF-β1, BMP-2, BMP-4 and BMP-7 (Geiser et al, 2005; Bandyopadhyay et al, 
2006). 
1.5.2 Clinical Issues Associated with Bone Repair 
1.5.2.1 Alveolar Ridge Augmentation 
Tooth extraction is a very common procedure in dentistry with healing of the 
extraction socket being by large without incident. However, the extraction of one or 
more teeth from the alveolar ridge typically results in loss of mass of the alveolar 
ridge, in addition to structural and compositional changes to the soft tissues that 
superimpose the extraction socket. Removal of single premolars and molars in adult 
patients results in around a 50% reduction in alveolar ridge width with two thirds of 
this reduction occurring 3 months post-extraction (Schropp et al, 2003; Botticelli et 
al, 2004). It is common for an extracted tooth to be replaced with an artificial 
implant, which is placed into the resulting socket in the bone. However, the 
resorption of the alveolar ridge presents a challenge with regards to adequate bone 
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mass being present to permit the placement of an implant with the potential for 
long-term survival.  
1.5.2.2 Non-Union Fractures 
Bone fractures have a generally predictable outcome, however, there are 
conditions in which the normal healing process is hindered in some way. Fractures 
can sometimes take longer to heal than anticipated (termed delayed union) or do 
not heal at all, due to the termination of normal biological healing processes 
whereby a union does not occur (non-union) (Griffin et al, 2011). It has been 
suggested that a lower number of osteocyte progenitor cells is present at non-
union sites in the tibia, compared with non-fractured sites (Hernigou and Beaujean, 
1997). It is also claimed that this low abundance of cells is a result of a decreased 
vascularity that is present at non-union fracture sites (Brighton and Hunt, 1991). 
Although there are discrepancies in reports which comment upon the incidence of 
non-union fractures, they are estimated to account for around 2.5% of long bone 
fractures (Phieffer and Goulet, 2006), although this figure rises dramatically up to 
46% when vascular injury is associated with the fracture (Dickson et al, 1994). Non-
union fractures present numerous complications for patients, most notably a loss of 
independence and reduced productivity (Aaron et al, 2004). 
1.5.2.3 Osteosarcoma 
Osteosarcoma represents 0.2% of newly diagnosed cancer, most diagnoses being 
made from tumours in the long bone of the arms and legs. Amputation was 
considered the standard method of treatment however now 90% of osteosarcoma 
cases are treated with excision of the affected tissue and thus preservation of the 
limb as a whole (Chen et al, 2005). Bone resection in the craniofacial region poses 
further implications, as psychological scarring occurs in addition to loss of function 
of the tissue (Bhumiratana and Vunjak-Novakovic, 2011). Although mechanical 
loading stimulates bone growth, the stresses and strains present in craniofacial 
bones are not yet fully understood and thus encouragement of bone growth poses 
a further challenge (Herring and Ochareon, 2005).  
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1.5.2.4 Osteoporosis 
Osteoporosis is a highly prevalent disease reported to affect around 75 million 
people worldwide (Durnell et al, 2011); and is characterised as an imbalance 
between bone remodelling and bone resorption, resulting in a reduction in BMD 
and disrupted bone architecture (Sandhu and Hampson et al, 2011). Osteoporosis is 
defined as a BMD of greater than 2.5 standard deviations below the young adult 
mean in a female population aged between 20 and 40 years of age (Lane, 2006). In 
females, ovarian senescence occurs gradually between the fourth and fifth decades 
of life leading to menopausal onset and a marked reduction in oestrogen 
production (Al-Azzawi and Palacios, 2009). Evidence indicates oestrogen influences 
several signalling pathways that regulate physiological turnover of bone. Receptor 
activator of nuclear factor Kappa-B (RANK) is a membrane-bound receptor present 
on the surface of osteoclast precursors, stimulated by RANK ligand (RANKL) 
(Michael et al, 2005). Binding of RANKL to RANK results in the phosphorylation and 
subsequent inactivation of Bad and caspase-9, thus preventing apoptosis (Wong et 
al, 1999). Oestrogen has been demonstrated to suppress the release of RANKL from 
osteoblasts (Eghbali-Fatourechi et al, 2003), thus promoting osteoclast apoptosis 
and aiding the maintenance of normal bone turnover. Recently, oestrogen has also 
been demonstrated to influence osteogenic signalling; estradiol administration to 
osteogenic precursor cells from mice enhanced BMP-4 induced expression of 
RunX2, Osx and OC expression, with BMP-4 induced mineralisation being facilitated 
by oestrogen treatment (Matsumoto et al, 2013). 
1.5.2.5 Diabetes Mellitus 
Diabetes is a chronic condition, which is estimated to affect around 300 million 
people globally (Sherwin and Jastreboff, 2012). A diabetic disease state has been 
implicated in the hindrance of bone turnover and repair. Diabetic patients are 
reported to be at an increased bone fracture risk compared with the general 
population, most notably at the hip (Khazai et al, 2009). Diabetes also causes an 
increase in the healing duration, with displaced fractures being reported to take 
187% of the normal expected fracture healing time of non-diabetic patients (Loder, 
1988). Many reports have commented upon the potential mechanisms for hindered 
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bone repair in diabetics. Advanced glycation end-products (AGEs) accumulate in a 
variety of tissues as a natural process in ageing, however hypergycemia that occurs 
in diabetic patients results in hastened production of AGEs in tissues (Yamaguchi 
and Sugimoto, 2011). Previous reports have indicated that AGEs influence cellular 
behavior, with it being demonstrated that AGEs diminish the proliferative capability 
of MSCs, encourage apoptosis and prevent differentiation into osteoblasts, in 
addition to chondrocytes and adipocytes (Kume et al, 2005). Type I diabetic (T1D) 
mouse models have demonstrated that hyperglycemic mice undergoing tibia 
fracture followed by intramedullary pin fixation present a significantly higher 
number of osteoclasts, compared to mice with normal glycemic levels. 
Furthermore, mRNA expression levels of RANKL are noted to be raised, preventing 
osteoclast apoptosis (Kayal et al, 2007), supporting the notion that there is a 
relationship between T1D and osteopenia in up to 55% of cases (Chen et al, 2013).  
The pathology of type II diabetes (T2D) is more complex. Patients with T2D are 
noted to have higher BMDs than those suffering with T1D, although the fracture 
risk in the hip is elevated by 1.4 fold in T2D patients (Vestergaard, 2007). High 
glucose in conjunction with TNF-α induces apoptosis of MG-63 human osteoblast-
like cell lines and thus is postulated to result in delayed fracture healing (Sun et al, 
2016). 
1.5.3 Interventions for Enhancing Bone Repair 
1.5.3.1 Autologous Bone Grafts (ABGs) 
As a result of the various complications associated with hindered bone healing, 
several technologies are in clinical practice to reduce the burden of bone defects, 
each with their own advantages and disadvantages. 
Bone grafting is a procedure involving the placement of whole bone or bone 
substitute material within the bone defect to stimulate incorporation of the graft or 
the generation of bone tissue. ABGs, where bone is harvested from and is placed in 
the same patient, are the most common bone grafting procedure (Panagiotis, 
2005). ABGs are considered the “gold standard” treatment for bone defects, as they 
possess the required properties necessary for complete bone healing; 
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osteoinduction (stimulation of osteoprogenitor cells to differentiate into 
osteoblasts), osteogenesis (deposition of bone material by osteocytes) and 
osteoconduction (presence of a scaffold for new bone development). ABGs are able 
to express these properties as they contain growth factors, osteoprogenitors, and a 
scaffold, respectively. ABGs are also advantageous in the respect that as they are 
obtained from the patient with whom they are to be implanted, they are also 
histocompatible and non-immunogenic, therefore the risk of infection transmission 
and immune-rejection are minimised (Dimitriou et al, 2011). 
The most common site for ABGs to be harvested from is the ileac crest, with reports 
indicating that volumes of yieldable bone ranging between 5-72cm3 for the anterior 
and 25-88cm3 for the posterior ileac crest (Ahlmann et al, 2002). However, the 
excellent properties attained by ABGs from the ileac crest along with large 
obtainable volumes are overshadowed by operative complications of the 
procedure. In the case of patients undergoing an ABG for large bone defects prior 
to the placement of a dental implant, an additional surgical procedure is involved to 
obtain the grafting material. Moreover, the use of general anaesthesia, intra-
operative complications and post-operative pain negate the use of ABGs for 
treating bone defects (Brugnami et al, 2009). Success rates of ABGs for implant 
placement are generally high, with reports indicating that using a graft overlay 
technique of bone grafting typically result in 84-97% success rates at 6 months or 
more post-operation (Clementini et al, 2011). ABGs have also demonstrated 
successful treatment of non-union fractures, with tibia unions being reported to be 
between 87-100% following ABG treatment (Sen and Miclau, 2007).  
Despite the overall good rates of success for autologous bone grafts, there are 
contra-indications that result in attenuated rates of success. Diabetes is recognised 
as a significant factor in the chance of graft survival (Kaing et al, 2011), with one 
study revealing a failure rate of 75% for bone grafts in diabetic patients (Schwartz-
Arad et al, 2005). In addition, osteoporosis is indicated as a risk factor for alveolar 
bone augmentation via grafting. Implant survival rate for post-menopausal female 
patients has been reported to be 43.7%, compared to 80% for male patients 
(Kramer et al, 1999). 
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1.5.3.2 Bone Allografts 
Allografts of bone are obtained from the same species and offer the benefits of 
ABGs including osteoconduction and osteoinduction, but without the associated 
issues of donor site morbidity and pain associated with their harvest. After 
implantation, the physiological process of bone remodelling occurs and eventually 
the graft is resorbed and replaced with bone tissue from host origin. However, 
issues relating to disease transmission and immune-rejection are raised with 
allograft formulations. Transmission of hepatitis C and human immunodeficiency 
virus (HIV) have been well documented in allograft transplants (Delloye et al, 2007). 
As a result of the risks associated with disease transmission, allografts are required 
to undergo extensive sterilisation, typically by irradiation. However, these 
procedures are reported to diminish the mechanical integrity (Cornu et al, 2000) 
and osteoinductive properties (Han et al, 2008). As a result, they are associated 
with increased unpredictability compared to autografts. Commercially prepared 
allografts are reported to contain BMP-2, BMP-4 and BMP-7, albeit at lower 
concentrations than from fresh bone preparations (Shigeyama et al, 1995). Allograft 
quality is also donor-dependent and variations in clinical outcome also depend 
upon the processing and handling methods of the allograft (Calori et al, 2011). 
1.5.3.3 Bone Tissue Engineering (BTE) 
To alleviate the shortcomings associated with traditional bone grafting techniques, 
the field of bone tissue engineering (BTE) is emerging, with the aim of providing 
suitable bone grafts substitutes. Scaffolds are regarded as an essential component 
for BTE as they are required to provide a porous, 3D environment, which permits 
the attachment and proliferation of cells, in addition to providing mechanical 
integrity to bone defects (Ma and Langer, 1999; Fröhlich et al, 2008). 
As such, scaffolds that can mimic the natural ECM of bone are regarded as one of 
the most important challenges in successful tissue engineering (Vasita and Katti, 
2006). Bone tissue constitutes around 10-30% protein by mass, with the remaining 
70-90% comprising of calcium phosphate-based mineral, primarily hydroxyapatite 
(HAp) (Gokhale et al, 2001). Of the protein component of bone ECM, collagenous 
proteins constitute around 90% of the protein mass, of which around 90% is type I 
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collagen (Anselme, 2000; Young, 2003). The remaining 10% of bone protein is 
composed of non-collagenous proteins (NCPs), including OPN, BSP, OC and 
molecules containing arginine-glycine-aspartic acid (RGD) sequences, such as 
fibronectin and thrombospondins (Clarke, 2008). Additional NCPs include SLRPs, 
such as biglycan, decorin, perlecan and syndecan, which are able to bind osteo-
inductive growth factors (Lamoureux et al, 2007). 
As the principle component of bone, type I collagen is regarded as a model 
candidate for a scaffold material (Aravamudhan et al, 2013), as it is 
characteristically biocompatible and biodegradable with the capacity to promote 
attachment, proliferation and differentiation of cells (Hiraoka et al, 2003). However, 
the mechanical properties of type I collagen are poor (Harley et al, 2007). HAp has 
also been widely studied as a bone-grafting substitute, owing to its excellent 
integration with host tissue (Bauer et al, 1991), high biocompatibility; and 
osteoinductive and osteoconductive properties, relating to its ability to bind and 
concentrate BMPs in vivo (LeGeros et al, 2002; Wei and Ma, 2004). However, HAp 
ceramics for bone tissue engineering are usually restricted to areas of low load 
bearing, due to its low mechanical strength (Zhou and Lee, 2011). 
A number of commercially available bone grafting substitutes are currently 
available and have demonstrated positive results in augmentation of bone tissue. 
Studies analysing the efficacy of Bio-Oss®, comprised of deproteinised bovine bone, 
have yielded conflicting results. When placed into tooth extraction sockets, Bio-
Oss® has demonstrated little bone growth accompanied with extensive connective 
tissue (Becker et al, 1998), in contrast to observed osseointegration and bone 
formation in another study, albeit with poor resorption (Artzi et al, 2000).  
A range of other naturally derived substitutes for use in BTE have also been 
investigated, including chitosan (Venkatesan and Kim, 2010; Croisier and Jérôme, 
2013) and silk-based matrices (Jones et al, 2009; Uchida et al, 2014). These 
naturally derived polymers are attractive candidates as bone grafting substitutes, as 
they demonstrate excellent biocompatibility and degradability (Freier et al, 2005; 
Yang et al, 2007a; Lu et al, 2011). 
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Synthetic scaffolds are of additional interest in BTE, as they offer several 
advantages over biological scaffolds, such as lower cost, improved batch 
consistency and long shelf life (Dhandayuthapani et al, 2011). Synthetic polymers 
used for tissue engineering applications, include poly (glycolic acid), poly (lactic 
acid) and poly (propylene fumarate), which have been shown to be biocompatible 
and degradable (James et al, 1999; Wolfe et al, 2002; Liu and Ma, 2004; Gentile et 
al, 2014). Studies investigating the efficacy of these bone-grafting alternatives in 
humans are currently limited.  
1.6 Dentine Matrix and Bioactivity 
1.6.1 Dentine Structure and Constituents 
Dentine is a mineralised tissue present within mammalian teeth that resides 
between the outer layer of enamel and pulp chamber, with the main function of 
protecting the dental pulp. Dentine is secreted and maintained by odontoblasts, 
which reside on the boundary of the dentine and pulp; and project cell processes 
into tubules present within dentine (Arana-Chavez and Massa, 2004). These tubules 
are typically around 2-4μm in diameter and are present at an abundance of around 
20,000/mm2 (Schilke et al, 2000). 
By weight, dentine is composed of 70% mineral, 20% organic protein and 10% 
water (Goldberg et al, 2012), similar to bone, which contains 60% mineral, 25% 
organic matrix and 15% water. Around 90% of the organic matrix of dentine and 
bone consists of type I collagen (Berkovitz et al, 2011), with the remaining 10% 
consisting of NCPs (Butler and Ritchie, 1995). These include BSP, dentine matrix 
protein 1 (DMP-1), dentine sialoprotein (DSP) and dentine phosphoprotein (DPP), 
with the latter two being characteristically found in dentine. These NCPs belong to 
a family of molecules called the small integrin-binding ligand N-linked glycoproteins 
(SIBLINGs), which contain RGD domains for which function as nucleating factors for 
the process of mineralization (Smith et al, 2012).  
While presence of these ECM proteins has been long established, the vast 
proteome of dentine has only recently been extensively studied. The first 
comprehensive proteomic analysis of human dentine revealed 233 total proteins 
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from three different patients, with sixty-eight of these proteins common between 
donors (Park et al, 2009). Chun et al, (2011) revealed 147 ethylenediamine tetra-
acetic acid (EDTA) soluble tooth proteins, which were confirmed by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and liquid 
chromatography/mass spectroscopy (LC/MS). The extracted proteins exhibited 
differentiation enhancement of dental pulp-derived, stem cells (DPSCs), to produce 
mineral deposits when co-cultured in osteogenic differentiation medium.  A later 
study revealed that extraction of human dentine by EDTA, followed by further 
extraction with guanidium hydrochloride, revealed a total of 289 different protein 
fractions (Jágr et al, 2012). 
In addition to a range of matrix proteins, dentine also serves as a reservoir for a 
number of bioactive growth factors. TGF-β1 has been identified as a pertinent 
growth factor in dentine with roles acknowledged for migration and proliferation of 
dental pulp-derived cells (Nie et al, 2006; Howard et al, 2010). Crucially, TGF-β1 is 
implicated in odontoblast differentiation and subsequent matrix production in 
dentinogenesis (Smith et al, 1995; Tziafas and Papadimitriou, 1998). FGF-2 induces 
migration (Suzuki et al, 2011) and proliferation of dental pulp cells (He et al, 2008). 
PDGF enhances proliferation of fibroblasts in human dental pulp (Rutherford et al, 
1992), in addition to stimulating expression of DSP in rat dental pulp cells (Yokose 
et al, 2004). VEGF serves to induce endothelial differentiation of human dental pulp 
cells (Marchionni et al, 2009) and has been shown to increase micro-vessel density 
in human severed dental pulps (Mullane et al, 2008). IGF-1 is proposed to drive 
differentiation of dental pulp cells (Joseph et al, 1993; Caviedes-Bucheli et al, 2007). 
BMPs possess potent effects on differentiation of dental pulp cells, notably BMP-2, 
BMP-4 and BMP-7 (Nakashima et al, 1994; Jepsen et al, 1997; Six et al, 2002; Saito 
et al, 2004). 
1.6.2 Dentinogenesis 
The process of tooth formation originates from the interaction of dental epithelial 
cells with underlying mesenchyme, leading to the formation of a bud. Once the bud 
has formed, the dental epithelium undergoes significant proliferation initially 
forming a cap which progresses to form a bell shaped structure (Duailibi et al, 
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2000). Within the formed invagination, differentiation of neural crest-derived cells 
into odontoblasts occurs (Ruch et al, 1995), which form small processes towards 
the enamel organ and subsequently become accentuated as the cell body of the 
odontoblast migrates towards the pulpal tissue. During migration, odontoblasts 
secrete large type III collagen fibrils, around 0.1-0.2µM in diameter, known as 
mantle dentine (Aguiar and Arana-Chavez, 2007; Goldberg et al, 2011). Fibronectin 
is also secreted and possesses a role in odontoblast polarisation (Lesot et al, 2001). 
Odontoblasts additionally synthesise and secrete a range of NCPs, including dentine 
sialophosphoprotein (DSPP) (Begue-Kirn et al, 1998), DMP-1 (Narayanan et al, 
2006), biglycan and decorin (Goldberg et al, 2005). Mantle dentine calcifies at a 
mineralisation front as a result of the interactions between NCPs and 
hydroxyapatite crystals. CS-conjugated biglycan and decorin are closely associated 
with dentine calcification at the mineralisation front and are considered as 
pertinent components for regulation of dentine mineralisation (Embery et al, 2001; 
Waddington et al, 2003b; Milan et al, 2005). 
Once the initial dentine has been formed, referred to a primary dentine, the 
odontoblasts retain their functional capacity and continue to form additional 
dentine, known as secondary dentine. This physiological process occurs throughout 
the life of the tooth, although at a reduced rate compared to primary dentine 
formation. Secondary dentine possesses a similar morphology to primary dentine 
with regards to the structure of the tubules (Aguiar and Arana-Chavez, 2007; Sloan 
and Smith, 2007). 
1.6.3 Dentine Repair 
Dentine has the capacity to be regenerated when damaged, with the production of 
a third type of dentine, known as tertiary dentine. Tertiary dentine can be further 
characterised into reactionary dentine and reparative dentine. Reactionary dentine 
is produced by odontoblasts that are responsible for the production of primary and 
secondary dentine. Mild stimuli, such as attrition, caries and the preparation of the 
tooth for a restoration, can cause surviving odontoblasts to deposit reactionary 
dentine to repair the tooth. The content of organic matrix and inorganic mineral are 
noted to be similar to that found in primary and secondary dentine (Smith et al, 
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1995; Arana-Chavez and Massa, 2004).  Reparative dentine is laid down in response 
to a strong stimulus, such as deep caries. The stimulus is great enough to cause 
death of odontoblasts and a population of undifferentiated cells within the pulp 
differentiates into odontoblast-like cells, which secrete reparative dentine and 
preserves viability of the pulp (Smith et al, 1995). Morphologically, reparative 
dentine is generally different from reactionary dentine. Reparative dentine has 
been shown to contain cells entrapped within the matrix which was also devoid of 
dentinal tubules, thus resembling structure of bone. Furthermore, OPN has been 
detected within reparative dentine matrix, whereas OPN was not identified within 
the matrix of non-reparative dentine (Aguiar et al, 2007). 
1.6.4 Osteogenic Potency of Dentine Matrix 
One of the earliest recorded examples of exploring dentine as a grafting material 
for bone regeneration dates back to the 1960s, where it was acknowledged that 
rabbit dentine grafted into bone defect sites resulted in induction of bone 
formation, with demineralised dentine demonstrating greater induction ability than 
calcified dentine (Yeomans and Urist, 1967). A couple of decades later, dentine 
slices placed into inter-radicular osseous defects in dogs resulted in a 100% success 
rate for bone formation, with no bone resorption recorded (Catanzaro-Guimarães 
et al, 1986). More recently, several studies have further investigated the 
effectiveness of dentine matrix in stimulating the repair of bone tissue. Slices of 
demineralised dentine matrix (DDM) have been demonstrated to improve the 
volume of bone matrix compared to controls, when placed into mandibular defects 
in rabbits, whilst being resorbed during the bone remodelling process (Carvalho et 
al, 2004). DDM slices placed into surgical defects of diabetic rabbit parietal bone, 
using a polytetrafluoroethylene (PTFE) barrier have shown an increased radiopacity 
and improved trabecular bone arrangement, rivalled to non-treated rabbits and 
those treated with PTFE only (Gomes et al, 2008). Of late, it has been discovered 
that DDM placed into the tooth sockets of rats hastens the repair of the defect by 
improving the rate of new bone formation, in addition to enhancing the expression 
of VEGF compared to sockets treated with a blood clot control (Reis-Filho et al, 
2012). Furthermore, human DDM placed into rat tooth sockets resulted in 
32 
 
increased numbers of osteoblasts expressing BMP-2 and BMP-4, compared with 
unfilled sockets after 10 days (de Oliveira et al, 2013). 
1.6.5 Clinical Translation of Autologous Dentine for Bone Augmentation 
Based on the well documented potential for dentine matrix to enhance bone 
regeneration, Kim et al (2010) proposed a method for preparation of autologous 
teeth to be used as a bone graft substitute in humans, referred to as an autologous 
bone-tooth graft (AutoBT). In the study, grafting material is prepared by extraction 
of teeth (usually for orthodontic reasons), followed by crushing into powder, 
dehydrating and sterilising with ethylene oxide. AutoBT has demonstrated bone 
healing capacity, in addition to augmented bone formation and remodelling when 
implanted into alveolar bone (Kim et al¸2010). A more recent clinical trial has 
determined AutoBT as effective as a grafting material as Bio-Oss®, in addition to no 
reported incidences of infection or secondary complications (Pang et al, 2016). 
Despite the preliminarily promising results of AutoBT as a bone graft substitute, the 
procedure is time consuming and can take between days and weeks to prepare the 
graft material post-extraction (Binderman et al, 2014). In addition, there is a limited 
productivity for commercialisation due to required dehydration, which decreases 
shelf-life (Kim, 2015). Furthermore, whilst harvesting dentine from a single tooth 
provides sufficient volume of particulate to fill extraction sockets (Binderman et al, 
2014), the aforementioned studies relating to the efficacy of autologous dentine for 
bone augmentation have only been used for applications relating to extraction 
sockets. Thus, the use of autologous dentine for bone repair may be limited to oral 
applications, as there is a deficit of studies relating to humans for the use of dentine 
as a bone graft for extra-oral sites. In addition, there are currently also very limited 
reports investigating the use of allogenic dentine as a bone-grafting substitute in 
human trials. However, in vivo studies in animals demonstrate positive bone 
forming capacity of allogenic dentine for enhancing bone repair (Al-Namnam et al, 
2010). Due to the issues raised regarding dentine as a grafting material, 
determination of the components present within DDM that contribute towards 
osteogenesis may lead to the development of technologies that could result in 
clinically translatable BTE substitutes. 
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1.7 Aims and Objectives 
The aim of this Thesis was to determine the potential for DDM in directing 
osteogenic responses of human BMMSCs and the cellular influences of DDM, 
relating to the process of bone repair through osteogenic differentiation. The 
presence and concentrations of a panel of growth factors, in addition to biglycan 
and decorin, within DDM, was examined and the significance of these factors for 
driving osteogenesis was determined. The potential for a biocompatible substrate 
containing demineralised dentine matrix for supporting osteogenesis was also 
assessed. These aims were achieved via the following: 
- Characterisation of BMMSCs isolated, via adherence to fibronectin, for use 
with determining the osteogenic potential of DDM (Chapter 2) 
 
- Determining the effects of DDM on cell expansion, apoptosis, migration and 
differentiation (Chapter 3) 
 
- Elucidation of growth factor profile in DDM, via Western blot and 
quantification of their abundance by enzyme-linked immunosorbent assays 
(ELISAs). Depletion of growth factors from DDM via heparin-affinity 
chromatography and assessment of the osteogenic induction potential of 
fractionated-DDM (Chapter 4) 
 
- Confirmation of presence of the SLRPs, biglycan and decorin, in DDM, 
depletion via immunoprecipitation and assessment of the osteogenic 
induction potential of SLRP fractionated DDM (Chapter 5) 
 
- Preliminary analysis of silk-fibroin/gelatin (SF/G) based substrates loaded 
with DDM for supporting osteogenesis of BMMSCs (Chapter 6) 
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It is hypothesised that within the vast proteome of dentine, selected constituents 
may be imperative for its osteogenic properties, which can be identified as 
possessing roles for directing bioactivity towards BMMSCs. 
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Chapter 2 - Selection and Characterisation of Human Bone Marrow-
Derived, Mesenchymal Stem Cells (BMMSCs) 
 
2.1 Introduction 
Over recent years, there has been a marked increase in interest in the study of 
mesenchymal stem cells (MSCs) for their use in tissue engineering and regenerative 
medicine. Friedenstein et al, (1970) originally identified MSCs from bone marrow, 
and since then many other tissue sources of MSCs have been identified, including, 
but not limited to, umbilical cord blood (Mareshci et al, 2001), adipose tissue (Zuk 
et al, 2001), dental pulp (Gronthos et al, 2000) and articular cartilage (Alsalameh et 
al, 2004). Amongst MSC sources, the efficacy for bone marrow-derived, 
mesenchymal stem cells (BMMSCs) in stimulating bone repair has been widely 
studied with promising results (Fang et al, 2007; Mankani et al¸2007; Brennan et al, 
2014). 
Due to variations of tissue source, methods of isolation and culture, criteria were 
developed to aid in the standardisation of MSCs to avoid discrepancies between 
laboratories. Criteria relating to surface adherence, cell surface marker expression 
and differentiation potential have been outlined to assist in characterisations of 
MSCs. Amongst others, cells must demonstrate positive expression for CD105, CD90 
and CD73, as well as negative expression for CD34 and CD45 (Dominici et al, 2006). 
Embryonic markers of pluripotency, such as Oct4 and Nanog, are additionally 
proposed as candidates for determining undifferentiated MSCs in vitro (Tsai et al, 
2012). Although various additional markers have been suggested, no definitive 
marker is solely specific for determining MSC phenotype (Feng-Juan et al, 2014). 
MSCs exist as a heterogeneous population, consisting of clonal and non-clonal cells. 
Analyses of clonal MSCs demonstrate a hierarchy of lineage commitment, by which 
tri-potent progenitors yield more restricted bi-potent cells.  These bi-potent cells 
subsequently give rise to slow growing precursors of differentiation potential to a 
single lineage (Phinney, 2012). As a consequence of the existence of a 
differentiation hierarchy, clonal populations of BMMSCs demonstrate variability 
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with regards to differentiation potential, by sequential loss of adipogenic and 
chondrogenic potential, to produce osteoprogenitors (Muraglia et al, 2000; Russell 
et al, 2011). Furthermore, osteogenic potential of BMMSCs is reported to vary 
between donors (Phinney et al, 1999; Mendes et al¸2002). 
The existence of a lineage hierarchy and resulting variations in differentiation 
potential of BMMSCs results in inconsistencies with regard to therapeutic efficacy 
(Siddappa et al¸2007; Prins et al¸2009). Primitive cells express high levels of α5β1 
integrin (Jones and Watt, 1993); and can be isolated via rapid adhesion to 
fibronectin (Wu et al, 1993), thus providing a method for isolating a sub-population 
of undifferentiated cells from heterogeneous cell preparations. Fibronectin 
adherence of MSCs has demonstrated isolation of primitive MSCs from bone 
marrow and dental pulp (Waddington et al, 2009; Harrington et al, 2014). 
Undifferentiated MSCs possess the ability to proliferative and subsequently 
differentiate into osteoblasts that deposit reparative bone matrix and thus, results 
in fracture repair (Tseng et al, 2008; Knight and Hankenson, 2013). 
This Chapter aimed to characterise commercially available MSCs from bone marrow 
origin, with regards to expansive capacity and gene expression relating to a range of 
cell surface markers to confirm MSC phenotype. Isolation of a fibronectin-adherent 
(FNA) sub-population was performed with marker expression and expansive 
capacity characterised and compared to unselected cells.  Pertinently, the purpose 
of this Chapter was to identify a population with greater homogeny for primitive 
BMMSCs that were used for all forthcoming experimental procedures within this 
Thesis. 
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2.2  Materials and Methods 
2.2.1  Cell Source 
Human BMMSCs were obtained commercially (Lonza, UK). BMMSCs were certified 
to be >90% positive for CD105, CD166, CD29 and CD44 and <10% positive for CD14, 
CD34 and CD45. Donation of BMMSCs was from a 30-year-old male.  
2.2.1.1  Culture Expansion of BMMSCs in vitro 
All cells were cultured in Minimum Essential Media, Alpha Modifications (α-MEM), 
containing ribonucleosides and deoxyribinucleosides (Gibco, Thermo Fisher 
Scientific, USA). Medium was supplemented with 10% foetal bovine serum (FBS) 
(Invitrogen, UK), 100µM L-ascorbic-2-phosphate (Sigma-Aldrich, UK), 100 units/mL 
penicillin, 0.1µg/mL streptomycin and 0.25µg/mL amphotericin B 
(Antibiotic/Antimycotic, Sigma-Aldrich).  
Cryopreserved cells were thawed by mixing with 5mL of media, warmed to 37°C 
and then centrifuging at 450g for 5 min. Supernatant was aspirated and the 
remaining cell pellet re-suspended in 5mL of media. Cell solution was centrifuged at 
450g for 5 min, supernatant aspirated and cell pellet re-suspended in 1mL of media. 
Cell numbers were determined by mixing 10µL of the resulting suspension in a 1:1 
ratio with a 0.4% Trypan Blue solution (Sigma-Aldrich); counted in a Bürker 
haemocytometer. Cell viability was determined by assessing the ratio of live cells 
relative to total cells counted. Cells were cultured in vented culture flasks or culture 
dishes (Sarstedt, UK), 37°C, 5% CO2, at a seeding density of 5x10
3 cells/cm2. 
At 70-80% confluence, culture medium was aspirated and cells were briefly washed 
with Phosphate Buffered Saline (PBS). Cells were treated with Accutase (PAA, 
Austria), at 37°C, until all cells had detached from the culture surface. Accutase was 
neutralised by adding an equal volume of serum-containing culture medium and 
pipetting up and rinsing down the culture surface 10 times pooled all of the cells. 
The Accutase/medium solution was aspirated from the culture flask and 
centrifuged at 450g for 5 min to pellet cells. The supernatant was decanted and 
cells were re-suspended in 1mL of culture medium by pipetting up and down 30 
times.  
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2.2.1.2  Fibronectin-adherence Selection of BMMSCs 
Fibronectin from human plasma (Sigma-Aldrich) was reconstituted in PBS, 
supplemented with 1mM calcium chloride (CaCl2) (Sigma-Aldrich) and 1mM 
magnesium chloride (MgCl2) (Sigma-Aldrich) (PBS
++), to a final concentration of 
10µg/mL. 1mL of this solution was plated into individual wells of two 6-well plates 
(Sarstedt), wrapped in Parafilm (Bemis, USA) and stored overnight at 4°C. The 
Fibronectin/PBS++ solution was aspirated and BMMSCs of 5.9 population doublings 
(PDs) were seeded onto the fibronectin-coated plates, at a density of 4x103 
cells/cm2. The plates were incubated at 37°C at 5% CO2 for 20 min. Cell culture 
medium was aspirated, replaced with fresh medium and cells returned to 
incubation. FNA BMMSCs were cultured and propagated throughout expansive 
culture, as described previously (Section 2.2.1.1). 
2.2.1.3 Determination of Population Doublings (PDs) 
Cell numbers were determined, as described previously (Section 2.2.1.1). Cell 
counts were used to determine PDs, proportional to the number of cells seeded 
initially, using the equation: 
PDs 
 = (log10(total cell count obtained) – log10(total cell count re-seeded)) / log10(2) 
Cells were reseeded at 4x103/cm2. Remaining cells were centrifuged at 450g for 5 
min, re-suspended in 1mL of freezing media (Bambanker, Wako, USA) at densities 
of 5x105-2x106 cells/mL and stored at -196°C. Reseeded cells were propagated 
throughout expansive culture to obtain stocks of each passage. Cells were tested 
for contamination by Mycoplasma every 2 weeks and were treated with BM Cyclin 
treatment (Roche, Germany), for 2 weeks if found positive for Mycoplasma 
contamination. Cells were tested for Mycoplasma again and were cultured as 
normal if found to be negative, or discarded if still tested positive. 
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2.2.2  β-galactosidase Stain for Cellular Senescence 
BMMSCs/FNA BMMSCs were cultured to suspected senescence as indicated by 
expansive plateau (15.2 PDs BMMSCs, 21.3 PDs FNA BMMSCs) and morphological 
appearance. Cells were passaged and seeded into 3 wells of a 6-well plate. Cells 
from pre-senescent cultures (12.7 PDs BMMSCs, 17.6 PDs FNA BMMSCs) were also 
plated in an identical fashion. β-galactosidase staining was performed using a 
Senescent Cells Histochemical Staining Kit (Sigma-Aldrich), following the 
manufacturers protocol. Two days after plating, culture media was aspirated and 
cells were washed twice with 1mL of PBS per well, ensuring thorough removal of 
residual fluid. Fixation Buffer was diluted to a 1x working concentration, 1.5mL 
applied to each well and incubated at room temperature for 6-7 min. The plate was 
rinsed thrice with 1mL of PBS per well, followed by addition of 1mL per well of pre-
prepared Staining Solution. Culture plates were sealed with Parafilm (Bemis) to 
prevent drying out and were incubated at 37°C overnight to enhance staining. Five 
random and independent areas per well were photographed under light 
microscopy, using a Panasonic DMC-G1 Camera. 
2.2.3 RNA Extraction for Analysis of Gene Expression 
BMMSCs and FNA BMMSCs of earlier and later culture points were seeded at 4x103 
cells/cm2 in 3 wells of a 6-well plate and cultured until 90-100% confluent. RNA was 
extracted using an RNeasy kit (Qiagen, Germany), following manufacturer protocol. 
All centrifugation steps were performed at 17,000g at ambient temperature.  
Culture media was aspirated and each well was washed with 600µL of PBS. Cells 
were lysed using 600µl of RLT Lysis Buffer supplemented with 1% 2-
mercaptoehtanol (Sigma-Aldrich), with further lysis performed by transfer of the 
cell lysate to a QIAshredder™ tube and centrifuging for 2 min. 
Shredded cell lysate was mixed with an equal volume of 70% (v/v) ethanol (Sigma-
Aldrich), 600μL transferred to an RNeasy Mini Kit column and centrifuged for 15 s. 
Flow through was discarded and remaining cell lysate solution applied through the 
column. The column was washed with 350µL of RW1 Buffer by centrifuging for 2 
min. The flow through was discarded and 10µL of RNase-free DNase was mixed 
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with 70µL of RDD Buffer and applied to the column membrane for 15 min. Columns 
were washed with 350µL of RW1 Buffer by centrifuging for 15 s. Two further 
column washes were performed with 500µL of RPE Buffer, centrifuging for 15 s for 
the first wash and 2 min for the second wash, with flow through discarded after 
each wash. The columns were transferred to sterile RNase-free 1.5mL micro 
centrifuge tubes (Eppendorf, UK); and 30µL of RNase-free water was added to the 
column and centrifuged for 2 min to yield RNA. 
Total RNA concentration was measured using a NanoVue spectrophotometer (GE 
Healthcare, UK), calibrated with 2µL of RNase-free water. 2µL of RNA solution was 
used for RNA quantification. A260/A280 ratio was additionally recorded with 
A260/A280 ratio of >1.7 judged acceptable for purity of RNA. 
2.2.4 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
All reagents used for reverse transcription-polymerase chain reaction (RT-PCR) 
were from Promega (UK). 1µg of extracted RNA was mixed with 1µL of Random 
Primers and made up to a total volume with nuclease-free water of 15µL, in a 
sterilised 0.2mL tube (Eppendorf). 1µg of total human RNA (Clontech, France) was 
additionally converted to cDNA in an identical manner to cell extract RNA, as a 
positive control for markers anticipated to not be expressed. A reverse transcription 
(RT) negative was generated using nuclease-free water in place of RNA.  Reagents 
were incubated at 70°C for 5 min in a Thermal Cycler (G-Storm, UK), before being 
immediately cooled and stored on ice. 
A master mix was prepared by adding 5µL of 5x MMLV Reaction Buffer, 1.25µL of 
10mM dNTPs, 0.6µL of RNasin, 1µL of MMLV enzyme and 2.15µL of nuclease-free 
water, in a sterilised 1.5mL tube (Eppendorf). 10µL of master mix was transferred to 
the 15µL of RNA/Random Primer mix before incubating at 37°C for 1 h. Resulting 
cDNA was stored at -20°C. 
2.2.4.1 Polymerase chain Reaction (PCR) cycling 
For each gene to be analysed (as shown in Table 2.1), a master mix consisting of 5μL 
of 5X Buffer, 0.5µL of 10mM dNTPs, 1.25µL of 3mM for each primer (forward and 
reverse), 1µL of 25mM MgCl2 (1mM final concentration), 0.25µL of Taq Polymerase 
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and 14.75µL of nuclease-free water, was prepared in a sterile 0.2mL tube 
(Eppendorf). 1µL of cDNA/RT negative was added to the master mix. 1μL of 
nuclease-free water served as a negative control for the PCR cycling. The sample 
was placed in a Thermal Cycler (G-Storm) and cycled as follows: one initial 
denaturation at 95°C for 4 min, thirty-five cycles of annealing and extension at 95°C 
for 1 min, annealing temperature for 1 min and 72° for 1 min; and one final cycle 
extension at 72° for 10 min. Samples were stored at 4°C, prior to gel visualisation. 
GAPDH was used as an internal reference gene. 
2.2.4.2  Agarose Gel Electrophoresis of PCR Products 
A 2% agarose gel was prepared by adding 1.4g of Hi-Res Agarose powder (AGTC 
Bioproducts, USA) to 70mL of 0.5x tris/borate/EDTA (TBE) buffer (89mM Trizma 
Base, Sigma-Aldrich, 89mM boric acid, Sigma-Aldrich, and 2mM ethylenediamine 
tetra-acetic acid (EDTA), Sigma-Aldrich), in a sterilised beaker. The solution was 
heated in a microwave until the agarose had dissolved. The solution was cooled 
slightly, prior to adding 7µL of Safeview DNA stain (NBS Biologicals, UK) and mixing. 
The mixture was poured into an electrophoresis cast tray, assembled with a well 
comb and allowed to set at ambient temperature. The gel was transferred to an 
electrophoresis tank containing 0.5x TBE. 5µL of 100bp DNA ladder (Promega) was 
added to the first well and 10µL of PCR samples for analysis were added to 
subsequent wells. The samples were separated at 90V for approximately 40 min, or 
until the sample dye had run to approximately ¾ the length of the gel. Band 
visualisation was performed using a Benchtop UV Transilluminator (UVP, Canada), 
with resulting images recorded. 
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Gene 
product 
Primer sequence: 5’-3’ Annealing 
temperature 
(°C) 
Product 
length 
(bp) 
Primer 
designer 
GAPDH F: TTCTTTTGCGTCGCCAGCCGA 
R: GTGACCAGGCGCCCAATACGA 
55 96 Author 
CD105 F: GAAACAGTCCATTGTGACCTTCAG 
R: GATGGCAGCTCTGTGGTGTTGACC 
55 344 Dr. Amr 
Alraies 
(Cardiff 
University) 
CD90 F: ATGAACCTGGCCATCAGCATCG 
R: CACGAGGTGTTCTGAGCCAGCA 
55 425 Dr. Amr 
Alraies 
(Cardiff 
University) 
CD73 F: GTCGCGAACTTGCGCCTGGCCGCCAAG 
R: TGCAGCGGCTGGCGTTGACGCACTTGC 
55 352 Dr. Amr 
Alraies 
(Cardiff 
University) 
CD146 F: TGTGTAGGGAGGAACGGGTA 
R: TGGGACGACTGAATGTGGAC 
55 101 Author 
CD34 F: GCTTTGCTTGCTGAGTTTGC 
R: CCATGTTGAGACACAGGGTGC 
55 180 Author 
CD45 F: CCCCACTGATGCCTACCTTA 
R: ATGCACCTCATTGTTTGTGC 
55 238 Author 
Oct4 F: GGTGGAGAGCAACTCCGAT 
R: ATGGTCGTTTGGCTGAATACC 
55 246 Author 
Nanog F: AGGTCCCGGTCAAGAAACAG 
R: CCCTGCGTCACACCATTG 
55 235 Author 
 
Table 2.1 - Primer sequences used for identification of gene expression for MSC markers. 
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2.3  Results 
2.3.1  Culture Expansion of BMMSCs 
Upon acquisition, BMMSCs demonstrated 85% viability (indicated by Trypan Blue 
staining) when thawed and readily expanded in culture. Expansive culture was 
prolonged for around fifty-five days and ten passages (15.2 PDs), at which point 
BMMSCs demonstrated arrest in expansive potential. Time between passages was 
around five days up to passage seven (13.1 PDs), which increased to around seven 
days up until the tenth passage (Figure 2.1). 
BMMSCs of passage three (5.9 PDs) were plated out and isolated via adhesion to 
fibronectin. Adherent cells (FNA BMMSCs) reached passage confluence after four 
days and propagated in expansive culture to 21.3 PDs (thirteen passages) after 
which expansive capacity declined (20.4 PDs at passage fourteen). Time between 
passages was around four to five days until passage eleven (19.1 PDs), where time 
between passages increased, as with BMMSCs, to around seven days (Figure 2.1). 
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Figure 2.1 - Population doubling level of BMMSCs (as acquired) and FNA BMMSCs. Non-
selected BMMSCs undergo around 15.2 PDs prior to reaching expansive plateau, whereas 
FNA BMMSCs achieve 21.3 PDs before expansion declines. 
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2.3.2  Morphological Appearance Throughout Expansive Culture 
At earlier culture of BMMSCs (3.9 PDs), morphology is typical of MSC cultures 
indicated by small, elongated and fibroblast-like appearance. At later culture (12.7 
PDs), cells lose their definitive elongated shape and appear larger with stress-
related fibres becoming apparent. At latest culture (15.1 PDs), cells completely lose 
fibroblast-like shape and become very large and flattened, accompanied with 
marked cytoplasmic accumulations (Figure 2.2). 
FNA BMMSCs at earlier culture (10.5 PDs) demonstrated elongated, fibroblast-like 
shape, which is maintained through to later culture (17.6 PDs), with no discernible 
change in morphological appearance. Latest culture (20.4 PDs) demonstrated 
morphological changes akin to latest culture BMMSCs, characterised by loss of 
spindle shape, increased cell size and cytoplasmic debris (Figure 2.2).
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Figure 2.2 - Representative micrograph images of BMMSCs and FNA BMMSCs during 
expansive culture at earlier, later and latest time-points. BMMSCs and FNA BMMSCs 
demonstrated spindle-shaped morphology at earlier points, which was maintained in FNA 
BMMSCs in later culture; however, BMMSCs began to appear larger. Both cell populations 
exhibited cell flattening and increased cytoplasmic aggregations (yellow arrows) at the 
latest culture points. White bars represent 100μM. 
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2.3.3 β-galactosidase Staining for Senescence Analysis 
Cultures of both BMMSCs (15.1 PDs) and FNA BMMSCs (20.4 PDs) were obtained 
and assessed for β-galactosidase staining to assess the senescent nature of the cell 
population. In Figure 2.3, both cell populations were shown to contain a large 
proportion of cells that had blue staining evident within distinct regions of the cell 
cytoplasm. However, not all cells demonstrated positive staining for β-
galactosidase, despite demonstrating morphological appearances similar to that of 
positively stained cells. Both cell populations were additionally stained for β-
galactosidase enzyme activity at pre-senescent cultures (BMMSCs 12.7 PDs, FNA 
BMMSCs 17.6 PDs), with positive staining only present in a very small 
proportion of cells (Figure 2.3). 
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Figure 2.3 - Micrographs of BMMSCs stained for β-galactosidase enzyme activity at pre-
senescent (left) and senescent (right) culture and percentage of positively stained cells. 
BMMSCs in pre-senescent culture appear smaller and less than 5% stain for β-galactosidase 
(black arrows).  Conversely, cells in later culture appear to possess larger, flattened 
morphology concurrent with prominent (>50%) blue staining (white arrow heads). White 
bars represent 100μM. 
 
 
 
 
Cell population Cells positively stained for β-galactosidase (%) 
BMMSCs (Late culture, 12.7 PDs) 3.0% 
BMMSCs (Latest culture, 15.1 PDs) 58.7% 
FNA BMMSCs (Late culture, 17.6 PDs) 2.4% 
FNA BMMSCs (Latest culture, 20.4 PDs) 75.0% 
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2.3.4 Mesenchymal stem cell (MSC) Marker Expression 
A panel of different markers were assessed by PCR for characterisation of earlier 
(3.9 PDs BMMSCs/10.5 PDs FNA BMMSCs), and later culture (12.7 PDs BMMSCs/ 
17.6 PDs FNA BMMSCs) BMMSCs and FNA BMMSCs. Both cell populations 
expressed the mesenchymal markers, CD105, CD90 and CD73, up to late culture, in 
addition to CD146. CD34 and CD45 displayed very low expression levels in both cell 
populations at both earlier and later culture. Embryonic markers, Oct4 and Nanog, 
were positively expressed in both cell populations with maintained expression 
throughout culture. Osteogenic commitment marker RunX2 was not expressed in 
BMMSCs throughout culture and was not identified in earlier culture of FNA 
BMMSCs, however very weak expression is apparent in FNA BMMSCs at later 
culture (Figure 2.4). No bands were detected in RT negative or PCR negative 
reactions. CD34, CD45 and RunX2 demonstrated prominent expression in DNA 
obtained from total human RNA, thus indicating validity of primers.
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Figure 2.4 - PCR characterisation panel for BMMSCs and FNA BMMSCs at earlier and later 
culture. Mesenchymal markers, CD105, CD90, CD73 and CD146, were expressed in all cell 
populations tested, with very weak expression of CD34 and CD45 visible. Embryonic 
markers, Oct4 and Nanog, were expressed in all cell populations, with the latter 
demonstrating perceivably higher expression in FNA BMMSCs, compared to BMMSCs. Low 
expression of RunX2 was noted in FNA BMMSCs at 17.6 PDs. CD34, CD45 and RunX2 were 
positively expressed in total human positive control, thus confirming primer efficacy. 
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2.4 Discussion 
Heterogeneity in BMMSC populations is well acknowledged and results in 
inconsistencies in differentiation potential between cell populations. Experimental 
procedures within this Chapter were performed to acquire and characterise a 
population of more refined cells from a heterogeneous population, via adhesion to 
fibronectin. FNA BMMSCs maintained MSC marker expression throughout culture in 
addition to an expansive capacity around 33% greater than whole BMMSCs, prior to 
reaching senescence. FNA BMMSCs thus represent a refined population of 
characterised, immature cells with which cell behaviour has been assessed in 
subsequent Chapters. 
Initial acquisition of BMMSCs was from a commercially available source and the 
cells provided were certificated to conform to MSC characteristics with regards to 
tri-lineage differentiation potency and marker expression, including CD105+, CD90+, 
CD73+, CD34- and CD45-. Even though the term MSC is used to define cells adhering 
to the International Society for Cellular Therapy (ISCT) guidelines (Dominici et al, 
2006), mounting reports highlight the heterogeneity of MSCs with regard to these 
defining criteria. Heterogeneity of MSCs can simply been noted via micro-graphical 
observations of MSCs, with three observed phenotypes noted; spindle-shaped, star-
shaped and large/flat cells (Muraglia et al, 2000; Xiao et al, 2010).  
Due to the reported heterogeneity of MSCs, adherence of BMMSCs to fibronectin 
was utilised to purify a more immature sub-population of cells. Fibronectin serves 
as a ligand to cells expressing α5β1 integrin (Wu et al, 1993). Cell surface expression 
of β1 integrin and rapid adhesion to extracellular matrix (ECM) molecules correlates 
with proliferative capacity and high colony forming efficiency, with a two-fold 
increase of surface β1 integrin expression present on stem cells, compared to transit 
amplifying cells (Jones and Watt, 1993; Jones et al, 1995). Consequently, primitive 
cells with high β1 integrin expression can be isolated via adherence to fibronectin 
(Jones et al, 1995; Dowthwaite et al, 2004, Waddington et al, 2009). Isolation of 
FNA cells derived from bone marrow has yielded cells positive for CD105, CD90 and 
CD73 with negative CD34 expression, along with high and low proliferative 
potential (Xiao et al, 2010). Populations of FNA MSCs derived from bone marrow 
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display heterogeneity with regards to proliferative potential and population 
doubling level. However, with differentiation potential towards osteogenic, 
chondrogenic and adipogenic lineages present in all cells isolated via fibronectin-
adherence (Harrington et al, 2014).  
During expansive culture, BMMSCs achieved 15.2 PDs prior to reaching a plateau of 
cell doubling, however, fibronectin isolation of BMMSCs was successfully achieved 
in this study and yielded a population of FNA BMMSCs with expansive capacity in 
vitro of 21.3 PDs, prior to expansive decline. Various literature studies report 
discrepancies between the expansive capacities of BMMSCs derived from human 
donors. Wagner et al, (2008) analysed six donor populations of BMMSCs and 
reported cumulative PDs ranging from between six to sixteen prior to reaching 
growth arrest, in addition with an estimated additional seven to nine PDs during 
initial colony formation. Ren et al, (2013) reported PDs of BMMSCs from seven 
donors to vary from twenty-five to forty before expansive capacity was achieved. 
Although BMMSCs used in this Thesis underwent fewer PDs compared to those 
analysed within literature reports, they were received at passage two with no 
receipted reference to PDs from initial isolation. Therefore, expansive capacity from 
original isolation would have been greater than indicated. It is additionally 
important to note that discrepancies between observed expansive capacities of 
human BMMSC preparations can be attributable to specific methods of isolation 
and culture (Siddappa et al, 2007; Ho et al, 2008). 
Studies involving the characterisation of MSCs in vitro have extensively utilised 
expression of cell surface markers to determine cellular phenotype. As no single 
marker for determining MSCs has been identified to date, assessing the expression 
of a panel of diverse markers is regularly utilised to determine MSC phenotype in 
vitro. CD105 is highly expressed in human MSC preparations (Schieker et al, 2007), 
with over 95% of MSCs expressing CD105 (Lodie et al, 2002). CD90 is indicated as a 
universally expressed marker for MSCs that maintains expression throughout MSC 
in vitro culture (Musina et al, 2005; da Silva Meirelles et al, 2006). Additionally, 
CD73 expression has been affiliated with MSCs (Haynesworth et al, 1992; Etheridge 
et al, 2004). Co-current with ISCT guidelines (Dominici et al, 2006), BMMSCs and 
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FNA BMMSCs expressed mRNA for CD105, CD90 and CD73 throughout expansive 
culture. However, the positive expression of CD105, CD90 and CD73 has also been 
affiliated in fibroblasts and endothelial cells (Narravula et al, 2000; Alt et al, 2011); 
and therefore the expression of these markers alone are not specific for MSCs.  
Literary reports demonstrate a general consensus regarding negative expression of 
endothelial cell markers, CD34 and CD45, within MSC preparations (Pittenger et al, 
1999; Zuk et al, 2002; Dominici et al, 2006; Saccheti et al, 2007). Regarding results 
presented in this Thesis, PCR analyses of BMMSCs and FNA BMMSCs indicated that 
relative to other markers, CD34 and CD45 mRNA expression in both cell types was 
shown to be very low, although not entirely negative. Kaiser et al (2007) reported 
that a small proportion of isolated MSCs positively express CD34 and CD45. In 
addition, MSCs from populations both negative and positive for both CD34 and 
CD45 demonstrate adipogenic and osteogenic differentiation potency. 
Furthermore, freshly isolated and uncultured MSCs from bone marrow origin 
demonstrate positive expression for CD34 (Simmons and Torok-Storb, 1991). 
Consequently, the presence, albeit small, of MSCs expressing haematopoietic 
surface markers is believed to result as a consequence of cell culturing (Lin et al, 
2012). 
Due to increasing awareness of other markers believed to be expressed in MSCs, 
additional analyses were undertaken in attempt to further characterise and 
compare BMMSCs with their FNA counterparts. CD146 is a transmembrane 
glycoprotein constitutively expressed in human endothelial cells (Bardin et al, 
2001), with expression also observed in cells of smooth muscle, melanoma and 
follicular dendrite origin (Bardin et al, 1996). More recently, CD146 has been 
associated with expression in MSCs from bone marrow origin (Shi and Gronthos, 
2003). CD146+ MSCs have been demonstrated to be able to differentiate into 
osteoblasts (Saccheti et al, 2007), chondrocytes and adipocytes (Baksh et al, 2007), 
in addition to possessing extended proliferation during in vitro culture compared to 
CD146- MSCs (Sorrentino et al, 2008). Moreover, CD146 has been proposed as a 
marker of cell pluripotency, with clonal populations expression around 2-fold higher 
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for tri-lineage potential clonal populations, compared to uni-potent clones (Russell 
et al, 2010). 
In this Chapter, Oct4 and Nanog were indicated to be expressed in both BMMSCs 
and FNA BMMSCs at earlier and later cultures. Although Oct-4 is characteristic of 
ESCs, expression has been identified in MSCs of bone marrow origin (Greco et al, 
2007; Reikstina et al, 2009). Increases in Oct4 expression in MSCs has been 
demonstrated to increase differentiation efficiency towards osteogenic and 
adipogenic lineages (Roche et al, 2007). Nanog is reported to not be expressed in 
freshly isolated MSCs. However, expression is identified after in vitro culture in 
MSCs not induced to differentiate (Pierantozzi et al, 2011). Forced expression of 
Nanog in BMMSCs encourages maintenance of expansion (Go et al, 2008). Ectopic 
overexpression of Oct4 and Nanog in MSCs enhances proliferation and 
differentiation potential in culture, however, knock-down of Oct4 and Nanog 
reverses these observations (Tsai et al, 2012). Expression of Oct4 and Nanog is 
terminated in MSCs differentiated into osteoblasts, however, is maintained in MSCs 
prior to differentiation (Arpornmaeklong et al, 2009). Although Oct4 expression 
appears to be saturated for BMMSCs and FNA BMMSCs at earlier and later culture 
periods, Nanog expression appears to be greater for FNA BMMSCs, compared with 
BMMSCs. Resultantly, the perceived increase in Nanog expression supports the 
more immature and less heterogenic nature of FNA BMMSCs, compared to 
unselected BMMSCs. 
In addition to analysing expression of mesenchymal and embryonic markers, 
expression of RunX2 was also investigated to further characterise BMMSCs and FNA 
BMMSCs throughout expansive culture. BMMSCs at earlier and later PDs did not 
demonstrate positive mRNA expression for RunX2, whereas FNA BMMSCs were 
negative for RunX2 expression at earlier PDs, however weak expression was 
identified at later PDs. RunX2 is widely regarded as the critical regulator in the 
initiation of osteoblastic differentiation (Otto et al, 1997; Sadhakar et al, 2001; 
Cohen, 2013). RunX2 is strongly expressed in immature osteoblasts. However, 
expression is down regulated during osteoblastic development and maturation 
(Maruyama et al¸2007). Expression of RunX2 is, therefore, associated with directing 
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multipotent MSCs towards the osteoblastic lineage (Komori, 2010) and expression 
also results in inhibition of differentiation of MSCs to adipocytes and chondrocytes 
(Komori, 2006). The observed expression of RunX2 in addition to maintained 
expression of other mesenchymal markers at later PDs of FNA BMMSCs indicates a 
change in profile of cells regarding population homogeneity. RunX2 expression 
indicates the lineage commitment of a proportion of FNA BMMSCs towards the 
osteoblastic lineage. Thus, any cells beyond this number of PDs did not constitute a 
purified population of primitive cells and were not utilised for upcoming 
experimental procedures within this Thesis. 
With prolonged culture, MSCs enter a senescent state and undergo phenotypic 
changes, including broadening and flattening of cells, accumulation of stress fibres, 
granular cytoplasm and increases in cellular debris (Bruder et al, 1997; Wagner et 
al, 2008). The point of growth arrest of both BMMSCs and FNA BMMSCs 
demonstrated these observations, which were not present during earlier culture 
periods. In addition, FNA BMMSCs did not exhibit these senescence-associated 
phenotypic observations at a comparable population doubling level to which 
BMMSCs appeared to be senescent, further indicating that FNA BMMSCs are at a 
more immature state than unselected BMMSCs.  β-galactosidase is reported to only 
be active in senescent cells, however, it is not active in differentiated, quiescent or 
pre-senescent cells (Dimri et al, 1995); and is postulated to be as a result of 
increasing lysosomal mass during prolonged cellular replication (Lee et al, 2006). β-
galactosidase activity is MSCs can be used as an additional measure of senescent 
state. β-galactosidase staining was performed on both populations of cells at the 
stage of suspected senescence, with positive staining observed in a large proportion 
of cells, however, not all senescence-phenotype cells stained positively. β-
galactosidase assays are reported to predominantly stain large senescent cells and 
thus, is not an absolute determinant of senescence (Wagner et al, 2008; Zhou et al, 
2008). Hence β-galactosidase staining was used in conjunction with morphological 
observations and expansion data to determine cellular senescence. Collectively, 
senescence of BMMSCs and FNA BMMSCs was determined to be reached after 15.1 
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PDs and 20.4 PDs, respectively, indicating the extended expansive capacity of FNA 
BMMSCs compared to BMMSCs. 
Overall, results from this Chapter have demonstrated the isolation of a primitive 
population of cells from a heterogeneous population via fibronectin-adherence 
selection. The cells obtained possess greater expansive capacity in vitro compared 
to unselected cells with a prolonged culture period senescence and also 
demonstrate expression of a range of markers used to characterise MSCs. Thus, the 
FNA BMMSCs isolated present a purified population with less heterogeneity 
compared with unselected BMMSCs, and were utilised for all forthcoming 
experiments in this Thesis (here on in referred to as BMMSCs). 
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Chapter 3 - Characterisation of Biological Effects of Demineralised 
Dentine Matrix (DDM) on Bone Marrow-Dervied, Mesenchymal Stem 
Cells (BMMSCs) 
 
3.1 Introduction 
Bone has a high capacity for in vivo regeneration, attributable to the presence of a 
tightly regulated signalling environment and associated factors, including 
inflammatory cytokines (Einhorn et al, 1995; Rundle et al, 2006), growth factors 
(Bostrom et al, 1995; Cho et al, 2002; Hughes et al, 2006) and mesenchymal stem 
cells (MSCs) (Nakahara et al, 1990; Einhorn, 1998). However, delayed union or non-
union of fractures occurs in 5-10% of cases of bone trauma (Gómez-Barrena et al, 
2015). Moreover, bone regeneration is hindered in several clinical situations, 
including osteoporosis (Nikolaou et al¸2009), diabetes mellitus (Loder, 1988); and as 
a consequence of ageing (Gruber et al, 2006). Such conditions compromise intrinsic 
bone healing and require intervention to achieve adequate tissue repair. To 
accomplish sufficient regeneration of large bone volumes, autologous bone grafts 
(ABGs) are required and although their rates of success are high, post-operative 
complications negate their use (Brugnami et al, 2009). Bone allografts provide an 
alternative source of tissue to augment tissue repair, however, success rates are 
much more variable due to batch variations and methods of processing (Calori et al, 
2011). 
Like bone, dentine is acknowledged to consist of a plethora of bioactive 
constituents, including growth factors (Finkelman et al, 1990; Roberts-Clark and 
Smith, 2000), inflammatory molecules (Graham et al, 2007) and extracellular matrix 
() proteins (Embery et al, 2001), all with proposed roles in orchestrating tissue 
repair responses. Sequestration of factors within the matrix is proposed to act as a 
‘reservoir’ of signalling molecules (Tziafas et al, 2000; Goldberg et al, 2004). Carious 
injury to dentine results in demineralisation (Hojo et al, 1994; Larmas et al, 2001); 
subsequently sequestered factors are released and are proposed to contribute 
towards reparative dentinogenesis (Smith et al, 1995; Cooper et al, 2010). Clinically 
58 
 
induced release of bioactive factors from dentine using ethylenediamine tetra-
acetic acid (EDTA), calcium hydroxide (CaOH2) and mineral trioxide aggregate 
(MTA) provides successful pulp capping, by inducing reparative responses of the 
dentine-pulp complex (Duque et al, 2006; Graham et al, 2006; Tomson et al, 2007). 
The bioactivity of dentine for augmenting bone repair has been recognised in vivo, 
with demineralised dentine matrix (DDM) acknowledged to stimulate reparative 
responses in rat tooth sockets (Reis-Filho et al, 2012) and diabetic rabbit bone 
defects (Gomes et al, 2008). Whilst postulated that DDM can emulate the signalling 
environment required for bone repair, characterisation of bioactivity towards bone 
marrow-derived, mesenchymal stem cells (BMMSCs) is less well acknowledged. 
However, the potential for dentine matrix to induce osteogenic differentiation of 
BMMSCs has been noted in heterogeneous BMMSCs derived from rats (Yu et al, 
2014). 
Proteomic analyses of dentine have identified the presence of a wide array of 
various constituents with potential roles in orchestrating bone repair and 
mineralisation, including transforming growth factor-β1 (TGF-β1), bone 
morphogenetic protein-2 (BMP-2), biglycan and decorin (Park et al, 2009; 
Casagrande et al, 2010; Jagŕ et al, 2012). This Chapter aimed to determine the 
bioactive nature of dentine matrix by assessing the effects observed when applied 
to fibronectin-adherent (FNA) BMMSCs (as characterised in Chapter 2). Effects of 
DDM on cellular expansion, migration and apoptosis were investigated. Crucially, 
the potency of DDM to stimulate differentiation on BMMSCs was analysed, with the 
concentration required for observed effects additionally elucidated. Determining 
the potential bioactive nature of dentine matrix on BMMSCs provided an indication 
to the potential for enhancing the bone repair process. 
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3.2 Materials and Methods 
3.2.1.1  Ethical Approval and Tooth Acquisition 
Human teeth were obtained from the Cardiff University, School of Dentistry 
Governance Committee, following ethical approval from the Research Ethics 
Committee, under South East Wales Tissue Bank approval 12/WA/0289. Teeth were 
stored at -80°C, prior to processing. 
3.2.1.2 Preparation of Demineralised Dentine Matrix (DDM) 
All residual soft tissues were removed using a scalpel and teeth were washed thrice 
in 1% (w/v) sodium azide (Sigma-Aldrich, UK), prior to further processing. Teeth 
were embedded in wax and the upper crown sectioned off, followed by partitioning 
of the whole tooth down the saggital plane, using an IsoMet low speed saw with a 
diamond tipped blade (Buehler, USA). Exposed pulp tissue was removed using 
tweezers and tooth sections were washed once in 1% (w/v) sodium azide (Sigma-
Aldrich). The resulting tooth sections were individually processed by mechanical 
removal of cementum and remaining enamel material using a dental hand-piece 
equipped with a slow-speed diamond burr. Isolated dentine sections were frozen in 
liquid nitrogen for 10 min and then powdered in a 6750 Freezer/Mill (Spex 
CertiPrep, USA), impacted at intensity 100 for 2 min. Resulting dentine powder 
from 10 teeth (approximately 7.5g) was split equally into two 50mL tubes (Sarstedt, 
UK). Dentine matrix components from each tube were extracted using 40mL of a 
7.5% EDTA disodium salt (Fisher Scientific, UK) solution, supplemented with the 
protease inhibitors 1mM iodoacetic acid (Sigma-Aldrich), 5mM n-ethylmaleimide 
(Sigma-Aldrich) and 5mM benzamidine-hydrochloride (Sigma-Aldrich), at 4°C, with 
gentle agitation for a total of 14 days.  On alternate days, the tubes were 
centrifuged at 1,100g for 10 min and supernatant collected and fresh extraction 
solution was applied. Pooled supernatants were exhaustively dialysed using 
12,000Da molecular weight cut-off (MWCO) dialysis tubing (Sigma-Aldrich), against 
repeated changes of deionised distilled H20 (ddH2O) for 10 days at 4°C. Dialysed 
extracts were lyophilised and resulting DDM was stored at -20°C. 
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3.2.1.3  DDM Reconstitution and Concentration Determination 
DDM was reconstituted in tris buffered saline (TBS) to an anticipated concentration 
of approximately 1mg/mL, vortex mixed for 30 s and sterile filtered through a 
0.22µM syringe filter (Millipore, USA). Protein concentration was determined using 
a Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific, USA), following 
manufacturers protocol. Briefly, 25μL of a reconstituted protein sample was 
pipetted into a 96-well plate (Sarstedt) in triplicate. Pre-prepared bovine serum 
albumin (BSA) standards (25μg-2,000 μg/mL) represented a standard curve. 200μL 
of Working Reagent was added to each well; the plate was mixed on a plate shaker 
at 750rpm for 30 s and incubated at 37°C for 30 min. The plate was cooled to 
ambient temperature and colorimetric absorbance at 562nm read using a 
SPECTROstar Omega Plate Reader (BMG Labtech, Germany). Absorbance readings 
were blank corrected and averaged; and protein concentrations calculated from the 
generated standard curve equation with Microsoft® Excel® 2010. 
3.2.2 Cellular Expansion 
BMMSCs (10-10.5 population doublings, PDs) were seeded in triplicate into 96-well 
plates, at 4x103 cells/cm2 in 5% foetal bovine serum (FBS) (Invitrogen, UK) culture 
media, conditioned with DDM at 10µg/mL, 1µg/ml, 0.1µg/mL and 0µg/mL (control). 
Media changes were performed every 48 h. After 0, 24, 48, 72 and 96 h, culture 
medium was aspirated and replaced with fresh culture medium supplemented with 
20μL of thiazolyl blue tetrazolium blue (MTT) assay reagent (Sigma-aldrich) 
(5mg/mL MTT in phosphate buffered saline (PBS)). Plates were incubated for 5 h 
under standard culture conditions. Culture medium was aspirated and replaced 
with 100µL of dimethyl sulfoxide DMSO (Fisher Scientific) and incubated for 30 min 
under standard culture conditions. Plates were cooled to ambient temperature and 
colorimetric absorbance at 540nm was read using a FluoSTAR Omega Plate Reader 
(BMG Labtech). Wells incubated with MTT containing culture media without cells 
served as a blank reading. The assay was performed on three separate occasions. 
3.2.3 Apoptotic Activity 
A Caspase-Glo® 3/7 Assay (Promega, UK) was used to quantify apoptotic activity of 
cells cultured in varying concentrations of DDM-conditioned media. Caspase-Glo® 
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3/7 Reagent was prepared by thawing the Caspase-Glo® 3/7 Buffer and adding the 
entire contents to Caspase-Glo® 3/7 Substrate, with gentle agitation to ensure 
complete mixture of the reagents. Prepared Caspase-Glo® 3/7 Reagent was stored 
for up to 1 week at 4°C, with warming to ambient temperature before use. 
BMMSCs (14-15 PDs) were seeded in triplicate into white-walled, optically clear 96-
well plates (Corning, USA), at 4x103 cells/cm2 in 10% FBS culture media conditioned 
with DDM at concentrations of 10µg/mL, 1µg/mL, 0.1µg/mL and 0µg/mL (control). 
After 6, 24 and 48 h, plates were removed from incubation and cooled to ambient 
temperature. 50µL of Caspase-Glo® 3/7 Reagent was added to each well and the 
plate was incubated on a plate shaker at 300rpm for 30 s followed by incubation at 
room temperature for 1 h, protected from light. The plate was transferred to a 
FluoSTAR Optima Plate Reader (BMG Labtech) set to maximum optical gain settings, 
and arbitrary relative luminescence units (RLUs) were measured. Wells containing 
no cells incubated with Caspase-Glo® 3/7 reagent and culture media served as a 
blank reading. The assay was performed on three separate occasions. 
3.2.4 Cellular Migration 
24-well tissue culture inserts (Boyden inserts) with 8µM pores (Greiner Bio One, 
Austria), were coated with 10µg of type I collagen from rat-tail (Sigma-Aldrich). 
Type I collagen was supplied as a 3.7mg/mL stock solution in 0.02N acetic acid. For 
1.08mL of collagen gel, 52.54µL of type I collagen was added to 1,016.88µL of α-
MEM and then neutralised with 10.58µL of 0.1N sodium hydroxide (NaOH) solution 
(Fisher Scientific). 60µL of collagen solution was applied to the upper membrane of 
each cell culture insert, which were subsequently placed in 24-well plates (Sarstedt) 
and incubated at 37°C overnight to allow solidification of collagen. Excess culture 
media was aspirated and cell culture inserts were allowed to air dry, under laminar 
flow, for 1 h at room temperature. BMMSCs (12-13.5 PDs) were cultured with 
serum-free media for 24 h, passaged and seeded at 104 cells/cm2 in 200µL of 
serum-free culture media in the upper compartment of collagen-coated inserts. 
600µL of serum-free culture media conditioned with DDM at 10µg/mL, 1µg/mL, 
0.1µg/mL and 0µg/mL (control), was added to the lower compartment and the 
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culture plates were incubated under standard culture conditions for 20 h. Figure 3.1 
depicts the layout of a Boyden insert. 
 
 
Figure 3.1 - Schematic diagram demonstrating the layout of a Boyden insert placed into a 
tissue culture plate. Cells were seeded into the upper chamber and were able to migrate 
through the collagen coated permeable membrane of the insert into the lower chamber. 
Migrated cells were fluorescently labelled for quantification. 
 
Culture media was aspirated from the lower compartment and replaced with 450µL 
of serum-free culture media supplemented with 8µM calcein-AM (Sigma-Aldrich); 
and incubated under standard culture conditions for 45 min. Culture media was 
removed from the lower compartment and replaced with 500µL of trypsin (Sigma-
Aldrich) diluted 1:5 in PBS, per well. Plates were incubated for 10 min at 37°C, 
followed by gentle agitation and 200µL of trypsin/PBS solution from each well was 
removed and placed into a well of a black-walled optically clear 96-well plate 
(Corning). The plate was transferred to a FluoSTAR Optima plate reader (BMG 
LABTECH) and fluorescence read using 485nm excitation/520nm emission 
wavelengths. The experiment was performed on three separate occasions. 
3.2.5 Mineral Deposition 
Basal media (non-osteogenic) was prepared by supplementing α-MEM with 10% 
FBS and 1% antibiotic/antimycotic solution. Osteogenic media (positive control) was 
prepared by supplementing basal media with 10mM β-glycerophosphate (Sigma-
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Aldrich) and 10nM dexamethasone (Sigma-Aldrich). DDM-conditioned media was 
prepared by supplementing basal media with DDM at final concentrations of 10 
µg/mL, 1 µg/mL and 0.1 µg/mL. 
BMMSCs (15.2-16.5 PDs) were seeded into 24-well tissue culture plates and 
cultured in 10, 1 and 0.1 µg/mL DDM, osteogenic media (positive control) and un-
supplemented media (negative control) for 28 days. Media changes were 
performed every 2 days. After 28 days, media was aspirated and cells washed twice 
with PBS. Cells were fixed in 10% formaldehyde (Sigma-Aldrich) for 30 min at room 
temperature. Formaldehyde was aspirated and cells were washed twice with ddH2O 
and used immediately for Alizarin red staining. 
3.2.5.1 Alizarin Red Staining 
500µL of 2% (w/v) Alizarin red S (pH 4.1-4.3) (Sigma-Aldrich) was added to each well 
and incubated for 20 min with gentle agitation. Alizarin red solution was aspirated 
and cells washed five times for 5 min each with ddH2O, or until wash solution was 
colourless. All residual wash solution was aspirated and the plate air-dried under 
ambient conditions. Cells were photographed under light microscopy, using a 
Panasonic DMC-G1 Camera. 
3.2.6 Differentiation Gene Expression 
BMMSCs (16.5-17 PDs) were seeded at 104 cells/cm2 into 6-well or 12-well culture 
plates (Sarstedt) and cultured in un-supplemented media (negative control), 
osteogenic induction media (positive control) and DDM supplemented media at a 
final concentration of 10 µg/mL. Media was changed every 2 days. After 2, 5 and 28 
days, RNA was extracted and converted to cDNA via reverse transcription, as 
described previously (Sections 2.2.3 - 2.2.4). Resulting cDNA was diluted 1:10 with 
nuclease-free water (Promega) (1:5 dilution for 500ng of cDNA). For each 
quantitative real time-polymerase chain reaction (q-PCR), 2µL of 3µM primers 
(forward and reverse sequences, detailed in table 3.1) were mixed with 10µL of 2x 
PrecisionFAST q-PCR Master Mix (Primer Design, UK) and 1µL of nuclease-free 
water. 5µL of diluted cDNA was pipetted in triplicate into white 96-well q-PCR 
plates (Primer Design), followed by 15µL of pre-prepared Master Mix. Plates were 
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covered with adhesive optical seals (Primer Design); and centrifuged at 500g for 3 
min. q-PCR runs were performed in a QuantStudio™ 6 Flex Real-Time PCR System 
(Thermo Fisher Scientific), using QuantStudio™ Real-Time PCR Software (v1.0). 
Reaction conditions were as follows: one initial denaturation at 95°C for 20 s, forty 
cycles of denaturation for 1 s and annealing for 20 s. After cycling was completed, 
melt curve analysis was performed as follows: 95°C denaturation for 15 s, 60°C 
dissociation for 1 min and 95°C denaturation for 15 s. Primer sequences are 
detailed in Table 3.2.1. GAPDH was used as an internal reference for normalisation 
of data. 
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Gene 
product 
Primer sequence: 5’-3’ Annealing 
temperature 
(°C) 
Product 
length 
(bp) 
Primer 
designer 
GAPDH F: TTCTTTTGCGTCGCCAGCCGA 
R: GTGACCAGGCGCCCAATACGA 
55 96 Author 
RunX2 F: GGTTAATCTCCGCAGGTCACT 
R: CCCTCTGTTGTAAATACTGCTTGC 
55 80 Author 
OPN F: TCTCCTAGCCCCACAGAATG 
R: CGTTGGACTTACTTGGAACGG 
55 80 Author 
COL1A1 F: TGCTGTTGGTGCTAAGGG 
R: GCAATACCAGGAGCACCATTG 
55 177 Dr. Wayne 
Ayre 
(Cardiff 
University) 
OC F: GGCAGCGAGGTAGTGAAGAG 
R: CTCACACACCTCCCTCCT 
55 102 Dr. Wayne 
Ayre 
(Cardiff 
University) 
 
Table 3.1 – Table detailing primer sequences used for q-PCR analysis of genes expressed 
during osteogenic differentiation of BMMSCs. 
3.2.7 Statistical Analyses 
Statistical analyses were performed utilising One-Way ANOVA, with a post-hoc 
Tukey test when comparing 3 or more groups, or a 2-tailed T-test when comparing 
2 groups, using GraphPad InStat 3 (v3.06). Statistical values were defined as 
significant (*, P<0.05), very significant (**, P<0.01), or extremely significant (***, 
P<0.001). 
 
66 
 
3.3 Results 
3.3.1  Effect of DDM on Cellular Expansion 
 Over 96 h in culture, DDM evoked a reduction of BMMSC expansion in an observed 
dose-dependent manner. After 24 h, DDM at 10μg/mL resulted in a significant 
reduction in cell expansion, compared to cells cultured with DDM at 1μg/mL 
(P<0.001) and 0.1μg/mL (P<0.01), and controls (P<0.001). After 48 h, expansion of 
BMMSCs cultured with DDM at 1μg/mL was significantly reduced, compared to 
BMMSCs cultured in un-conditioned media (P<0.05). After 72 h, DDM at 0.1μg/mL 
reduced BMMSC expansion compared to controls (P<0.05). After 96 h, DDM at 
1μg/mL reduced expansion compared to cells cultured with 0.1μg/mL DDM; 
however, expansion of cells with DDM at 0.1μg/mL was not significantly different 
compared to controls (P<0.05) (Figure 3.2). 
 
 
Figure 3.2 - BMMSC expansion over 96 h when cultured with 0-10μg/mL DDM. DDM 
reduced cell expansion in a dose-dependent manner, with 10μg/mL DDM eliciting a 
significantly reduced rate of BMMSC expansion after 24 h in culture, compared to media 
supplemented with DDM at lower concentrations. After 96 h, BMMSC expansion was 
reduced with DDM at 1μg/mL compared with un-conditioned cells, however expansion 
was not changed with DDM supplemented at 0.1μg/mL. Error bars represent ±SD of 
mean (n=3). *=P<0.05, **=P<0.01, ***=P<0.001. 
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3.3.2 Apoptotic Activity of BMMSCs Cultured with DDM 
DDM-conditioned media did not increase caspase 3/7 activity of BMMSCs after 6 
and 24 h in culture. After 48 h in culture, BMMSCs cultured in media conditioned 
with 10μg/mL DDM demonstrated a statistically significant reduction of caspase-
3/7 enzyme activity, compared to BMMSCs cultured with un-conditioned media 
(P<0.05) (Figure 3.3). 
 
 
 
Figure 3.3 - Apoptotic activity of BMMSCs cultured with DDM. No increase in apoptotic 
activity was observed for BMMSCs cultured in DDM up to 10μg/mL. Apoptotic activity was 
demonstrated to be significantly lower in BMMSCs cultured in DDM at 10μg/mL, compared 
to cells cultured in un-conditioned media after 48 h. Error bars represent ±SD of mean 
(n=3). *= P<0.05. 
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3.3.3 Migratory Activity of DDM on BMMSCs 
DDM provoked an inverse dose-dependent effect on migratory behaviour of 
BMMSCs; migration decreased with increasing DDM concentration. DDM at 
0.1μg/mL enhanced migratory behaviour of cells (P<0.05), whereas DDM at 
10μg/mL suppresses migratory activity (P<0.05), compared to un-conditioned 
controls. DDM at 1μg/mL had no effect on migratory behaviour of BMMSCs (Figure 
3.4).  
 
 
Figure 3.4 - Migratory effect of DDM on BMMSCs. DDM at 0.1μg/mL enhances migration of 
cells compared to controls, however, DDM at 10μg/mL appears to be anti-migratory. DDM 
at 1μg/mL had no effect on BMMSC migration. Error bars represent ±SD of mean (n=3). *= 
P<0.05, *** = P<0.001. 
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3.3.4 Osteogenic Potency of DDM towards BMMSCs 
After 28 days, BMMSCs cultured in osteogenic differentiation media stained with 
Alizarin red demonstrated brightly red stained nodules of mineralisation, indicative 
of successful osteogenic differentiation. BMMSCs cultured in 10μg/mL DDM 
showed minor mineral deposition, as indicated by faint Alizarin red staining of 
distinctly localised foci. No Alizarin red staining was evident for BMMSCs cultured in 
DDM at 1μg/mL, 0.1μg/mL or basal media (Figure 3.5). Thus, 10μg/mL DDM was 
chosen to assess changes in gene expression during the osteogenic differentiation 
process.  
After 2 days in culture, gene expression of RunX2 was not enhanced in BMMSCs 
cultured with either osteogenic differentiation media or media conditioned with 
10μg/mL DDM (Figure 3.6). Expression of RunX2 was up-regulated by osteogenic 
differentiation media (P<0.001) and 10 μg/mL DDM (P<0.05), relative to basal media 
after 5 days in culture.  
After 28 days in culture, BMMSCs cultured in 10μg/mL DDM demonstrated a 
statistically significant up-regulation of collagen type I (COL1A1) expression relative 
to cells in basal media (P<0.05). An increase of osteocalcin (OC) expression is also 
observed for BMMSCs cultured in DDM, with up-regulation approaching statistical 
significance (P=0.06). Conversely, osteopontin (OPN) expression was up regulated in 
BMMSCs cultured in un-conditioned media relative, to BMMSCs cultured 10μg/mL 
DDM culture (P<0.05) (Figure 3.7). Gene expression analysis of BMMSCs cultured in 
osteogenic differentiation media for 28 days was not performed due to difficulties 
for the extraction of RNA from the heavily mineralised matrix. 
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Figure 3.5 - Micrograph images of BMMSCs stained by Alizarin red for mineral deposition 
analysis after 28 days in culture. Cells cultured in 10μg/mL DDM demonstrate weakly 
stained mineralised foci (black arrow). Cells cultured in osteogenic differentiation media 
show more intense and diffuse staining (white arrow heads). Mineral deposition staining 
was not evident during culture in 1 μg/mL DDM, 0.1 μg/mL DDM or basal culture media 
(negative control). White bars represent 100 μm. 
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Figure 3.6 - Expression of RunX2 in BMMSCs cultured in DDM-conditioned, osteogenic, and 
basal media for 2 and 5 days. After 2 days in culture, RunX2 gene expression was not 
changed in BMMSCs cultured in DDM supplemented or osteogenic induction media, 
compared with BMMSCs cultured in un-supplemented media. RunX2 expression is 
significantly increased in BMMSCs cultured in both DDM-conditioned media and osteogenic 
induction media, compared with BMMSCs cultured in un-supplemented media. Error bars 
represent ±SD of mean (n=3). *= P<0.05, ** = P<0.01, *** = P<0.001. 
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Figure 3.7 - Expression of OPN, COL1A1 and OC mRNA in BMMSCs cultured in 10μg/mL 
DDM media and basal media after 28 days. OPN expression for cells cultured with DDM is 
down-regulated, compared to controls (P <0.05), however COL1A1 is increased (P < 0.05). 
OC up-regulation approaches significance in DDM-treated cells (P=0.06). Error bars 
represent ±SD of mean (n=4). *= P<0.05. 
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3.4 Discussion 
Although several in vivo studies have identified the osteogenic potency of dentine 
matrix for augmentation of bone repair, little is currently known regarding the 
influences of DDM on BMMSCs. Repair of bone in vivo is a complex and highly 
organised process involving the migration, proliferation and differentiation of 
BMMSCs. Within this Chapter, DDM has been demonstrated to induce migration, 
reduce cell expansion and attenuate apoptosis of BMMSCs. Critically, the highest 
tested concentration of 10µg/mL demonstrated osteogenic responses and 
mineralised matrix deposition by BMMSCs. 
In this study, it was demonstrated that DDM induced migration of BMMSCs in an 
inverse dose-dependent manner with DDM at 0.1μg/mL stimulating migration of 
BMMSCs. However, 10μg/mL DDM elicited anti-migratory effects on BMMSCs. 
MSCs are able to migrate towards sites of bone fracture, where they differentiate 
and participate in repair of the bone fracture site (Kumagai et al, 2008; Granero-
Moltó et al, 2009; Alm et al, 2010). Although the mechanisms of migration are not 
fully understood, MSC homing is acknowledged to occur through chemokine 
signalling (Honczarenko et al, 2006; Ponte et al, 2007) and hypoxia (Rochefort et al, 
2006). The matrix of dentine is additionally acknowledged as a reservoir of pro-
inflammatory cytokines, including the interleukins (IL-) IL-1α, IL-1β, IL-4, IL-6 and IL-
8 (Graham et al, 2007). Odontoblasts are reported to constitutively express IL-8, 
which can be up-regulated following exposure to E. coli-derived lipopolysaccharide 
(LPS) and it postulated be become sequestered within dentine (Levin et al, 1999). 
Migration of human BMMSCs in vitro is inducible by IL-6 (Rattigan et al, 2010) and 
IL-8 (Anton et al, 2012); and therefore, resident cytokines within DDM may be 
acting as chemotactic agents of BMMSCs. Growth factors, such as TGF-β1, have 
been demonstrated to induce migration of dental papilla-derived cells (Kwon et al, 
2010) and dental pulp-derived, stem cells (DPSCs) (Howard et al, 2010). TGF-β1 is 
additionally a pertinent component of bone matrix, which can induce migration of 
osteoblast-like cells (Pfeilschifter et al, 1990) and BMMSCs; and is postulated to 
couple bone resorption with formation to maintain the balance of bone remodeling 
(Tang et al, 2009). Fibroblast growth factor (FGF) is reported to be present within 
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both bone and dentine matrices (Roberts-Clark and Smith, 2000; Shimizu-Sasaki et 
al, 2003) and has been implicated in stimulating migratory behaviour of dental 
pulp-derived cells (Howard et al, 2010; Shimabukuro et al, 2009). Activation of FGF-
receptor (FGFR) in dental pulp cells has been shown to increase formation of focal 
adhesions and enhance migration (Zhang et al, 2015a), potentially indicating a 
pertinent role for FGF in providing chemotactic stimuli. Furthermore, migratory 
behaviour of pulpal cells is noted to be promoted by dentine sialoprotein (DSP) (Lee 
et al, 2012a) and dentine phosphophoryn (Yasuda et al, 2008); and may additionally 
be responsible for directing migration of BMMSCs. Although components of DDM 
are acknowledged to participate in the promotion of cellular migration, DDM at 
10μg/mL demonstrated the opposite effect. This observation may be as a result of 
DDM providing a chemotactic gradient for which encourages the recruitment of 
cells from a distant location towards the site of implantation. Additionally, higher 
concentrations may be inducing differentiation of BMMSCs, as opposed to 
stimulating migration. 
The application of DDM to BMMSCs demonstrated a dose-dependent effect on the 
reduction of cell expansion over a 4-day incubation period. A decrease in expansion 
was observed for cells cultured with 1μg/mL DDM after 48 h, which was maintained 
up to 96 h, whereas expansion was reduced for cells cultured with DDM at 
0.1μg/mL after 72 h only, compared to controls. However, cell expansion was 
reduced for BMMSCs cultured with 10μg/mL DDM after 24 h in culture, with a 
marked reduction of expansion observed after 96 h. DDM at comparable 
concentrations has been shown to dose-dependently enhance expansion of DPSCs, 
with 10μg/mL providing the greatest effect (Lee et al, 2015). Other studies have 
acknowledged DDM as eliciting an inverse dose-dependent effect on cell expansion, 
identifying lower concentrations as stimulatory and higher concentrations being 
inhibitory for expansion of odontoblast-like cells, pulp-derived cells (Musson et al, 
2010) and endothelial cells (Zhang et al, 2011a). The effects of expansion DDM on 
BMMSCs have been less well studied, although Yu et al, (2014) demonstrated that 
DDM up to 10μg/mL does not affect expansion of BMMSCs, although a reduction is 
noted for cells cultured with DDM at 100μg/mL. However, cells used by Yu et al, 
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(2014), represented an un-purified population and thus, results may differ from 
those demonstrated in this Thesis due to the immature nature of the BMMSCs. 
Demineralised tooth matrix (DTM) has been reported to decrease expansion of 
clonally-derived, BMMSCs, in a dose-dependent manner (Harrington, 2014). Even 
though no concentration of DDM tested in this study enhanced cell expansion, the 
reduction of expansion occurring with DDM in an apparent dose-dependent 
manner, predominantly at 10μg/mL, suggests that this concentration may be 
suppressing expansion and stimulating alternative cell responses. 
The observed effects of DDM attenuating BMMSC expansion may be attributable to 
an inverse relationship of an increase in cell apoptosis or initiation of 
differentiation, whereby differentiation down-regulates proliferation (Stein and 
Lian, 1993). Assessment of the activity of caspase-3/-7 in DDM-treated BMMSCs 
was performed to dismiss the observed reduction in expansion resulting from 
apoptotic activity. Over-conditioning of dentine with EDTA in vitro can decrease 
odontoblast survival (Murray et al, 2000), potentially as a result of over-stimulation 
from TGF-β1 (He et al, 2005). TGF-β1 can also induce apoptosis of BMMSCs by 
stimulating mitochondrial reactive oxygen species (ROS) production (Zhang et al, 
2015b). In addition, apoptosis of osteoblasts occurs at sites of bone fracture and is 
postulated to act as an event coupled with osteoblast proliferation as a regulatory 
mechanism of callus formation and remodelling (Landry et al, 1997; Li et al, 2002), 
with BMP-2 identified as an inducer of osteoblast apoptosis (Haÿ et al, 2001). 
Attenuation of pro-apoptotic signals at bone regeneration sites can prolong matrix 
secretion and ossification, and thus prolong and enhance bone repair (Komatsu et 
al, 2007). 
Culture of BMMSCs with DDM demonstrated a decrease in apoptotic activity 
compared to un-treated cells, with a dose-dependent effect observed. DDM at 5-
10μg/mL has been reported to reduce apoptosis of DPSCs, in addition to reducing 
expression of caspase-3 and increasing expression of Akt-1 (Lee et al, 2015). 
Activation of Akt-1 is reported as one of the principal pathways for encouraging cell 
survival and tolerance of apoptotic stimuli (Song et al, 2005). Platelet-derived 
growth factor (PDGF) has been implicated in activation of Akt-1 and Akt-2 signalling 
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pathways (Romashkova and Makarov, 1999). Recombinant human DSP can activate 
signalling to result in the phosphorylation and activation of Akt-1 in human DPSCs 
(Lee et al, 2012a); and additionally in human cementoblasts, when combined with 
BMP-2 (Lee et al, 2014). High inorganic phosphate, which results from carious 
demineralisation of teeth (Larmas, 2001), reduces viability and increases apoptosis 
of MO6-G3 odontoblast-like cells (Bourgine et al, 2011). However, dentine matrix 
protein-1 (DMP-1) attenuates phosphate-induced apoptosis of odontoblasts 
(Rangiani et al, 2012). Dentine phosphoprotein (DPP) has suppressive activities 
against phosphate-induced apoptosis of odontoblast-like cells (Fujisawa et al, 
2009), in addition to activating Akt in pre-odontoblasts (Eapen and George, 2015). 
When cultured in the presence of 10μg/mL DDM for 28 days, BMMSCs elicited a 
detectable mineralised matrix deposition as indicated by Alizarin red staining. 
DPSCs cultured in the presence of DDM are noted to deposit mineralised matrix 
(Lee et al, 2015), concomitant with the ability of dentine to induce reparative 
matrix production (Smith et al, 1995; Goldberg et al, 2011). The potency of DDM to 
provoke mineral deposition of DPSCs was not explored in this Thesis. However, 
EDTA soluble proteins from whole tooth preparations have been reported to elicit 
less potent in vitro differentiation of MSCs derived from bone marrow and adipose 
tissue, compared to MSCs derived from the dental pulp (Chun et al, 2009). DPSCs 
produce a dense mineralised matrix when cultured in media conditioned with DTM, 
in addition to significantly increased gene expression of OC. Though, clonal 
BMMSCs only develop small and sparse mineralised nodules when cultured with 
comparable concentrations of DTM (Harrington, 2014). The greater potency of DTM 
to induce mineralisation of DPSCs can be potentially attributable to the hierarchical 
model of differentiation potential, whereby a small proportion of heterogeneous 
DPSCs is postulated to consist of highly proliferative, multipotent cells present 
within a larger proportion of progenitors with more restricted lineage commitment 
(Gronthos et al, 2002). Within this Thesis, the osteogenic effects of DDM were 
performed on primitive BMMSCs and thus, the effects of differentiation may be less 
pronounced.  
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10μg/mL DDM was shown to up-regulate gene expression of the early osteogenic 
marker, RunX2, in BMMSCs after 5 days in culture, compared to un-treated cells. As 
a marker of early osteogenic commitment, the ability to up-regulate RunX2 
expression indicates potential for DDM to direct BMMSC differentiation. 
Odontoblastic differentiation and subsequent mineralised nodule production of 
dental pulp-derived cells is additionally associated with an increase in RunX2 
expression (Zhang et al, 2007b; Han et al, 2014). RunX2 expression is associated 
with exit from the cell cycle and osteoblast maturation (Pratap et al, 2003); and 
thus, may be responsible for the decline in expansion observed for BMMSCs 
cultured in the presence of DDM. After 28 days in culture, 10μg/mL DDM increased 
mRNA expression of COL1A1 accompanied with a statistically non-significant 
increase in OC expression, compared to cells cultured in control media. The slightly 
elevated expression of OC in BMMSCs cultured with DDM correlates with the low 
abundance of mineralised matrix detected by Alizarin red staining and hence, 
demonstrates a mild osteoinductive effect in vitro. OPN mRNA expression was 
down regulated in DDM-treated cells, compared to controls. OPN expression is 
acknowledged to peak during early osteogenic differentiation, followed by a 
decrease in expression during later differentiation (Nakamura et al, 2009). 
Therefore, this suggests that BMMSCs in control culture were beginning to increase 
commitment towards the osteoblast lineage as an artefact of increased expansion 
and progression down the lineage hierarchy (as discussed in Chapter 2). 
Furthermore, OPN is reported to inhibit ectopic calcification in vivo and can actively 
block the growth of hydroxyapatite crystals (Steitz et al, 2002). Therefore, down 
regulation of OPN in DDM-treated BMMSCs suggest permission of mineralisation. 
Taken together, the up-regulation of osteogenic markers RunX2, COL1A1 and 
deposition of a mineralised matrix indicates the bioactive nature of DDM for 
directing differentiation of BMMSCs towards the osteoblast lineage, which drives 
the bone repair process. 
This Chapter has demonstrated that supplementation of DDM in vitro can alter 
cellular behaviour of BMMSCs that favours osteogenesis. DDM reduces expansion 
of BMMSCs, whilst not inducing an apoptotic response. However, DDM at 10μg/mL 
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induced differentiation characterised by up-regulation of osteogenic genes and 
deposition of mineralised matrix. DDM was additionally migratory at low 
concentrations. These observed cellular effects largely correlate with the events 
that occur during bone repair, by which undifferentiated can migrate to the site of 
injury and differentiate into cells that can participate in tissue repair by producing a 
mineralised ECM. Collectively, the responses of BMMSCs to DDM indicate high 
potential for augmentation of bone repair. Numerous non-collagenous proteins 
(NCPs) are secreted into dentine, such as DSP/DPP (MacDougall et al, 1997), DMP-1 
(George et al, 1993); and a plethora of growth factors, including TGF-β1, FGF-2, 
PDGF and VEGF (Finkelman et al, 1990; Roberts-Clark and Smith, 2000). Subsequent 
Chapters in this Thesis have investigated some of these proposed bioactive 
components of DDM and elucidate their role in directing the process of bone repair. 
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Chapter 4 - Determination of Bioactive Constituents in 
Demineralsed Dentine Matrix (DDM) for Directing Biological Activity 
of Bone Marrow-Derived, Mesenchymal Stem Cells (BMMSCs) 
 
4.1 Introduction 
The process of mineralised tissue formation and repair constitutes a complex 
cascade of events that ultimately lead to the functional production and 
regeneration of tissue, respectively. Amongst other elements, growth factors are 
fundamental mediators in coordinating development and regeneration of bone and 
teeth. Although not exhaustive, the growth factors transforming growth factor- β1 
(TGF-β1) (Bostrom and Asnis, 1998), bone morphogenetic proteins (BMPs) BMP-2, 
BMP-4, BMP-7 (Lian et al, 2006), fibroblast growth factor (FGF) (Naganawa et al, 
2006) and vascular epidermal growth factor (VEGF) (Gerber et al, 1999), are 
instrumental in the regulation of bone. Moreover, TGF-β1 (Tziafas et al, 1998), BMP-
2 (Casagrande et al, 2010) and BMP-7 (Six et al, 2002), are implicated in possessing 
roles for mediating reparative dentine formation.  
Although growth factors present within bone and dentine matrix are acknowledged 
as potent cell signalling molecules, additional proteins present in both matrices are 
proposed to participate in modulation of growth factor activity. Of note, biglycan 
and decorin are reported to bind to TGF-β1 (Hildebrand et al, 1994; Baker et al, 
2009), in addition to type I collagen (Schönherr et al, 1995; Svensson et al, 1995). 
Biglycan and decorin are hypothesised to sequester growth factors within the 
matrix and therefore, modulate their availability (Hildebrand et al, 1994; Baker et 
al, 2009). 
Heparin is a highly sulphated glycosaminoglycan (GAG) with alternatively modified 
sulphation patterns which can recognise specific structures (Ashikari-Hada et al, 
2004). Sulphated heparin and is able to bind a wide variety of growth factors, 
including TGF-β1 (McCaffrey et al, 1992), BMP-2 (Ruppert et al, 1996), FGF-2 and 
platelet-derived growth factor (PDGF) (Rajesh et al, 1995). The mechanism for 
growth factor binding is proposed to be a result of electrostatic interactions 
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between negatively charged sulphate groups and positively charged amino acids on 
proteins (Jeon et al, 2011). Heparin-affinity has successfully been exploited to 
isolate growth factors from bone matrix, with the isolated factors demonstrating 
bioactivity with regards to proliferation of endothelial cells and mitogenic potential 
for osteoblasts (Hauschka et al, 1986). 
Even though numerous growth factors have been identified in dentine matrix, no 
study has determined the concentrations of a range of osteogenic inducing factors 
and thus, the ratios of specific factors within the matrix that are postulated to 
contribute towards mineralised tissue repair is yet to be elucidated. Methods used 
in this Chapter quantified the abundance of a panel of potent osteogenic growth 
factors within a demineralised dentine matrix (DDM) preparation, using enzyme-
linked immunosorbent assays (ELISAs), thus revealing the optimal physiological 
ratios of these factors anticipated to orchestrate the induction of mineralised tissue 
formation. To determine whether these growth factors possess potency when 
isolated from dentine, growth factors were depleted from DDM via heparin-affinity 
chromatography and responses of bone marrow-derived, mesenchymal stem cells 
(BMMSCs) to fractionated DDM reassessed and compared to un-fractionated DDM. 
Critically, experimental procedures within this Chapter aimed to clarify a 
requirement for additional factors in regulating cellular responses to growth 
factors. 
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4.2 Materials and Methods 
4.2.1 DDM Sample Preparation 
DDM was obtained from human teeth, as previously described (Section 3.2.1.2). 
DDM was reconstituted in deionised distilled H2O (ddH2O) to an anticipated 
concentration of approximately 1mg/mL, mixed by vortex for 30 s and sterile-
filtered through a 0.22μm syringe filter (Millipore, USA). DDM solution was assayed 
for protein concentration, using a Pierce® BCA Protein Assay Kit (Thermo Fisher 
Scientific, USA) as previously described (Section 3.2.1.3). Aliquots of known 
concentration of DDM solution were pipetted into sterilised 1.5mL tubes 
(Eppendorf, UK), frozen at -80°C and lyophilised.  
4.2.2 Protein Separation with Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
2x Laemmli Sample Buffer (65.8mM tris-hydrochloride (Sigma-Aldrich, UK); pH 6.8, 
2.1% sodium dodecyl sulphate (SDS) (Fisher Scientific, UK), 26.3% (w/v) glycerol 
(Fisher Scientific), 0.01% bromophenol blue (Sigma-Aldrich)) (BioRad Laboratories, 
USA) was supplemented with 2-mercaptoethanol (Sigma-Aldrich) at 5% (v/v) and 
diluted 1:1 with ddH2O to generate 1x Laemelli Sample Buffer. DDM was 
reconstituted in 1x Laemmli Sample Buffer at a concentration of 0.67μg/μL (for 
silver staining, Section 4.2.2.1) or 2μg/μL (for protein electroblotting, Section 
4.2.2.2). DDM/Laemmli Buffer was heated to 95°C for 5 min and 15μL loaded into 4-
15% Mini Protean TGX pre-cast gels (BioRad Laboratories), alongside 7.5μL of 
Kaleidoscope Precision Plus Pre-Stained Protein Standards (BioRad Laboratories). 
Gels were placed into Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (BioRad 
Laboratories) in 10x SDS-PAGE running buffer (250mM tris-base (Sigma-Aldrich), 
1.92M glycine (Fisher Scientific), 1% SDS, pH 8.3), diluted to a 1x working 
concentration in ddH2O. Proteins were separated by electrophoresis at 200V for 30-
35 min, until the migration front reached the bottom of the gel. 
4.2.2.1 Silver Staining 
Silver staining was performed using a Silver Stain Plus™ kit (BioRad Laboratories), 
following manufacturer protocol. The SDS-PAGE gel was removed from casts and 
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placed in fixative solution (50% v/v methanol (Fisher Scientific), 10% v/v acetic acid 
(Fisher Scientific), 1% v/v Fixative Enhancer Concentrate, 30% v/v ddH2O) with 
gentle agitation for 20 min. The fixed gel was washed twice with 400mL ddH2O for 
10 min per wash. Staining solution was prepared by adding 5mL Silver Complex 
Solution, 5mL Reduction Moderator Solution and 5mL Image Development Reagent 
to 35mL ddH2O, with gentle stirring followed by addition of 50mL Development 
Accelerator Solution to Staining solution. The gel was placed in staining solution 
with gentle agitation for around 20 min until desired staining intensity was 
achieved. Staining reaction was stopped by placing the gel in 5% v/v acetic acid for 
15 min with a final wash in ddH2O for 5 min. The gel was imaged with a Gel Doc EZ 
System (BioRad Laboratories).  
4.2.2.2 Protein Electrobloting 
Gels used for protein electroblotting were removed from casts and soaked in 
transfer buffer (25mM tris-base, 192mM glycine, 20% (v/v) methanol, pH 8.3) for 10 
min. Two electroblot sponges, two sheets of thick blot filter paper (BioRad 
Laboratories) and nitrocellulose membrane (GE Healthcare, UK), were additionally 
soaked in transfer buffer for 5 min. One electroblot sponge was placed onto the 
back plate of a blotting module, followed by one sheet of filter paper, the TGX gel 
containing the proteins separated by electrophoresis, nitrocellulose membrane and 
a sheet of filter paper and finally the remaining electroblot sponge, thereby 
preparing an electroblot ‘sandwich’. The blotting module was clamped shut and 
placed into the Mini-PROTEAN® Tetra Vertical Electrophoresis Cell and transferred 
at 100V constant for 1 h. Protein transfer was confirmed by staining of the 
nitrocellulose with Ponceau Red S stain for 5 min, followed by de-staining in tris 
buffered saline (TBS) by repeated washing. 
4.2.2.3 Immunoblotting for Protein Detection 
Membranes were cut to size and placed into 50mL tubes (Sarstedt, UK). Non-
specific binding sites were blocked in 5% w/v non-fat dry milk (Tesco, UK), in TBS 
supplemented with 0.05% Tween-20 (Sigma-Aldrich) (TBS-T) solution for 1 h at 
room temperature, with gentle agitation. Membranes were transferred to blocking 
buffer solution with primary antibodies, as outlined in Table 4.1; and incubated 
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overnight at 4°C, with gentle agitation. Membranes were washed four times for 5 
min each in TBS-T, transferred to blocking buffer with respective secondary 
antibodies and incubated for 1 h at room temperature, as outlined in Table 4.1. 
Membranes were washed four times for 5 min each in TBS-T, with two additional 5 
min washes in TBS. Membranes were treated ECL Reagent (GE Healthcare) for 3 
min, sandwiched in development pouches and exposed to X-ray development film 
(GE Healthcare). 
Negative controls were performed by incubating primary antibodies with 10X 
excess of respective blocking peptide for 1 h at room temperature, prior to protein 
detection. Blocking peptides are listed in Table 4.1. 
To determine the molecular weight of proteins detected by silver 
staining/immunoblotting, the relative migration of the protein/band of interest was 
measured and compared to the calculated standard curve for the (Log) relative 
migration of molecular weight standards. 
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Primary 
antibody (Ab) 
Primary Ab 
Dilution 
Secondary Ab Secondary Ab 
dilution 
Blocking 
peptide 
TGF-β1 (V) -   
Santa Cruz 
(USA) 
1:200 Anti-rabbit 
HRP 
1:25,000 TGF-β1 (V) - 
Blocking 
Peptide  
Santa Cruz 
BMP-2 (N-14) 
- Santa Cruz 
1:500 Anti-goat HRP 1:50,000 BMP-2 (N-14) - 
Blocking 
Peptide 
Santa Cruz 
VEFG (A-20) - 
Santa Cruz 
1:200 Anti-rabbit 
HRP 
1:25,000 VEFG (A-20) – 
Blocking 
Peptide  
Santa Cruz 
 
Table 4.1 – Detailing antibodies and respective dilutions/blocking peptides used for protein 
electroblotting of DDM. 
4.2.3 ELISA Quantification of Growth Factors in DDM 
4.2.3.1  TGF-β1 
Determination of TGF-β1 concentration in DDM was performed using a Human TGF-
β1 Platinum ELISA kit (eBioscience, UK), according to manufacturer’s instructions. 
Standards, blanks and samples were assayed in duplicate. Incubation steps were 
performed at room temperature on a plate shaker at 400rpm, unless otherwise 
stated. 20µL of DDM samples were pipetted into 1.5mL tubes (Eppendorf) and 
mixed with 180µL of 1x Assay Buffer and 20µL of 1N hydrochloric acid (HCl) 
followed by 1 h incubation without shaking. Samples were neutralised with 20µL of 
1N sodium hydroxide (NaOH). TGF-β1 Standard supplied within the Kit was 
reconstituted in ddH2O to prepare a 4,000pg/mL stock, with working standards 
ranging from 2,000pg/mL to 31pg/mL prepared by serial dilution in 1x Assay Buffer. 
1x Assay Buffer served as a blank. 60µL of 1x Sample Buffer was added to sample 
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wells, followed by 40µL of pre-treated sample of each sample group in duplicate. 
Micro-wells were sealed with adhesive film and incubated for 2 h. Samples and 
standards were aspirated, micro-wells washed four times with 400µL of 1x Wash 
Buffer, followed by addition of 100 µL of pre-prepared 1x Biotin Conjugate to each 
well. Micro-wells were sealed and incubated for 2 h. Biotin Conjugate was aspirated 
and micro-wells washed, as previous. 100µL of pre-prepared 1x Streptavidin-HRP 
was added to each micro-well and incubated for 1 h. Streptavidin-HRP was 
aspirated and micro-wells washed as previous, followed by addition of 100µL of 
TMB Substrate Solution to each well. Micro-wells were incubated in the dark for 30 
min without shaking, followed by addition of 100µL of Stop Solution. Absorbance at 
450nm was read using a FluoSTAR OMEGA Plate Reader (BMG Labtech, Germany). 
Assay was performed on two separate occasions. 
4.2.3.2  Insulin-Like Growth Factor-1 (IGF-1) 
Determination of Insulin-like Growth Factor-1 (IGF-1) concentration in DDM was 
performed using a Human IGF-1 Quantikine® ELISA Kit (R&D Systems, UK) according 
to manufacturer’s instructions. IGF-1 Standard was reconstituted in 1ml of ddH20 to 
create a 60ng/mL stock. 360µL of Calibrator Diluent RD5-22 was pipetted into a 
1.5mL tube (Eppendorf). 200µL of Calibrator Diluent was added to six additional 
1.5mL tubes (Eppendorf). 40µL of 60ng/mL stock IGF-1 was added to the tube 
containing 360µL of Calibrator Diluent RD5-22 and thoroughly mixed to generate a 
6ng/mL standard. Additional standards were prepared by subsequent 1:1 dilutions 
with Calibrator Diluent RD5-22 to a concentration of 0.094ng/mL IGF-1. Calibrator 
Diluent RD5-22 served as a blank. 150µL of Assay Diluent RD1-53 was pipetted into 
all micro-wells. 50µL of each standard and sample was added to wells in triplicate 
and thoroughly mixed. Micro-well strips were sealed with adhesive film and 
incubated for 2 h at 4°C. Micro-wells were aspirated and washed four times with 
400µL of 1x Wash Buffer, with gentle tapping against clean paper towel after the 
last wash step. 200µL of IGF-1 Conjugate (at 4°C) was added to each well, micro-
well strips were sealed with adhesive film and incubated for 1 h at 4°C. Micro-wells 
were aspirated and washed, as previous. 200µL of Substrate Solution was added to 
each well and incubated at room temperature in the dark for 30 min. 50µL of Stop 
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Solution was added to each well and absorbance at 450nm for primary wavelength 
(540nm as reference wavelength), was read using a FluoSTAR OMEGA Plate Reader 
(BMG Labtech). Assay was performed on two separate occasions. 
4.2.3.3 BMP-4 and BMP-7 
Determination of BMP-4 and BMP-7 in human DDM was performed using Human 
BMP-4 and Human BMP-7 ELISA Kits, respectively (Sigma-Aldrich), following 
manufacturer’s instructions. Incubations were performed at room temperature on 
a plate shaker at 100rpm unless otherwise stated. The following steps were carried 
out individually for each Kit. 5x Assay Diluent B was diluted 5-fold with ddH2O to 
prepare 1x Assay Diluent B. BMP-4/BMP-7 Standards were reconstituted in 400µL 
of 1x Assay Diluent B, to prepare a 50ng/mL stock standard. 80µL of 50ng/mL 
standard was thoroughly mixed with 586.7µL of Assay Diluent B, to prepare a 
6,000ng/mL standard. Subsequent standards down to 8.23pg/mL were prepared by 
serial dilution of 6,000ng/mL in 1x Assay Diluent B. 1x Assay Diluent B served as 
blank. 100µL of each standard and sample was added to micro-wells in triplicate, 
sealed with adhesive film and incubated for 2.5 h. During incubation, Biotinylated 
Detection Antibody was reconstituted in 100µL of Assay Diluent B and diluted 65-
fold (BMP-4) or 80-fold (BMP-7), respectively, with 1x Assay Diluent B. Micro-wells 
were aspirated and washed four times with 300µL of 1x Wash Buffer, with gentle 
tapping of micro-wells onto clean paper towel after the final wash. 100µL of 
Biotinylated Detection Antibody was added to each well, which were sealed and 
incubated for 1 h. Wells were aspirated and washed, as previous. HRP-Streptavidin 
was diluted 80-fold (BMP-4) and 400-fold (BMP-7), respectively, with 1x Assay 
Diluent B; with 100µL being added to each well and incubated for 30 min. Micro-
wells were aspirated and washed, as previous; and 100µL of ELISA Colorimetric TMB 
Reagent added to each well and incubated in the dark for 30 min. 50µL of Stop 
Solution was added to each well and absorbance at 450nm was read using a 
FluoSTAR OMEGA Plate Reader (BMG Labtech). Assays were performed on two 
separate occasions. 
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4.2.3.4 BMP-2, VEGF, PDGF-BB and FGF-2 
Determination of BMP-2, VEGF, PDGF-BB and FGF-2 in human DDM was performed 
using respective Human Mini ELISA Kits (PeproTech, USA), following manufacturer’s 
instructions. Buffers used were obtained from an ELISA Buffer Kit (PeproTech). The 
following steps were carried out individually for each Kit. Incubations were 
performed at room temperature. Capture Antibody was reconstituted in ddH2O to a 
concentration of 100µg/mL. Capture Antibody was diluted to a working 
concentration of 0.5µg/mL in 1x Phosphate Buffered Saline (PBS), 100µL added to 
each well of a 96-well plate (PeproTech), sealed and incubated overnight. Wells 
were aspirated and washed four times with 300µL of 1x Wash Buffer, followed by 
gentle tapping against a clean paper towel. 1x Block Buffer was sterile filtered using 
a syringe and 0.22µM pore filter (Millipore), prior to addition of 300µL per well. The 
plate was sealed with adhesive film and incubated for 1 h. During incubation, 
Recombinant Standard was reconstituted in ddH2O to a stock concentration of 
1µg/mL. Recombinant Standards were diluted to concentrations of 4,000pg/mL 
(FGF-2), 2,000pg/mL (BMP-2) and 1,000pg/mL (VEGF and PDGF-BB) in 1x Diluent. 
200µL of diluted stock standards were added to wells in triplicate.  Wells were 
aspirated and washed as previous. 100µL of each standard, in triplicate, was serially 
diluted with 1:1 with 100µL 1x Diluent down to concentrations of 62.5ng/mL (FGF-
2), 31.25ng/mL (BMP-2) and 15.63ng/mL (VEGF and PDGF-BB). 1x Diluent served as 
a blank. 100µL of each standard/sample was added to wells in triplicate; the plate 
was sealed with adhesive film and incubated for 2 h. Wells were aspirated and 
washed as previous. Detection antibody was diluted to a working concentration of 
1µg/mL (BMP-2) or 0.25µg/mL (VEGF, FGF-2 and PDGF-BB) in 1x Diluent. 100µL of 
respective detection antibody was added to each well, the plate sealed and 
incubated for 2 h. Welld were aspirated and washed as previous. Avidin-HRP 
Conjugate was diluted 1:2,000 with 1x Diluent, 100µL was added to each well and 
plates were incubated for 30 min. Wells were aspirated and washed as previous, 
followed by addition of 100µL of ABTS Liquid Substrate to each well. Plates were 
incubated at room temperature for 25 min (FGF-2), 35 min (BMP-2 and VEGF) or 50 
min (PDGF-BB); and absorbance determined at 405nm for primary wavelength 
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(650nm for reference wavelength) using a FluoSTAR OMEGA Plate Reader (BMG 
Labtech). Assays were performed on two separate occasions. 
4.2.3.5 Determination of Growth Factor Concentrations from ELISAs 
For each assay, absorbance (for IGF-1, BMP-2, VEGF, PDGF-BB and FGF-2 assays, net 
absorbance readings were obtained by subtracting the reference wavelength from 
the primary wavelength) was plotted against standard concentrations. A standard 
curve to the polynomial of 3 was plotted between the points to generate a line of 
best fit with Microsoft® Excel® 2010. A R2 value of >0.95 indicated sufficient 
correlation of the standard dilutions against absorbance. Absorbance values from 
the samples within the standard curve range were plotted against respective 
standard curves to obtain concentration values of growth actors within DDM. All 
values were scaled up to total abundance of growth factor per mg of DDM. 
4.2.4 Fractionation of Heparin-Binding DDM Components via Affinity 
Chromatography 
Growth factors in DDM were fractionated by affinity chromatography using a 
Heparin HiTrap column (GE Healthcare), using a protocol adapted from Hauschka et 
al (1986). DDM was reconstituted in 30mL of binding buffer (0.01M tris-
hydrochloride/0.1M sodium chloride (NaCl) (pH 7) in 18.2MΩ water); and sterile 
filtered through a 0.22µm pore syringe filter (Millipore). Protein concentration was 
determined using a Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific), as 
described previously (Section 3.2.1.3). Heparin-affinity chromatography was 
performed, using AKTA Purifier apparatus controlled by Unicorn Software (GE 
Healthcare, v5.2). The system was washed in 20% (v/v) ethanol and pumped with 
18.2MΩ water during connection of the Heparin HiTrap column. AKTA apparatus 
was equilibrated in binding buffer to determine baseline of conductivity and 280nm 
absorbance. DDM reconstituted in binding buffer at approximately 120μg/mL in 
15mL was applied through the HiTrap column at a rate of 1mL/min, with flow 
through (FT) collected in 5mL fractions. DDM components bound to the column 
were eluted by a linear gradient increase of increasing NaCl concentration from 0.1-
3M over twelve column volumes, at a rate of 2mL/min. Elution volumes were 
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collected in 2.5mL fractions and subsequently pooled into two elution pools (EL1 
and EL2). 
Flow through and elution pools were transferred to 12,000Da molecular weight cut-
off (MWCO) dialysis tubing (Sigma-Aldrich) and dialysed against ddH20 for 2 days at 
4°C, with continuous agitation and dialysis solution changed thrice daily. Dialysed 
fraction pools were frozen at -80°C and lyophilised. Lyophilised fractions were re-
suspended in TBS, weighed for volume determination and protein concentration 
assayed using a Pierce® BCA Protein Assay Kit (Thermo Fisher Scientific), as 
described previously (Section 3.2.1.3). Fractions were pipetted into aliquots and 
stored at -20°C. 
4.2.4.1  ELISA Analyses of Growth Factors Heparin-Fractionated DDM 
Concentrations of abundant growth factors in heparin-purified DDM fractions and 
whole DDM were determined. Briefly, samples of each heparin-purified fraction 
were examined for concentrations of TGF-β1 and BMP-2, using ELISAs as described 
previously (Sections 4.2.3.1 and 4.2.3.4, respectively). Total abundance of TGF-β1 
and BMP-2 in each fraction was calculated using determined volume, as described 
previously (Section 4.2.3.5). 
4.2.4.2 Detection of Biglycan and Decorin in Un-fractonated DDM and FT 
Fraction 
Aliquots of un-fractionated DDM and FT fraction were lyophilised and underwent 
SDS-PAGE, protein electroblotting and protein detection, as described previously 
(Sections 4.2.2 and 4.2.2.2-4.2.2.3). Antibodies used for protein detection are listed 
in Table 4.2. 
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Primary 
antibody (Ab) 
Primary Ab 
Dilution 
Secondary Ab Secondary Ab 
dilution 
Blocking 
peptide 
Biglycan (L-15) - 
Santa Cruz 
1:500 Anti-goat HRP 
(sc-2020) – 
Santa Cruz 
1:50,000 Biglycan (L-15) 
Blocking 
Peptide - 
Santa Cruz 
Decorin (N-15) -  
Santa Cruz 
1:300 Anti-goat HRP 
(sc-2020) – 
Santa Cruz 
1:50,000 Decorin (N-15) 
Blocking 
Peptide -  
Santa Cruz 
 
Table 4.2 – Detailing antibodies and respective concentrations/blocking peptides for 
detection of biglycan and decorin in un-fractionated and FT of heparin-purified DDM.  
 
4.2.5 Expansion of BMMSCs Cultured with Heparin-Fractionated DDM  
For subsequent analyses of biological effects of heparin-fractionated DDM, 
concentrations of fractions applied to BMMSCs were proportional comparative to 
the percentage of total recovered protein, relative to 10μg/mL of un-fractionated 
DDM. 
Expansion of BMMSCs cultured with heparin-fractionated DDM was performed 
using modified protocol of the previously described thiazolyl blue tetrazolium blue 
(MTT) assay (Section 3.2.2). Briefly, BMMSCs (15.2-16.8 population doublings, PDs) 
were seeded into triplicate wells of a 96-well plate (Sarstedt) at 4x103cells/cm2 in 
5% FBS (Invitrogen, UK) culture media, conditioned with heparin-fractionated DDM 
fractions. Cells cultured in un-conditioned media served as a control. At each time 
point, 20μL of media was aspirated from each well and replaced with 20μL of sterile 
filtered MTT solution (5mg/mL in PBS). Plates were incubated and processed, as 
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described previously (Section 3.2.2). Experiments were performed on five separate 
occasions. 
4.2.6  Osteogenic Induction Ability of Heparin-Fractionated DDM 
Osteogenic gene expression of BMMSCs over 2 and 5 days cultured heparin-
fractionated DDM fractions was performed, as described previously (Section 3.2.6). 
Briefly, BMMSCs (15.2-16.8 PDs) were seeded into 6-well or 12-well culture plates 
(Sarstedt) at 104 cells/cm2, in media supplemented with heparin-fractionated DDM, 
or basal media (negative control). RNA was extracted using an RNeasy Mini Kit 
(Qiagen, Germany) (Section 2.2.3), converted to cDNA (Section 2.2.4) and 
quantitative real time-polymerase chain reaction (q-PCR) analysis (Section 3.2.6), 
performed for RunX2. GAPDH was used as an internal housekeeping gene for 
normalisation of data. Primer sequences are detailed in Table 3.2.1. Experiments 
were performed on three separate occasions. 
4.2.6.1  Mineral Deposition Analysis of BMMSCs Cultured with Heparin-
Fractionated DDM 
Mineral deposition of BMMSCs cultured with heparin-fractionated DDM and 
subsequent Alizarin red staining was performed, as described previously (Sections 
3.2.5 – 3.2.5.1). Briefly, BMMSCs (15.2-16.8 PDs) were seeded into 24-well culture 
plates (Sarstedt) at 104 cells/cm2, in media supplemented with heparin-fractionated 
DDM, osteogenic induction media (positive control) or basal media (negative 
control); and cultured for 28 days. Cells were fixed and stained with 2% Alizarin red 
(Sigma-Aldrich). Stained cells were photographed under light microscopy, using a 
Panasonic DMC-G1 Camera. Experiments were performed on three separate 
occasions. 
4.2.6.2  Quantification of Alizarin Red Staining 
Quantification of Alizarin red staining was performed, using a protocol adapted 
from Gregory et al (2004). Stained cells were incubated with 200µL per well of 10% 
(v/v) acetic acid (Fisher Scientific), for 30 min at room temperature on an orbital 
shaker at 75rpm. Cell monolayers were transferred with the acetic acid to a 1.5mL 
tubes (Eppendorf). Samples were mixed by vortex for 30 s and incubated at 85°C for 
92 
 
10 min. Samples were cooled on ice for 5 min, followed by centrifugation at 
17,000g for 15 min. 125µL of supernatant was transferred to a fresh 1.5mL tube 
(Eppendorf); and neutralised with 50µL of 10% (v/v) ammonium hydroxide (Sigma-
Aldrich). 50µL of each neutralised sample was pipetted into an optically clear, white 
walled 96-well plate (Corning, USA) in triplicate. Absorbance at 425nm was read 
using a FluoSTAR OMEGA Plate Reader (BMG Labtech). 
4.2.7 Statistical Analyses 
Statistical analyses were performed utilising One-Way ANOVA with a post-hoc 
Tukey test, using GraphPad InStat 3 (v3.06). Statistical values were defined as 
significant (*, P<0.05), very significant (**, P<0.01) or extremely significant (***, 
P<0.001). 
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4.3 Results 
4.3.1 Separation Profile of DDM with Silver Stain 
The protein separation profile of DDM via SDS-PAGE and silver staining indicated a 
wide variety of protein components, ranging from around 250 kDa to 6 kDa. Three 
distinct protein bands were present, with apparent molecular weights of 80 kDa, 70 
kDa and 50 kDa (Figure 4.1).  
 
 
 
Figure 4.1 - Profile of proteins in DDM separated by SDS-PAGE. Three distinct bands 
are present at 50 kDa, 70 kDa and 80 kDa (white arrows), amongst an array of 
additional proteins. 10μg sample loaded. L = Ladder, S = Sample. Silver staining was 
repeated once. 
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4.3.2 Western Blot Analyses of Growth Factors in DDM 
Western blot analyses identified the presence of TGF-β1, BMP-2 and VEGF in DDM. 
Apparent molecular weights were around 50 kDa for each growth factor. Pre-
incubation of primary antibodies used for protein blotting with respective blocking 
peptides resulted in an abolishment of signal, thus determining antibody specificity 
(Figure 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 - Western blot analyses for presence of growth factors within DDM. 
Positive signals were identified for TGF-β1, BMP-2 and VEGF. However signals 
were abolished when incubating primary antibodies with respective blocking 
peptides (BP). Western blots were repeated once. 
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4.3.3 ELISA Analyses of Growth Factor Concentrations in DDM 
Quantification of a range of growth factors within DDM revealed TGF-β1 as the 
most abundant factor, representing 11.3ng/mg. FGF-2, BMP-2, PDGF and VEGF 
demonstrated intermediate abundance at concentrations of 5.9ng/mg, 5.2ng/mg, 
4.7ng/mg and 3.7ng/mg, respectively. IGF-1, BMP-4 and BMP-7 constituted the 
lowest abundant factors, measuring concentrations of 1.6ng/mg, 120pg/mg and 
716pg/mg, respectively (Figure 4.3). 
 
 
Growth factor Abundance (ng/mg of DDM) 
TGF-β1 11.3 
VEGF 3.7 
BMP-2 5.2 
IGF-1 1.6 
FGF 5.9 
PDGF 4.7 
BMP-4 0.12 
BMP-7 0.72 
 
 
Figure 4.3 - Graph and table representing the absolute concentrations of osteogenic growth 
factors present within DDM. Error bars represent ±SD (n=2). 
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4.3.4 DDM Fractionation Heparin-Affinity Chromatography 
DDM was fractionated by heparin-affinity chromatography to isolate heparin-
binding components. Fractions A1-A6 contained unbound constituents of DDM and 
was denoted flow-through (FT). Upon application of elution buffer application, a 
small absorption peak was observed in fractions A7-A9, followed by a smooth tail-
off of absorption from fractions A10-B11. Based on the chromatogram profile, 
fractions A7-A9 and A10-B11 were pooled and denoted elution pool 1 (EL1) and 
elution pool 2 (EL2), respectively (Figure 4.4). 
 
 
Figure 4.4 - Representative chromatogram for DDM separated via heparin-affinity FPLC. 
The initial large peak (FT) related to unbound DDM and constituted the flow through (FT) 
fraction. A smaller peak (EL1) was present after the increasing gradient of eluent buffer was 
applied, with a smooth tail off of absorbance presented up to 100% eluent buffer 
application (EL2). Additional FPLC runs yielded identical chromatogram profiles. 
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4.3.4.1 Protein Recovery from Heparin-Fractionated DDM 
A bicinchoninic acid (BCA) assay was performed to determine the concentrations of 
proteins of total loaded and heparin-purified DDM fractions, with abundance 
calculated from the mass of respective fractions. Relative to total DDM applied 
through heparin-affinity chromatography, over 95% of protein was recovered in all 
fractions. 79.9% of recovered protein was present in FT fraction and represents 
components that did not bind to heparin. EL1 contained 8.8% of total recovered 
protein and the remaining 6.9% was present in EL2 (Figure 4.5). 
 
 
Figure 4.5 - Graph representing abundance of protein present in pre-fractionated DDM and 
subsequent heparin-purified DDM pools, as determined by BCA protein assay. Overall 
recovery of total protein from heparin-fractionation was over 95%. FT constituted 79.9% of 
recovered protein, whereas EL1 and EL2 contributed to 8.8% and 6.9% of recovered 
protein, respectively (n=1). 
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4.3.4.2 ELISA Analyses of TGF-β1 and BMP-2 in Heparin-Fractionated DDM 
ELISA analyses of TGF-β1 and BMP-2, growth factors known to be in high abundance 
in DDM, were performed to assess the degree of growth factor purification within 
heparin-fractionated DDM, relative to un-fractionated DDM. Neither TGF-β1 nor 
BMP-2 was completely depleted from DDM via heparin-affinity chromatography. 
Around 75% of TGF-β1 was depleted from DDM, with approximately 40% eluted 
into fraction EL2. Around 25% of BMP-2 was isolated from DDM with approximately 
7% recovered in EL1 and 1.5% in EL2 (Figure 4.6). 
 
 
Figure 4.6 - Graph representing the relative abundance of TGF-β1 and BMP-2 in heparin-
fractionated DDM, compared to un-fractionated DDM. Around 75% of TGF-β1 was depleted 
from DDM in the FT fraction, with 3% present in EL1 and 41% present in EL2. Around 25% 
of BMP-2 was depleted from DDM in the FT fraction, with 7% in EL1 and 1.5% in EL2 (n=1). 
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4.3.4.3  Western Blot Identification of Biglycan and Decorin in Un-Fractionated 
DDM and FT Fraction 
Western blot analyses for the immuno-detection of biglycan and decorin were 
performed for un-fractionated DDM and FT fraction, to determine the potential for 
growth factor binding. Distinct banding was present for biglycan (BGN) and decorin 
(DEC) core proteins, at around 50kDa and 48kDa, respectively. Additional banding, 
up to 250kDa and 200kDa was detected for biglycan and decorin, respectively, 
indicative of glycosylated protein. Pre-incubation of the primary antibodies with 
respective blocking peptide (BP) resulted in abolished protein detection (Figure 
4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 - Western blot analyses for biglycan (BGN) and decorin (DEC) in un-
fractioanted and FT fraction of DDM. Distinct bands representative of core proteins 
present at an apparent 50 kDa (BGN) and 48 kDa (DEC). No bands were observed 
when primary antibodies are pre-incubated with respective blocking peptides. 30μg 
total protein loaded. Western blots were repeated once. 
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4.3.5 Expansion of BMMSCs Cultured with Heparin-Fractionated DDM 
After 4 days in culture, expansion of BMMSCs cultured with un-fractionated DDM 
was reduced, compared to un-treated cells (P<0.01). Expansion of cells cultured 
with FT fraction was unchanged, compared to un-fractionated DDM, however, was 
lower than compared with un-treated cells (P<0.05). Expansion of cells cultured 
with EL1 fraction was higher than cells cultured with un-fractionated DDM (P<0.01), 
however, was unchanged compared with un-treated cells. No change in expansion 
was observed for cells cultured with EL2 fraction, compared with un-fractionated 
DDM or with un-treated cells (Figure 4.8). 
 
 
Figure 4.8 - Graph representing BMMSC expansion when cultured with heparin-
fractionated DDM. Cell expansion was lower for BMMSCs cultured with un-fractionated 
DDM and FT, fraction compared with un-treated cells. Expansion was greater for cells 
cultured with EL1 fraction compared with cells cultured with un-fractionated DDM. Error 
bars represent ±SD (n=5). * = P < 0.05, ** = P < 0.01, *** = P < 0.001. 
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4.3.6 RunX2 Expression by BMMSCs Cultured with Heparin-Fractionated DDM 
After 2 days in culture, RunX2 gene expression was down-regulated in BMMSCs 
cultured with FT fraction relative to un-fractionated DDM (P<0.05). RunX2 
expression of BMMSCs was not changed when cultured in any DDM fraction 
relative to un-treated cells. After 5 days, RunX2 expression was up-regulated for 
BMMSCs cultured in un-fractionated DDM, relative to cells cultured with FT (P 
<0.05), EL1 (P < 0.01) and EL2 (P < 0.01) fractions, in addition to un-treated cells (P < 
0.01). FT, EL1 and EL2 had no effect on RunX2 expression, compared with un-
treated BMMSCs (P > 0.05) (Figure 4.9). 
 
 
Figure 4.9 - Expression of RunX2 in BMMSCs cultured with heparin-fractionated DDM after 
2 and 5 days. No DDM fraction provoked an up-regulation of RunX2, compared with un-
treated cells after 2 days. However, un-fractionated DDM significantly up-regulated RunX2, 
expression relative to all other test groups after 5 days. Error bars represent ±SD (n=3). * = 
P < 0.05, ** = P < 0.01. 
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4.3.7 Alizarin Red Staining of BMMSCs Cultured with Heparin-Fractionated DDM 
After 28 days in culture, BMMSCs cultured with heparin-fractionated DDM were 
fixed and stained with Alizarin red, to highlight mineral deposition. BMMSCs 
cultured with un-fractionated DDM deposited small and sparse mineralised 
deposits. No prominent mineralised nodules were observed for cells cultured with 
FT, EL1 or EL2 fractions, or un-treated cells. BMMSCs cultured in osteogenic media 
produce numerous and large mineralised nodules, which stain readily with Alizarin 
red (Figure 4.10). 
  
 
 
 
 
 
 
 
 
 
Figure 4.10 - Micrograph images of BMMSCs stained by Alizarin red for mineral 
deposition analysis after 28 days in culture. BMMSCs cultured with un-fractionated DDM 
produce scarce mineralisation (white arrow). No visible mineralised nodule staining is 
evident for BMMSCs cultured with FT, EL1 or EL2 fractions, or un-treated cells. White 
bars represent 100μm. 
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4.3.7.1 Quantification of Alizarin Red Staining 
As a more sensitive method of determining the degree of Alizarin red staining of 
BMMSCs cultured with DDM fractions, the stain was quantified using spectroscopy. 
Alizarin red staining was up-regulated for BMMSCs cultured with un-fractionated 
DDM compared with BMMSCs cultured with all heparin-fractionated DDM 
(P<0.001). Increased Alizarin red staining was identified in FT (P<0.05), EL1 (P<0.05) 
and EL2 (P<0.001) treated BMMSCs compared to un-treated cells (Figure 4.11). 
 
Figure 4.11 - Graph representing intensity of Alizarin red staining of BMMSCs cultured with 
DDM fractions for 28 days. Error bars represent ±SD (n=3). * = P < 0.05, *** = P < 0.001. 
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4.4 Discussion 
This Chapter has elucidated the growth factor profile of DDM, by revealing the 
concentrations of these factors, including TGF-β1, BMP-2 and VEGF. A pertinent 
finding of this Chapter was that fractionation of growth factors via heparin-affinity 
chromatography reduced their potency compared to un-fractionated DDM; 
therefore, suggesting that interactions of growth factors with other matrix 
components in DDM are essential for osteogenic potency towards BMMSCs. 
SDS-PAGE and silver stain analysis of DDM in this Thesis showed a wide range of 
proteins with a highly prominent band at around 70kDa; and two further yet slightly 
less distinct bands at 50kDa and 80kDa. The band present at 70kDa is likely to be 
albumin, as this has been suggested to be sequestered within dentine (Thomas and 
Leaver, 1975); and is indicated to constitute a high abundance relative to other 
proteins in DDM (Park et al, 2009; Jágr et al, 2012). The presence of a band at 
50kDa may represent growth factors, in addition to the core proteins of the small, 
leucine-rich proteoglycans (SLRPs), biglycan and decorin, as these have pertinent 
roles in directing dentine formation and mineralisation (Embery et al, 2001; 
Haruyama et al, 2009). Literature reports indicate that dentine constitutes a vast 
array of various protein components, noted as 233 for ethylenediamine tetra-acetic 
acid (EDTA) (Park et al, 2009) and 289 for EDTA/guanidium hydrochloride extracted 
dentine (Jágr et al, 2012). Amongst candidates for proteins within EDTA extracted 
DDM in this Thesis, α2-HS glycoprotein (also known as fetuin) is acknowledged as a 
highly abundant protein within dentine (Jágr et al, 2012). Fetuin is a glycoprotein of 
around 55kDa (To et al, 1995) and is regarded as a regulator of mineralisation 
(Schafer et al, 2003); and is implicated in inhibition of the growth of hydroxyapatite 
crystals outside of collagen fibrils (Price et al, 2009). Collagenous proteins 
constitute around 85-90% of total dentine proteins (Linde, 1989). Type I collagen is 
the most predominant, with a lesser abundance of collagen types III, V and VII 
(Garant, 2003), regarded as structural proteins required for the deposition of 
hydroxyapatite crystals (Marshall et al, 1997). Due to the preparative protocols 
utilised in this Thesis, fibrillar collagenous proteins are likely to largely be excluded 
from DDM due to their insolubility, however soluble collagens may be present. The 
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remaining non-collagenous components of dentine represent a large number of 
proteins, with diverse roles including those involved with mineralisation, 
extracellular matrix (ECM) organisation, inflammation, immune response and cell 
signalling (Park et al, 2009, Smith et al, 2012). 
TGF-β1 was identified in DDM as an approximate 52kDa protein, in addition to being 
the most abundant growth factor analysed, at 11.3ng/mg. Unprocessed pre-cursors 
of TGF-β1 are reported to run at apparent molecular weights of 44-56kDa on SDS-
PAGE (Gentry et al, 1988), however, isoforms of 50kDa are still biologically active 
(Baillie et al, 1996). TGF-βs are secreted as latent-precursors containing a latency-
associated peptide (LAP) region, which requires proteolytic cleavage or physical 
interactions with other proteins to enable release of bioactive TGF-β1 (Verrecchia 
and Mauviel, 2002). TGF-β1 has been widely investigated in dental tissues and 
possesses well-acknowledged roles in stimulating migration (Howard et al, 2010), 
proliferation (Melin et al, 2000; Nie et al, 2006), ECM production and differentiation 
(Melin et al, 2000; Nie et al, 2006; He et al, 2008) of dental pulp-derived cells. 
Literary reports indicate that TGF-β1 is one the most abundant cytokines in human 
bone matrix at around 200ng/g (Hering et al, 2001). TGF-β1 does not solely induce 
osteogenic differentiation of mesenchymal stem cells (MSCs) (Kutagiri et al, 1994), 
however, it can indirectly influence osteogenesis by enhancing expression of BMP-1 
(Lee et al, 1997), which is required for the generation of mature collagen fibrils in 
the formation of bone (Asharani et al, 2012). TGF-β1 can also induce migration 
(Tang et al, 2009) and proliferation (Zhang et al, 2015a) of BMMSCs. 
BMP-2 was identified in DDM as a 50 kDa protein as determined by Western 
blotting, additionally determined by ELISA assay to be present at the concentration 
of 5.2ng/mg. BMP-2 is synthesised as a large inactive precursor of around 45kDa 
which is proteolytically cleaved to generate mature BMP-2 monomer (Roedel et al, 
2013). It is widely acknowledged that BMP-2 is a potent growth factor for driving 
osteogenesis of MSCs. Application of exogenous BMP-2 increases mRNA expression 
of RunX2 in human BMMSCs (Gori et al, 1999) and additionally promotes increased 
mRNA expression of osteocalcin (OC) and subsequent mineral deposition in 
BMMSCs (Fromigué et al, 1998). Lecanda et al (1997) report that exogenous BMP-2 
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applied to human BMMSCs enhances mRNA expression and protein synthesis of 
osteopontin (OPN), OC and collagen type I. Application of rhBMP-2 to human dental 
pulp cells enhances gene expression of dentine sialophosphoprotein (DSPP) (Saito 
et al, 2004). Blockage of BMP receptors in stem cells from human exfoliated, 
deciduous teeth (SHED) abolishes expression of DSPP and dentine matrix protein-1 
(DMP-1) (Casagrande et al, 2010). Furthermore, rhBMP-2 has been demonstrated 
to induce proliferation and migration of periodontal ligament (PDL)-derived cells, 
accompanied with enhanced cementum formation in a denuded PDL model in rats 
(King and Hughes, 2001). 
VEGF was detected in DDM at as an approximate 50 kDa protein via Western 
blotting and further determined to be present in DDM via ELISA at 3.7ng/mg. The 
existence of an inactive 47kDa isoform of VEGF is reported and requires proteolytic 
activation to induce bioactivity (Tee and Jaffe, 2001). VEGF is implicated in driving 
angiogenesis, to enhance fracture repair (Kaigler et al, 2013). VEGF is additionally 
associated with increasing the density of micro-vessels in severed human dental 
pulps in vitro (Mullane et al, 2008). Culture of human dental pulp-derived, stem 
cells (DPSCs) in osteogenic induction medium supplemented with VEGF enhances 
calcium deposition (D' Alimonte et al, 2011). 
Although Western blots indicated the presence of a few growth factors in DDM, 
ELISA analyses provided further data relating to the presence of additional growth 
factors, in addition to their relative concentrations in DDM, thereby uncovering the 
ratios of these factors relative to each other. FGF-2 and PDGF were identified in 
DDM at relatively intermediate concentrations, compared to IGF-1, BMP-4 and 
BMP-7, which were identified as being present in lower concentrations. 
FGF-2 has been demonstrated to extend ex vivo expansive capacity and maintain 
osteogenic precursors of human MSCs. FGF-2 is also reported to stimulate 
proliferation (Tsutsumi et al, 2001; Ahn et al, 2009) and migratory behaviour 
(Schmidt et al, 2006; Latifi-Pupovici et al, 2015) of MSCs in vitro. FGF-2 promotes 
the proliferation and migration of human dental pulp-derived cells; however, 
formation of calcified nodules is attenuated (Shimabukuro et al, 2009). 
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Furthermore, FGF-2 enhances proliferation and suppresses RunX2, type I collagen 
and calcium deposition in stromal cells, derived from the PDL (Lee et al, 2012b). 
PDGF is suggested to not possess a direct role in the differentiation of human MSCs 
towards an osteoblastic lineage, as inhibition of receptors does not negatively 
affect staining for mineral deposition or OC for cells treated with osteogenic 
induction medium (Kumar et al, 2010). PDGF has been demonstrated to elicit 
chemotactic responses of fetal rat calvarial cells in vitro (Hughes et al, 1992). PDGF 
is also reported to counter bone resorption during fracture healing by enhancing 
osteoprotegerin (OPG) production (McCarthy et al, 2009). In the dental pulp, PDGF 
enhances proliferation of human dental pulp-derived, fibroblasts (Rutherford et al, 
1992). 
IGF-1 may aid in acceleration of migratory activity by up-regulating CXCR4 on 
membranes of MSCs (Huang et al, 2012b). Both IGF-1 and IGF-1 receptor (IGF-1R) 
are expressed in human dental pulps, however, higher expression is noted for teeth 
with fully developed roots and therefore, has postulated roles in the differentiation 
and subsequent mineralisation of dental-derived, progenitor cells (Caviedes-Bucheli 
et al, 2004; 2007). 
The BMP family of growth factors exert effects on MSCs that induce osteogenic 
differentiation. Application of BMP-4 to human BMMSCs increases expression of 
collagen type I mRNA (Lecanda et al, 1997). Presentation of BMP-4 to canine dental 
pulps promotes the formation of reparative dentine (Nakashima et al, 1994). 
Furthermore, BMP-7 induces mineralisation of exposed rat pulp molars (Six et al, 
2002). Used in conjunction with osteogenic induction media, BMP-7 enhances up-
regulation of osterix (Osx) and OC of human BMMSCs (Shen et al, 2010). When 
applied together, BMP-4 and BMP-7 additionally modulate osteogenic 
differentiation of human MSCs and provoke mineralised matrix deposition (Lavery 
et al, 2008). 
Although the growth factors identified in DDM exert varying effects on MSCs, they 
may be potentially acting in synergy to exert various biological responses of 
BMMSCs (as described in Chapter 3). To determine the role of growth factors in the 
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osteogenic potency of DDM, heparin-affinity chromatography was performed with 
the aim of purifying growth factors from the matrix. Within this study, heparin-
affinity resulted in partial depletion of the assessed growth factors TGF-β1 and 
BMP-2 from DDM. Native TGF-β1 is reported to completely bind to heparin-
sepharose, which is eluted in 0.9-1.2M NaCl (McCaffrey et al, 1992). BMP-2 also 
contains a heparin-binding site with elution from heparin-sepharose achievable 
with 0.7M NaCl (Ruppert et al, 1996). Around 75% of TGF-β1 was depleted from 
DDM, with 40% recovered in EL2 fraction and around 25% remaining in the flow 
through and only 3% present in EL1. Conversely, only 25% of BMP-2 was depleted 
from DDM, with 7% recovered in EL1 fraction and just over 1% in EL2. For both 
growth factors analysed, full depletion was not achieved despite both factors 
containing heparin-binding sites, thus indicating variation with heparin-binding 
affinity potentially due to inhibition of other matrix components present in DDM. 
Biglycan and decorin are reported to be fundamental proteins in dentine matrix 
with proposed roles in sequestration of growth factors and prevention of over-
activation, notably TGF-β1 (Yamaguchi et al, 1990; Hildebrand et al, 1994). 
Furthermore, biglycan reportedly binds to BMP-2 (Mochida et al, 2006).  Western 
blot analysis of biglycan and decorin within the FT fraction identified the presence 
of these SLRPs, thereby suggesting these may be competitively inhibiting binding of 
TGF-β1 and BMP-2 to heparin and thus, are unable to be wholly isolated from DDM. 
Due to limited sample availability, the presence of additional growth factors in 
heparin-purification fractions was not analysed. PDGF-BB and FGF-2 both 
additionally bind to heparin-sepharose and are eluted at 0.5-0.6M NaCl 
(Mangrulkar et al, 1995) and 1.6-1.8M NaCl (Gospodarowicz et al, 1984), 
respectively. Consequently, any bound PDGF-BB and FGF-2 were likely to be eluted 
in the EL2 fraction, therefore suggesting EL2 to be a richer source of isolated growth 
factors from DDM relative to EL1. 
Whilst expansion of BMMSCs was reduced when cultured with un-fractionated 
DDM and FT fraction, compared with un-treated cells, EL1 and EL2 fractions did not 
change cell expansion over 4 days, compared to un-treated cells. To further 
determine the bioactivity of heparin-fractionated DDM, expression of RunX2 in 
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BMMSCs cultured with DDM fractions was assessed. Un-fractionated DDM 
provoked an up-regulation of RunX2 gene expression after 5 days, compared to un-
treated cells, concurrent with previous results (Section 3.3.4). Heparin-fractionation 
of DDM resulted in abolished up-regulation of RunX2 gene expression, compared to 
un-treated cells. Subsequently, mineralised matrix deposition of BMMSCs treated 
with heparin-fractionated DDM was diminished, compared to matrix deposition of 
cells treated with un-fractionated DDM. In contrast, heparin-binding components of 
EDTA extracted DDM is capable of stimulating reactionary dentinogenesis, following 
implantation into teeth (Smith et al¸1995). 
Relative to un-fractionated DDM, FT fraction was depleted of both BMP-2 and TGF-
β1, however, a greater percentage of depletion was evident for TGF-β1. Even though 
growth factor combinations of varying concentrations and ratios were determined 
in DDM fractions, osteogenic potency was attenuated compared to un-fractionated 
DDM, therefore indicating the importance of optimal matrix composition for 
potentiating osteogenesis of BMMSCs. TGF-β1 can synergistically act with BMP-2 to 
enhance bone formation by around 5-fold compared to BMP-2 alone (Tachi et al, 
2011) and therefore, depletion of TGF-β1 from the FT fraction may be responsible 
for diminished differentiation capacity, compared to whole DDM. Although not 
explored, several other heparin-binding components may additionally have been 
depleted from DDM and thus, potentially reduced their concentration within the FT 
fraction. TGF-β1, FGF-2 and PDGF-AB increase expression of BMP receptor-1B 
(BMPR-1B) in human bone cells, which augments cellular responses to BMP-2 via 
Smad 1/5/8 phosphorylation (Singhatanadgit et al, 2006). BMP-2 induced bone 
formation can also be synergistically enhanced by exogenous VEGF application, 
however, high proportions of VEGF: BMP-2 results in decreased synergism (Peng et 
al, 2005). Combination of rhBMP-2 and dentine sialoprotein (DSP) synergistically 
enhances OC gene expression and mineral deposition of cementoblasts, compared 
to singular application (Lee et al, 2014).  
Although growth factors were depleted from DDM and were recovered in 
subsequent elution fractions, neither recovered fraction elicited the extent of 
osteogenic induction relative to un-fractionated matrix. Concentrations of both 
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TGF-β1 and BMP-2 were greater than 10-fold smaller in fraction EL1, relative to un-
fractionated DDM. Therefore, EL1 treated BMMSCs may not have been exposed to 
concentrations of growth factors high enough to induce osteogenic effect, due to 
the dose-dependent response of DDM on BMMSCs (see Chapter 3 for details). TGF-
β1 was predominantly present within fraction EL2, relative to BMP-2. However, 
TGF-β1 does not exert osteogenic potency towards BMMSCs (Katagiri et al, 1994). 
RunX2 expression can be repressed by TGF-β1 and thus, inhibit osteoblastic 
differentiation (Alliston et al, 2001), with differentiation potential restored 
following TGF-β1 inhibition (Takeuchi et al, 2010). Modulation of TGF- β1 bioactivity 
by sequestration by biglycan and decorin is acknowledged (Hildebrand et al, 1994; 
Baker et al, 2009). Analysis of SLRPs in elution fractions would have been beneficial 
to determine the nature of TGF-β1, with regards to activity regulation by biglycan 
and/or decorin. However, limited sample availability prevented this investigation. 
In conclusion, DDM contains a plethora of different protein components amongst 
which are a range of growth factors with various roles in directing osteogenesis. 
The low concentration of growth factors present within DDM alludes to synergistic 
action to stimulate biological responses. Purification of DDM via heparin-affinity 
chromatography diminishes osteogenic induction capability relative to un-
fractionated matrix, therefore suggesting that DDM presents a ‘cocktail’ of 
bioactive factors with optimal biological ratios to exert osteogenic effect. 
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Chapter 5 - Determination of the Significance of Biglycan and 
Decorin for the Osteogenic Potency of Demineralised Dentine Matrix 
(DDM) 
5.1 Introduction 
Biglycan and decorin belong to the small, leucine-rich proteoglycan (SLRP) family 
and consist of protein cores of around 45 kDa, associated with two or one attached 
glycosaminoglycan (GAG) chains, respectively (Embery et al, 2001; Seidler et al, 
2006). Both biglycan and decorin are ubiquitously expressed in a variety of tissues, 
including bone, kidneys, eyes and skin (Bianco et al, 1990). Models of SLRP knock-
out (KO) are associated in a variety of diseases such as osteoporosis, osteoarthritis 
and Ehler’s-Danlos syndrome (Ameye et al, 2002). As both biglycan and decorin in 
bone (Ingram et al, 1993), KO models for these SLRPs in rodents have determined 
their importance in maintenance of skeletal tissues. In mouse KO models, the 
absence of decorin does not affect skeletal mass (Corsi et al, 2002). However, dual 
KO of both biglycan and decorin results in marked osteopenia. The KO of biglycan 
alone results in viable animals at birth, with no apparent bone defects although 
mild osteopenia is noted for aged mice (Xu et al, 1998). Both biglycan and decorin 
are also present within dentine and are proposed to serve roles in the regulation of 
cell proliferation and matrix mineralisation (Waddington et al, 2003b). 
Although regarded as pertinent constituents of mineralised tissues, SLRPs are 
additionally implicated in the binding and modulation of growth and signalling 
factors. Both biglycan and decorin are reported to bind to type I collagen and 
transforming growth factor-β1 (TGF-β1) with a postulated role in the sequestration 
of TGF-β1 to the extracellular matrix (ECM) (Hildebrand et al, 1994). Biglycan can 
enhance bone morphogenetic protein-4 (BMP-4) induced RunX2 expression by 
increasing of BMP-4 binding to its receptor (Chen et al, 2004). Biglycan can also 
bind bone morphogenetic protein-2 (BMP-2) and its receptor to promote 
osteogenic differentiation (Mochida et al, 2006). Decorin is able to enhance 
responses to BMP-2 (Moreno et al, 2005; Gutierrez et al, 2006).  Additionally, 
biglycan can interact with Wnt3a ligand and its receptor LRP6, to enhance canonical 
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Wnt signalling in osteogenesis (Berendsen et al, 2011). Therefore, SLRPs are 
obtaining increasing recognition as important mediators in modulation of cell 
signalling events both with and without associated factors. 
Whilst numerous studies have explored the importance of biglycan and decorin in 
rodent tissues and cells, comparatively few studies are currently available that 
investigates the effects of these SLRPs on human bone marrow-derived, 
mesenchymal stem cells (BMMSCs) and their influence in osteogenesis. This 
Chapter aimed to elucidate the importance of biglycan and decorin in the 
osteogenic potency of demineralised dentine matrix (DDM) towards human 
BMMSCs. 
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5.2 Materials and Methods 
5.2.1 Immunoprecipitation (IP) of Biglycan and Decorin from DDM 
DDM was obtained from human teeth, as previously described (Section 3.2.1.2). 
Immunoprecipitation (IP) of biglycan and decorin from DDM was performed using a 
Pierce® Crosslink IP Kit (Thermo Fisher Scientific, USA), according to manufacturer’s 
protocol. All steps were performed at 4°C, unless otherwise stated; and all 
centrifugation performed at 1,000g for 1 min. IP was performed in separate spin 
columns for each protein to be isolated. Both individual and dual depletion of 
biglycan and decorin from DDM was performed.  
20μL of Pierce Protein AG Plus Agarose was pipetted into a Spin Column, 
centrifuged and flow-through was discarded. Resin was washed twice with 100μL of 
Couple Buffer.  The base of the column was tapped onto a clean paper towel and 
sealed with a bottom plug. 10μg of biglycan and decorin antibodies (as detailed in 
Table 5.1) were added to 5μL of 20x Couple Buffer and total volume adjusted to 
100μL with 18.2MΩ H2O. Solutions of biglycan and decorin antibodies were added 
to resin-containing spin columns, which were sealed and incubated at room 
temperature for 1 h, with gentle agitation. Columns were centrifuged and washed 
once with 100μL and twice with 300μL of Couple Buffer, with each flow through 
discarded. 2.5μL of 20x Couple Buffer, 9μL of 2.5mM disuccinyl suberate (DSS) and 
38.5μL of 18.2MΩ H2O was added to each spin column, followed by incubation at 
room temperature for 1 h, with gentle agitation. Columns were centrifuged, 
followed by addition of 50μL of Elution Buffer, and centrifugation again. Columns 
were washed twice with 100μL of Elution Buffer followed by washing twice with 
200μL of IP Lysis/Wash Buffer. Columns were sealed, stored in 200μL of IP 
Lysis/Wash Buffer and stored at 4°C until required. 
For pre-clearing, 80μL of Control Agarose Resin Slurry (40μL of settled resin) was 
pipetted into fresh spin columns, centrifuged and washed with 100μL of Couple 
Buffer. DDM was reconstituted in tris buffered saline (TBS) to an anticipated 
concentration of 1mg/mL and sterile filtered through a 0.22μM syringe filter 
(Millipore, USA); and final volumes adjusted to 1.2mL with TBS. Protein 
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concentrations were determined using a Pierce® BCA Protein Assay Kit (Thermo 
Fisher Scientific), as described previously (Section 3.2.1.3). 600μL of DDM solution 
was added to each column containing 40μL of settled resin, the columns were 
sealed and incubated for 30 min, with gentle agitation. Spin columns were 
centrifuged and flow through retained for the IP procedure. 
Columns containing immobilised antibodies were washed twice with 100μL of TBS 
and sealed with a bottom plug. 600μL of DDM solution at 500-1000μg/mL was 
added to each spin column, the column sealed and incubated overnight at 4°C with 
gentle agitation. DDM solution was eluted and columns were washed thrice with 
200μL of TBS, followed by one wash of 100μL of Conditioning Buffer. Columns were 
placed into a 1.5mL collection tube containing 5μL of 1M tris base (pH 9.5) (Fisher 
Scientific, UK), 10μL of Elution Buffer added to each column and centrifuged. 
Columns were retained in collection tubes, 50μL of Elution Buffer added to the 
resin and incubated for 5 min at room temperature. Columns were centrifuged and 
flow through retained. Elution steps were repeated into a fresh collection tube and 
elution volumes for each isolated protein pooled. 
Depleted flow-through fractions of DDM were weighed for volume determination. 
Volumes for biglycan and decorin depleted flow through and enriched elution pools 
utilised in forthcoming experiments were proportional, relative to the total volume 
of depleted elution. 
For dual-depletion, the above steps were performed, however, DDM was 
sequentially depleted of biglycan, followed by decorin.  
5.2.1.1 Protein Separation Using Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Protein Electroblotting 
Fractions from the IP procedure were assayed to determine depletion and 
subsequent recovery of biglycan and decorin from DDM, in addition to co-depleted 
TGF-β1, as previously described (Sections 4.2.2 and 4.2.2.2). Briefly, IP fractions 
were lyophilised and reconstituted in 1x Laemmli Sample Buffer to a concentration 
relative to 2μg/μL of un-depleted DDM. Samples were heated to 95°C for 5 min and 
15μL loaded into 4-15% Mini Protean TGX pre-cast gels (BioRad Laboratories, USA), 
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alongside 7.5μL of Kaleidoscope Pre-Stained Protein Standards (BioRad 
Laboratories). Gels were placed in an electrophoresis cell with sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) running buffer (25mM tris-
base (Sigma-Aldrich, UK), 192mM glycine (Fisher Scientific), 0.1% SDS (Fisher 
Scientific), pH 8.3) and separated by electrophoresis at 200V for 30-35 min, until 
the migration front reached the bottom of the gel. 
Gels were soaked in transfer buffer (25mM tris-base, 192mM glycine, 20% (v/v) 
methanol (Fisher Scientific), pH 8.3); and proteins transferred onto nitrocellulose by 
electroblotting. 
5.2.1.2 Immunoblotting for Protein Detection 
Detections of proteins were performed, as previously described (Section 4.2.2.3). 
Briefly, membranes were blocked in 5% (w/v) milk (Tesco, UK) in TBS/0.05% Tween-
20 (Sigma-Aldrich) (TBS-T) for 1 h at room temperature, followed by incubation 
with primary antibodies overnight at 4°C. Membranes were washed four times with 
TBS-T and incubated with respective secondary antibodies for 1 h at room 
temperature. Membranes were washed four times in TBS-T and a further twice in 
TBS. Membranes were treated with ECL Reagent (GE Healthcare, UK) and exposed 
to X-ray development film (GE Healthcare). Details of antibodies used are shown in 
Table 5.1. 
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Primary antibody 
(Ab) 
Primary Ab dilution Secondary Ab Secondary Ab 
dilution 
Biglycan (L-15) – 
Santa Cruz (USA) 
1:500 Anti-goat HRP (sc-
2020) – Santa Cruz 
1:50,000 
Decorin (N-15) – 
Santa Cruz 
1:300 Anti-goat HRP (sc-
2020) – Santa Cruz 
1:50,000 
TGF-β1 (V) – Santa 
Cruz 
1:200 Anti-rabbit HRP (sc-
2030) – Santa Cruz 
1:25,000 
 
Table 5.1 – Detailing antibodies used in IP and respective dilutions used for protein 
detection of IP fractions. 
5.2.2 Expansion of BMMSCs Cultured with DDM IP Fractions 
Expansion of BMMSCs cultured with DDM IP fractions were performed over 4 days, 
using modified protocol of the previously described thiazolyl blue tetrazolium blue 
(MTT) assay (Section 3.2.2). Briefly, BMMSCs (16-17.5 population doublings, PDs) 
were seeded into triplicate wells of a 96-well plate (Sarstedt, UK) at 4x103cells/cm2, 
in 5% FBS (Invitrogen, UK) culture media conditioned with un-depleted, SLRP-
depleted and SLRP-enriched IP fractions. Cells cultured in un-conditioned media 
served as a control. At each time point 20μL, of media was aspirated from each well 
and replaced with 20μL of sterile filtered MTT solution (5mg/mL in PBS) (Sigma-
Aldrich). Plates were incubated and processed, as described previously (Section 
3.2.2). Experiments were performed on three separate occasions. 
5.2.3 Osteogenic Induction Ability of DDM IP fractions 
Osteogenic gene expressions by BMMSCs over 2, 5 (individual and dual depleted) 
and 28 (individual depletion only) days cultured with DDM IP fractions were 
performed, as described previously (Section 3.2.6). Briefly, BMMSCs (16-17.5 PDs) 
were seeded into 6-well or 12-well culture plates (Sarstedt) at 104 cells/cm2, in 
media conditioned with IP DDM fractions or un-conditioned media (negative 
control). RNA was extracted using an RNeasy Mini Kit (Qiagen, Germany) (Section 
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2.2.3), converted to cDNA (section 2.2.4.) and quantitative real time-polymerase 
chain reaction (q-PCR) analysis performed for RunX2 (days 2 and 5) and osteocalcin 
(OC) (day 28) gene expression (section 3.2.6). GAPDH was used as an internal 
housekeeping gene for normalisation of data. Primer sequences are detailed in 
Table 5.2. Experiments were performed on three separate occasions. 
Gene 
product 
Primer sequence: 5’-3’ Annealing 
temperature 
(°C) 
Product 
length 
(bp) 
Primer 
designer 
GAPDH F: TTCTTTTGCGTCGCCAGCCGA 
R: GTGACCAGGCGCCCAATACGA 
55 96 Author 
RunX2 F: GGTTAATCTCCGCAGGTCACT 
R: CCCTCTGTTGTAAATACTGCTTGC 
55 80 Author 
OC F: GGCAGCGAGGTAGTGAAGAG 
R: CTCACACACCTCCCTCCT 
55 102 Dr. Wayne 
Ayre (Cardiff 
University) 
 
Table 5.2 – Details of primer sequences used for q-PCR analysis of genes expressed by 
BMMSCs during culture with SLRP IP fractions. 
 
5.2.3.1 Mineral Deposition Analysis of BMMSCs Cultured with DDM IP fractions 
Alizarin red staining of BMMSCs cultured with DDM IP fractions was performed, as 
described previously (Sections 3.2.5.1 – 3.2.5.2). Briefly, BMMSCs (16-17 PDs) were 
seeded into 24-well culture plates (Sarstedt) at 104 cells/cm2, in media conditioned 
with DDM IP fractions or un-conditioned media (negative control). Cells were 
cultured for 28 days, with media changes performed every 2 days. Cells were 
washed, fixed with 10% v/v formaldehyde (Sigma-Aldrich) and stained with 2% 
Alizarin red (Sigma-Aldrich). Stained cells were washed with deionised distilled H2O 
(ddH2O), air-dried and photographed under light microscopy, using a Panasonic 
DMC-G1 Camera. Experiments were performed on three separate occasions. 
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5.2.3.2 Quantification of Alizarin Red Staining 
Quantification of Alizarin red staining was performed, as described previously 
(Section 4.2.6.2). 
5.2.4 Statistical Analyses 
Statistical analyses were performed utilising One-Way ANOVA with a post-hoc 
Tukey test, using GraphPad InStat 3 (v3.06). Statistical values were defined as 
significant (*, P<0.05), very significant (**, P<0.01) or extremely significant (***, 
P<0.001). 
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5.3  Results 
5.3.1 Conformation by Western blot of IP of Biglycan and Decorin from DDM  
Biglycan and decorin, present in DDM, were successfully depleted and recovered 
using immunoprecipitation. For both biglycan, banding at around 50 kDa was 
detected via Western blot in un-depleted DDM and respective enriched-DDM, 
indicative of core protein. For decorin, banding at around 48kDa was observed in 
un-depleted DDM and respective enriched-DDM. For respective enriched DDM 
fractions of biglycan and decorin, additional bands are noted up to around 150 kDa, 
indicative of glycosylated core proteins. No bands were detected in depleted 
matrices and thus, confirmed depletions (Figure 5.1). 
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Figure 5.1 – Western blot analyses of DDM for immuno-depletion of biglycan and decorin 
for individual depletion (top) and dual depletion (bottom). Core proteins of 50 kDa 
(biglycan) and 48kDa (decorin) were present in un-depleted DDM, which are not present in 
depleted matrix. Respective bands, in additional to bands indicative of glycosylated 
proteins in the enriched matrices indicate the recovery of immuno-depleted proteins. 
Western blots were repeated once. 
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5.3.2 Western Blot Determination of TGF-β1 Co-Depletion from DDM 
Western blot analysis for the immuno-detection of TGF-β1 was performed on 
immunoprecipitation fractions of DDM to detect co-precipitation. TGF-β1 was 
present in DDM at around 50 kDa, as determined previously (Section 4.3.2).  
Banding was not present in DDM depleted of biglycan or decorin, however, bands 
were present in fractions of respective elution pools (Figure 5.2). 
 
 
Figure 5.2 - Western blot for TGF-β1 presence in individual immunoprecipitation fractions. 
Bands at around 50 kDa were present in un-depleted DDM, biglycan-enriched and decorin-
enriched fractions. No bands are detectable in biglycan- and decorin-depleted, DDM 
fractions. 
 
 
 
122 
 
5.3.3 Expansion of BMMSCs Cultured with Individually Immuno-Precipitated 
DDM Fractions 
Over 96 h in culture, expansion of BMMSCs cultured with un-depleted DDM was 
reduced after 48 h, compared to un-treated cells (P<0.01), however this reduction 
was not significant after 96 h. Expansion of cells cultured with biglycan-depleted 
DDM was not changed compared to cells cultured with un-depleted DDM, or un-
treated cells. After 72 h in culture, expansion of cells cultured with decorin-enriched 
DDM was higher compared to un-treated cells (P<0.01), whereas cell expansion 
when cultured with biglycan-enriched DDM was significantly higher than un-treated 
cells after 96 h (P<0.05). Expansion of cells cultured with decorin-depleted DDM 
was not changed compared to un-treated cells over 96 h (Figure 5.3).  
 
 
Figure 5.3 - Graph representing BMMSC expansion when cultured with individual immuno-
depletion DDM fractions. After 96 h, culture of cells with biglycan- and decorin-enriched 
DDM resulted in enhanced cell expansion compared with cells cultured with un-depleted 
DDM, in addition to un-treated cells. Error bars represent ±SD (n=3). * = P<0.05, ** = 
P<0.01, *** = P<0.001. 
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5.3.4 Expansion of BMMSCs Cultured with Dual Immuno-Precipitated DDM 
Fractions 
After 96 h in culture, expansion of BMMSCs cultured with un-depleted and 
BGN/DEC-depleted DDM was significantly reduced compared to un-treated cells 
(P<0.05). Cell expansion for BMMSCs cultured with biglycan/decorin-enriched DDM 
was significantly higher than for cells cultured with un-depleted (P<0.01) and 
biglycan/decorin-depleted (P<0.05), DDM. BMMSC expansion was not changed 
when cultured with biglycan/decorin-enriched DDM, compared with un-treated 
cells. No differences in cell expansion were observed between experimental groups 
up to 72 h in culture (Figure 5.4). 
 
 
 
Figure 5.4 - Graph representing BMMSC expansion when cultured with dual immuno-
depletion DDM fractions. BMMSCs cultured with un-depleted and biglycan/decorin-
depleted DDM was reduced, compared to un-treated cells after 96 h. However, expansion 
was not affected by culturing with biglycan/decorin enriched DDM, compared to un-
treated cells. Error bars represent ±SD (n=3). * = P<0.05, ** = P<0.01. 
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5.3.5 RunX2 Expression of BMMSCs cultured with Individual Immuno-
Precipitated DDM Fractions 
After 2 days in culture, RunX2 gene expression was down-regulated in BMMSCs 
cultured with decorin-enriched DDM, compared with cells cultured with all other 
DDM IP fractions, except for decorin-depleted DDM. After 5 days in culture, only 
BMMSCs cultured with decorin-depleted DDM demonstrated statistically 
significantly higher RunX2 expression, compared with un-treated cells (P<0.05). 
RunX2 expression was significantly lower for cells treated with biglycan-depleted 
DDM, compared to un-depleted (P<0.05) and decorin-depleted (P<0.01), DDM 
fractions (Figure 5.5). 
 
 
Figure 5.5 - Expression of RunX2 in BMMSCs cultured with individually immuno-depleted 
DDM fractions after 2 and 5 days. Culture of cells with decorin-enriched DDM resulted in a 
reduction of RunX2 expression, compared to all other groups after 2 days. After 5 days in 
culture, decorin-depleted DDM resulted in the highest expression of RunX2 in BMMSCs, 
whereas treatment of cells with decorin-enriched DDM resulted in the lowest RunX2 
expression. Error bars represent ±SD (n=3). * = P<0.05, *** = P<0.001. 
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5.3.6 RunX2 Expression of BMMSCs Cultured with Dual Immuno-Precipitated 
DDM Fractions 
After 2 days in culture, there were no differences in RunX2 gene expression 
between all of the groups analysed. After 5 days in culture, there were additionally 
no distinct changes in RunX2 gene expression, although cells cultured with un-
fractionated DDM demonstrated the highest level of expression (Figure 5.6). 
 
 
Figure 5.6 - Expression of RunX2 in BMMSCs cultured with dual immuno-depleted DDM 
fractions after 2 and 5 days. No statistically significant differences for gene expression were 
observed at the two time-points (P>0.05). Error bars represent ±SD (n=3). 
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5.3.7 Osteocalcin (OC) Expression of BMMSCs Cultured with Individual Immuno-
Precipitated DDM Fractions 
After 28 days in culture, there was no difference in expression of OC in BMMSCs 
treated with un-depleted DDM, compared to biglycan-depleted DDM and decorin-
depleted DDM. Whilst OC expression appeared to be lower for BMMSCs in other 
treatment groups, compared to un-depleted DDM, only cells cultured with decorin-
enriched DDM demonstrated statistically significantly lower OC expression, 
compared to un-depleted DDM (P<0.05). BMMSCs cultured in decorin-depleted 
DDM demonstrated significantly greater OC expression, compared to un-treated 
cells (P<0.01) (Figure 5.7).  
 
Figure 5.7 - Expression of OC in BMMSCs cultured with individual immuno-depleted DDM 
fractions after 28 days. Up-regulation of OC gene expression in BMMSCs was observed 
when treated with un-depleted DDM, biglycan-depleted DDM and decorin-depleted-DDM, 
compared to un-treated cells. However, statistical significance was only achieved for cells 
cultured with decorin-depleted DDM, compared to un-treated cells. Error bars represent 
±SD (n=3). * = P<0.05, ** = P<0.01. 
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5.3.8 Alizarin Red Staining of BMMSCs Cultured with Individual Immuno-
Precipitated DDM Fractions 
After 28 days, Alizarin red staining of BMMSCs cultured with un-depleted DDM and 
decorin-depleted DDM yielded visible nodules of mineralisation (white arrows). 
Sparse, however, dense nodule formation occured with cells cultured with biglycan-
enriched DDM (black arrow). No prominent nodules of staining are present for cells 
cultured with biglycan-depleted or decorin-enriched DDM, akin to un-treated cells 
(Figure 5.8) 
 
Figure 5.8 - Micrograph images of BMMSCs stained by Alizarin red for mineral deposition 
analysis after 28 days in culture, with individually immuno-depleted DDM. BMMSCs 
cultured with un-depleted and decorin-depleted DDM produced mineralised foci (white 
arrows). Meagre staining was apparent for cells cultured with biglycan-depleted or decorin-
enriched DDM. White bars represent 100μm. 
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5.3.9 Quantification of Alizarin Red Staining of BMMSCs Cultured with Individual 
Immuno-Precipitated DDM Fractions 
Alizarin red staining was greater for BMMSCs treated with un-depleted DDM, 
compared to cells treated with biglycan-depleted DDM (P<0.01), decorin-enriched 
DDM (P<0.01) and un-treated cells (P<0.01). Staining for cells treated with decorin-
depleted DDM was unchanged from cells treated with un-depleted DDM, however, 
staining was greater compared with un-treated cells (P<0.01). Staining for cells 
treated with biglycan-depleted and decorin-enriched DDM was unchanged, 
compared to un-treated cells (Figure 5.9). 
 
Figure 5.9 - Graph representing intensity of Alizarin red S staining of BMMSCs cultured with 
individual immuno-depleted DDM fractions for 28 days. Un-depleted and decorin-depleted 
DDM fractions elicited the highest levels of staining of BMMSCs. Staining was unchanged in 
cells cultured with biglycan-depleted DDM or decorin-enriched DDM, compared to un-
treated cells. Error bars represent ±SD (n=3). ** = P<0.01. 
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5.3.10 Alizarin Red Staining of BMMSCs Cultured with Dual Immuno-Precipitated 
DDM Fractions 
After 28 days, Alizarin red staining of BMMSCs cultured with un-depleted DDM 
yielded visible nodules of mineralisation (white arrow). Very small nodules were 
present for cells treated with biglycan/derocin-depleted DDM and 
biglycan/decorin-enriched DDM (black arrows). No staining was observed for 
BMMSCs cultured with basal media (Figure 5.10).  
 
 
 
 
 
 
Figure 5.10 - Micrograph images of BMMSCs stained by Alizarin red for mineral 
deposition analysis after 28 days in culture with dual immuno-depleted DDM. BMMSCs 
cultured with un-depleted DDM produced defined mineralised foci (white arrow), 
however, smaller deposits are present for cells cultured with biglycan/decorin-depleted 
DDM and biglycan/decorin-enriched DDM (black arrows). Un-treated cells did not 
visibly stain. White bars represent 100μm. 
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5.3.11 Quantification of Alizarin Red Staining of BMMSCs Cultured with Dual 
Immuno-Precipitated DDM Fractions 
Alizarin red staining was greater for BMMSCs cultured with un-depleted DDM 
compared to cells cultured with biglycan/decorin-depleted DDM (P<0.01), 
biglycan/decorin-enriched DDM (P<0.05) and un-treated cells (P<0.01). There was 
no significant difference in staining for cells cultured with biglycan/decorin-
depleted DDM or biglycan/decorin-enriched DDM compared, with un-treated cells 
(Figure 5.11). 
 
 
Figure 5.11 - Graph representing intensity of Alizarin red staining of BMMSCs cultured with 
dual immuno-depleted DDM fractions, for 28 days. Un-depleted DDM provoked the highest 
levels of staining, however, staining was diminished when cells were treated with 
biglycan/decorin-depleted DDM and biglycan/decorin-enriched DDM. Error bars represent 
±SD (n=3). * = P<0.05, ** = P<0.01. 
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5.4 Discussion 
The results presented within this Chapter have acknowledged the roles for biglycan 
and decorin in DDM for orchestrating osteogenic responses of BMMSCs. Both 
individual and dual depletion of biglycan and decorin resulted in the co-depletion of 
TGF-β1. Depletion of biglycan from DDM impeded osteogenic potency towards 
BMMSCs, accompanied with abolished mineralisation, which is not recovered with 
isolated biglycan. Conversely, decorin depletion from DDM has no effect on the 
osteogenic effects towards BMMSCs. Dual-depleted DDM resulted in the 
abolishment of osteogenic potential of DDM towards BMMSCs, which was not 
recovered with the application of isolated biglycan/decorin. Collectively, biglycan 
and decorin, along with TGF-β1, are proposed to possess differential roles in 
orchestrating cellular responses to DDM, which strengthens the evidence for their 
role in the regulation of osteogenic differentiation. 
The work within this study identified that DDM contained both biglycan and 
decorin, in accordance with previous literature reports (Waddington et al, 2003b; 
Goldberg et al, 2005). For both SLRPs analysed in this study, co-depletion of TGF-β1 
was noted in both individual and dual immuno-precipitated DDM, therefore 
indicating interactions of both of these SLRPs with TGF-β1. Both biglycan and 
decorin have been recognised to be able to form complexes with TGF-β1, which can 
be increased by de-glycosylation of both SLRPs, thus indicating binding of TGF-β1 is 
to the respective core protein component (Hildebrand et al, 1994). Baker et al 
(2009) reported that depletion of biglycan or decorin individually from DDM does 
not affect the affinity of TGF-β1 to the matrix. However, dual depletion reduces 
affinity by around 50%, compared to un-depleted matrix, thus proposing roles for 
biglycan and decorin in sequestering TGF-β1 within DDM.  
Compared to un-depleted DDM, culturing of BMMSCs with decorin-enriched DDM 
resulted in enhanced cell expansion, cumulative with reduced RunX2 and OC mRNA 
expression; and abolished mineralisation in culture, compared to cells treated with 
un-depleted DDM. Conversely, the depletion of decorin from DDM did not alter 
RunX2 nor OC expression, or calcium accumulation, compared to un-depleted DDM. 
Decorin is known to possess differential proliferative effects on a variety of cells, by 
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reducing proliferation of fibroblasts (Zhang et al, 2007a; Ferdous et al, 2010); and 
enhancing proliferation of myoblasts (Kishioka et al, 2008). Consequently, 
controversy exists over the mechanisms of action that decorin possesses in altering 
cellular behaviours. As determined in this study, decorin forms a complex with TGF-
β1, which has been proposed to lead to inactivation of the growth factor (Border et 
al, 1992), potentially by sequestering TGF-β1 to collagenous components of the 
ECM (Markmann et al¸ 2000). Conversely, formation of a decorin-TGF-β1 complex is 
noted to activate the growth factor and enhance bioactivity towards MC3T3-E1 pre-
osteoblast cells (Takeuchi et al, 1994). Taken together, the formation of complexes 
of TGF-β1 with decorin may be enhancing bioactivity of TGF-β1, and thus stimulating 
expansion of BMMSCs via TGF-β1 signalling. Regarding differentiation, the results 
from this Chapter suggest that decorin depletion from DDM does not affect the 
potential for osteogenic differentiation of BMMSCs or the subsequent calcium 
accumulation. Intestinal epithelial cells of decorin-KO mice experience 1.6-fold 
greater β-catenin signalling, compared to wild-type cells (Bi et al, 2008). 
Additionally, decorin antagonises β-catenin levels from non-canonical Wnt 
signalling (Buraschi et al, 2010). Murine BMMSCs deposit an ECM containing 
decorin amongst other components, such as collagens I, III and V, fibronectin and 
biglycan, which promotes increased colony-forming efficiency and represses 
spontaneous differentiation (Chen et al, 2007). In vivo KO of decorin from mice has 
been demonstrated not to alter skeletal mass, compared to wild-type animals (Corsi 
et al, 2002). Concomitant with the results of this Chapter, this data suggests that 
isolated decorin may be acting as a repressor of osteogenic differentiation and may 
be redundant for formation of bone mass.  
In contrast to decorin, the depletion of biglycan from DDM did not alter BMMSC 
expansion, however, resulted in reduced RunX2 mRNA expression and abolished 
potential for mineralised matrix deposition, compared to un-depleted DDM. 
Biglycan has been implicated in several studies in the modulation of osteogenesis. 
Biglycan has been shown to enhance BMP-4-induced differentiation of mouse 
osteoblasts, via RunX2 signalling (Chen et al, 2004). In rat mandible defects, BMP-2 
signalling is enhanced when combined with de-glycated biglycan, compared to 
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biglycan associated with GAGs (Miguez et al, 2011). Aside from modulation of 
growth factor binding, biglycan is also implicated in the alteration of cell signalling 
and can modulate the Wnt pathway by co-binding of Wnt3a ligand and its receptor 
LRP6, resulting in downstream RunX2 transcription (Berensden et al, 2011). 
Interestingly, BMMSCs cultured with biglycan-depleted DDM expressed comparable 
mRNA levels of OC as cells treated with un-depleted DDM, despite significantly 
lower RunX2 expression at day 5. A possible explanation for this observation may 
be that although biglycan enhances expression of DDM-induced RunX2 expression, 
biglycan-depleted DDM could be inducing OC expression via a RunX2-independent 
pathway, as BMP-2 can induce expression of osterix via Dlx5, independently of 
RunX2 expression (Lee et al, 2003; Ulsamer et al, 2008). 
Analysis of the gene expression levels for OC determined that there was no 
difference between expression levels in cells treated with un-depleted DDM, 
compared with biglycan-depleted DDM. Despite this, mineral accumulation by cells 
treated with biglycan-depleted DDM was abolished, compared to cells treated with 
un-depleted DDM. Therefore, this suggests that biglycan is indispensable for 
mineralisation of BMMSCs treated with DDM. In vivo, biglycan-KO mice experience 
reduced bone growth and skeletal mass, compared to wild-type animals (Xu et al, 
1998). In addition, biglycan is highly expressed in the calluses of mouse fracture 
sites, with KO of biglycan resulting in reduced callus size and less woven bone 
(Berensden et al, 2014). In vitro, transfection of MC3T3-E1 cells with biglycan 
enhances matrix mineralisation, however, mineralisation is depressed in biglycan-
KO cells (Parisuthiman et al, 2005). Soluble biglycan has been shown to function as 
a nucleator of hydroxyapatite (Gafni et al, 1999), in addition to being proposed to 
possess a stronger affinity for hydroxyapatite crystals than decorin, with affinity 
enhanced upon removal of GAG chains from the core protein (Sugars et al, 2003). 
Collectively biglycan possesses a key role in the mediation of matrix mineralisation. 
The depletion of biglycan and decorin individually from DDM indicates differential 
roles for these SLRPs in the osteogenic potential of DDM towards BMMSCs. Dual 
depletion of these SLRPs from DDM was assessed to determine the potential for 
coordinated activities in these proteins for directing osteogenesis. The dual 
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depletion of biglycan/decorin from DDM did not result in differences in BMMSC 
expansion, compared with un-depleted matrix. Interestingly expansion of BMMSCs 
with biglycan/decorin-enriched DDM was not changed compared to un-treated 
cells. In contrast, an increase in expansion for cells treated with biglycan-enriched 
and decorin-enriched DDM was noted, compared to un-treated cells. As both 
biglycan and decorin were demonstrated to form complexes with TGF-β1, their dual 
application to BMMSCs may have been beginning to induce a switch in fate 
between expansion and apoptosis, due to over-activation of TGF-β1 signalling (Bi et 
al, 2005). Although cell expansion was not changed, compared with un-depleted 
DDM, the dual depletion did result in a very slight reduction of RunX2 mRNA 
expression, compared to un-depleted DDM. This expression was not recovered 
following treatment of cells with biglycan/decorin-enriched DDM. Furthermore, 
dual depletion of biglycan/decorin resulted in abolished mineral accumulation of 
BMMSCs, compared to cells cultured with un-depleted DDM. In vivo, dual KO of 
both biglycan and decorin render mice severely osteopenic at 2 months of age, 
however, only mild osteopenia is observed for mice devoid of only biglycan (Xu et 
al, 1998). Concurrent with the results in this Thesis, it has been reported that dual 
KO of biglycan and decorin from mouse BMMSCs eliminates the mineralisation 
effect of exogenous BMP-2, however, RunX2 expression is not affected, compared 
to wild-type cells (Bi et al, 2005).  
In dentine, both biglycan and decorin are implicated to be profoundly involved with 
the process of mineralisation. Disruption of either SLRP in mice results in hypo-
mineralised dentine, with a more marked effect observed for decorin depletion 
(Goldberg et al, 2005). Reports indicate that decorin is localised predominantly in 
pre-dentine along the front of mineralisation (Yoshiba et al, 1996), whereas 
biglycan is distributed uniformly throughout dentine (Orsini et al, 2007). Decorin is 
considered as a regulator of collagen fibrillogenesis by arranging collagen molecules 
within microfibrils and preventing lateral fusion between molecules (Weber et al, 
1996). On the contrary, biglycan is reported to possess no influence for the 
promotion of fibrillogenesis (Sugars et al, 2003). The binding of decorin to collagen 
fibrils at the gap zone is additionally believed to block the initiation of 
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mineralisation (Hoshi et al, 1999). Consequently, decorin is postulated to regulate 
mineralisation. On the other hand, biglycan is recognised to possess a predominant 
role in the promotion of mineralisation, as biglycan possesses a higher affinity for 
hydroxyapatite than decorin (Boskey et al, 1997); and also competes with decorin 
for binding sites of type I collagen (Schönherr et al, 1995). Furthermore, in the 
development of bone tissue, biglycan demonstrates biphasic manifestation with DS-
conjugated, biglycan present during cell proliferation and CS-conjugated, biglycan 
present at the onset of mineralisation. Conversely, decorin manifestation remains 
constant throughout the process of bone formation (Waddington et al, 2003a). 
SLRPs present in mineralised dentine are associated with chondroitin sulphate GAG 
chains (Waddington et al, 2003b), where these conjugated GAGs are proposed to 
assist in mineralisation by possessing binding affinity to hydroxyapatite (Embery et 
al, 1998). Collectively, the SLRPs, biglycan and decorin, act temporally to co-
ordinate the process of mineralisation and thus, their dual absence results in 
diminished potential for mineralised tissue development. 
Overall, this Chapter has identified that the SLRPs, biglycan and decorin, present 
within DDM and possess differential roles in directing the osteogenesis of BMMSCs 
in response to DDM. Decorin is an expendable component of DDM for directing 
osteogenesis of BMMSCs in vitro and may be responsible for maintenance of multi-
potency of BMMSCs. However, in vivo effects in humans are not known. 
Conversely, biglycan is indispensable for the osteogenic potency of DDM towards 
BMMSCs and is required for the formation of a mineralised matrix by treated cells. 
Dual depletion of these SLRPs from DDM also diminishes their mineralisation 
potential. As a whole, SLRPs are substantially important constituents of DDM for 
directing repair of mineralised tissues. 
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Chapter 6 - Assessment of Silk-Fibroin/Gelatin (SF/G) Substrates 
Loaded with Demineralised Dentine Matrix (DDM) for Potential in 
Directing Osteogenesis of Bone Marrow-Derived, Mesenchymal Stem 
Cells (BMMSCs) 
6.1 Introduction 
Over recent years, the field of bone tissue engineering has expanded rapidly, with 
the aim of providing successful interventions for compromised bone repair, such as 
in cases of excessive trauma, ageing and disease-associated complications, where 
autologous bone grafts (ABGs) have met with numerous shortcomings (Rogers and 
Greene, 2012; Black et al, 2015). Although increasing progress is being achieved 
with regards to efficacious interventions for bone repair, tissue engineering of bone 
is currently faced with numerous challenges. Poor vascularisation of tissue-
engineered grafts reduces nutrient and oxygen permeation; and subsequently 
results in cellular necrosis and graft failure (Kanczler and Oreffo et al, 2008; 
Rouwkema et al, 2008).  
Growth factors, in particular the bone morphogenetic proteins (BMPs), BMP-2 and 
BMP-7, have been shown to demonstrate mediocre effects on in vivo bone 
regeneration in clinical trials (Friedlaender et al, 2001; Calori et al, 2008; Katayama 
et al, 2009). However, supraphysiological doses of these factors are required for 
clinical effect, due to their rapid proteolysis and uncontrolled diffusion 
(Krishnamurthy and Manning, 2002; Lee et al, 2011). Thus, a scaffold-based carrier 
is required to alleviate these issues, in addition to preventing undesirable side 
effects and enhancing cost effectiveness (Seeherman and Wozney, 2005; Dahabreh 
et al, 2009; Vo et al, 2012; Carragee et al, 2013). 
Scaffolds used in bone tissue engineering (BTE) are required to possess numerous 
characteristics, to maximise the potential for successful tissue engineering of bone. 
Aside from osteoinductive and osteoconductive capability, other desirable 
properties include biocompatibility, low immunogenicity, optimal porosity, 
mechanical robustness and degradability (Olszta et al, 2007; Murphy et al, 2010; 
Bose et al, 2012).  
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Broadly, the two general classes of bone scaffolds are natural or synthetic, each 
with their own advantages and disadvantages. Aside from ABGs, naturally-derived, 
bone grafts include allografts and xenografts. Naturally-derived, bone grafts 
possess osteoinductive and osteoconductive properties, due to their structural 
similarities to natural bone and the presence of bioactive factors embedded within 
them (Roberts and Rosenbaum, 2012). However, due to the associated risks with 
disease transmission and immunoreactions, osteoinductivity of these grafts are 
diminished, following irradiation and freeze drying methods (Lord et al, 1988; 
Delloye et al, 2007; Brydone et al, 2010). Naturally-derived, collagen scaffolds are 
biocompatible; and promote cell adhesion and proliferation (Hiraoka et al, 2003), 
however, suffer from poor mechanical integrity (Harley et al, 2007). Synthetic 
scaffolds can be composed of various commercially available materials, including 
ceramics, bioactive glasses and metals. Although synthetically-derived, scaffolds are 
less associated with immunoreactivity; and possess osteoinductive and 
osteoconductive properties, they are associated with poor degradation 
characteristics in vivo (Rezwan et al, 2006; Staiger et al, 2006, Amini et al, 2012; 
Oryan et al, 2014). 
Of late, silk biomaterials are receiving much attention for biomedical applications 
owing to desirable properties, including biocompatibility (Yang et al, 2007b; Shen et 
al, 2014), controllable biodegradation (Horan et al, 2005; Lu et al, 2011); and 
excellent mechanical properties (reviewed in Koh et al, 2015). Notably, silk-fibroin 
(SF) additionally possesses high oxygen and water permeability, in addition to 
eliciting minimal inflammatory reactions in vivo (Unger et al, 2007).  Resultantly, 
numerous studies have investigated the potential for SF-based, biomaterials for use 
in BTE (Jones et al, 2009; Uchida et al, 2014). Incorporation of BMP-2 into silk-
microparticles enhances in vitro and in vivo bone formation, compared to soluble 
BMP-2 (Bessa et al, 2010). Additionally, incorporation of BMP-2 and vascular 
epidermal growth factor (VEGF) into silk hydrogels has demonstrated increased in 
vivo bone formation, compared to un-loaded constructs (Zhang et al, 2011b). 
Although silk has widely been investigated as a natural polymer for use in 
biomedical applications, silk-fibroin obtained from Bombyx mori (B. mori) lacks the 
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integrin recognition arginine-glycine-aspartic acid (RGD) and thus, experiences 
attenuated cell attachment properties (Minoura et al, 1995). Consequently, 
blending of additional constituents with silk-fibroin is required to achieve cell 
attachment. Gelatin is naturally derived from denatured collagen and contains 
unmasked RGD motifs (Davis, 1992; Gullberg et al, 1992), which confers excellent 
cell attachment and proliferation properties of gelatin (Dubruel et al, 2007; Seo et 
al, 2009; Wu et al, 2011). Despite its excellent cell adhesion properties, gelatin is 
seldom utilised alone as it is highly soluble in aqueous environments and undergoes 
uncontrollable degradation (Mandal et al, 2009). Degradation of gelatin, however, 
can be utilised to permit the controlled release of bioactive factors for 
enhancement of wound repair sites (Yamamoto et al, 2001; Hori et al, 2007). 
This Chapter aimed to analyse the potential for silk-fibroin/gelatin (SF/G)-based 
matrices, to support the culture of bone marrow-derived, mesenchymal stem cells 
(BMMSCs) and to test the potential for osteogenic induction by incorporation of 
demineralised dentine matrix (DDM), with the intention of enhancing bioactivity of 
SF-based biomaterials. 
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6.2 Materials and Methods 
6.2.1 Processing of Silk-Fibroin (SF) and Gelatin 
Dr. Paul DeBank and Kim Luetchford performed processing and casting of SF/G and 
SF/G/DDM constructs, in collaboration with the University of Bath.  
SF was purified from raw silk of B. mori silk cocoons (Homecrafts Direct, UK). Silk 
cocoons were boiled in 0.2M sodium carbonate (Sigma-Aldrich, UK) for 1 h. Silk was 
washed five times in deionised distilled H2O (ddH2O) and air dried under ambient 
conditions. Dried silk was dissolved in 9M lithium bromide (Sigma-Aldrich) at 15% 
w/v, at 60°C for 4 to 5 h. The solution was cooled and dialysed against regularly 
changed ddH2O for 2 days. The concentration of the SF solution was determined by 
drying a known volume of the solution. SF solution was stored at 4°C, or lyophilised. 
The solution was used at a concentration of 5% w/v, unless stated otherwise.  
For blending with SF, type I porcine gelatin (Sigma-aldrich) was dissolved in ddH2O 
at approximately 60°C, at a concentration of 5% w/v. 
6.2.2 Casting of 2D films of SF/G and SF/G/DDM 
Aqueous solutions of SF (5% w/v) and gelatin (5% w/v) were blended in ratios of 
SF:G at 75:25, 50:50 and 25:75. Solutions were applied to 96-well and 12-well cell 
culture plates (Sarstedt, UK) at 105μL/cm2; and were allowed to fully evaporate 
under ambient conditions. 
For DDM inclusion into films, lyophilised DDM (obtained as described in Section 
3.2.1.2) was reconstituted in the SF component of the solution and then blended 
with additional SF and gelatin to produce concentrations of DDM at 20, 10 and 5 
μg/mL. SF/G/DDM films were cast into tissue culture plates, as described above. 
Dried films were treated with 100% (v/v) methanol (Fisher Scientific, UK) overnight 
to induce the conformational change of SF to insoluble β-sheet structure. Methanol 
was aspirated and the plates air-dried under ambient conditions. Dried plates were 
sterilised by exposure to UV light (253.7 nm), for 30 min. 
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6.2.3 Morphological Determination of BMMSCs on SF/G and SF/G/DDM films 
BMMSCs (15.2-16.8 population doublings, PDs) were seeded onto SF/G and 
SF/G/DDM films in triplicate 12-well plates at 4x103cells/cm2; and cultured for 48 h. 
Cells were photographed under light microscopy using a Panasonic DMC-G1 
Camera. 5 random and independent images were recorded per well. 
6.2.4 BMMSC Expansion on SF/G and SF/G/DDM Films 
Expansion of BMMSCs on SF/G and SF/G/DDM films was determined using a 
modified protocol of the previously described thiazolyl blue tetrazolium blue (MTT) 
assay (Section 3.2.2). Briefly, BMMSCs (14-17.5 PDs) were seeded onto SF/G and 
SF/G/DDM blended films in triplicate wells of a 96-well plate. Cells seeded into 
wells containing no SF/G films (SF/G plates) or un-loaded SF/G films (SF/G/DDM 
plates) served as controls.  After 0, 24, 48 and 72 h in culture, 20μL of culture 
medium was aspirated and replaced with 20 μL of sterile filtered MTT solution 
(5mg/mL in PBS) (Sigma-Aldrich). Plates were incubated and processed, as 
described previously (Section 3.2.1). Experiments were performed in triplicate. 
The SF/G blend ratio that best supported BMMSC expansion was chosen to assess 
the effects of DDM inclusion on the osteogenic effects of BMMSCs. 
6.2.5 Osteogenic Induction Ability of SF/G/DDM Films 
Osteogenic gene expression of BMMSCs over 5 days cultured on SF/G/DDM films, 
was performed as described previously (Section 3.2.6). Briefly, BMMSCs (17-17.5 
PDs) were seeded onto SF/G/DDM films in wells of a 6-well plate (Sarstedt) at 104 
cells/cm2, in un-conditioned media. Media changes were performed every 2 days. 
RNA was extracted using an RNeasy Mini Kit (Qiagen, Germany) (Section 2.2.3), 
converted to cDNA (Section 2.2.4) and quantitative real time-polymerase chain 
reaction (q-PCR) analysis performed for RunX2 gene expression (Section 3.2.6). 
GAPDH was used as an internal reference for normalisation of data. Primer 
sequences are detailed in Table 6.1. Experiments were performed in triplicate. 
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Gene 
product 
Primer sequence: 5’-3’ Annealing 
temperature 
(°C) 
Product 
length 
(bp) 
Primer 
designer 
GAPDH F: TTCTTTTGCGTCGCCAGCCGA 
R: GTGACCAGGCGCCCAATACGA 
55 96 Author 
RunX2 F: GGTTAATCTCCGCAGGTCACT 
R: CCCTCTGTTGTAAATACTGCTTGC 
55 80 Author 
 
Table 6.1 - Details of primer sequences used for q-PCR analysis of genes expressed by 
BMMSCs cultured on SF/G films. 
6.2.6 Mineral Deposition Analysis of BMMSCs on SF/G/DDM Films 
Mineral deposition of BMMSCs cultured on SF/G/DDM films and subsequent 
Alizarin red staining was performed, as described previously (Sections 3.2.5.1-
3.2.5.2). Briefly, BMMSCs (17-17.5 PDs) were seeded onto SF/G/DDM films in 12-
well plates at 104 cells/cm
2 in un-conditioned media. Media changes performed 
every 2 days. After 28 days in culture, media was aspirated, cells washed with 
phosphate buffered saline (PBS), fixed with 10% (v/v) formaldehyde (Sigma-
Aldrich); and stained with 2% Alizarin red (Sigma-Aldrich). Stained cells were 
washed with ddH2O, air-dried and photographed under light microscopy using a 
Panasonic DMC-G1 camera. Experiments were performed in triplicate. 
Statistical Analyses 
Statistical analyses were performed utilising One-Way ANOVA with a post-hoc 
Tukey test using GraphPad InStat 3 (v3.06). Statistical values were defined as 
significant (*, P<0.05), very significant (**, P<0.01) or extremely significant (***, 
P<0.001). 
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6.3 Results 
6.3.1 BMMSC Morphology on SF/G Blended Films 
BMMSCs seeded onto substrate blends of SF/G demonstrate cellular attachment to 
all blend ratios tested. BMMSCs seeded onto 75SF/25G and 50SF/50G blend exhibit 
fibroblast-like morphology, similar to cells cultured on plastic. BMMSCs on the 
25SF/75G blend, however, demonstrate appearance of associated globular 
structures and appear smaller (black arrows) (Figure 6.1). 
 
 
Figure 6.1 - Morphological appearance of BMMSCs on substrate blends of SF/G, 48 h post-
seeding. BMMSCs demonstrate fibroblast-like morphology on 50SF/50G and 75SF/50G 
blend ratios, however, morphology of cells cultured on 25SF/25G substrate appears 
altered. White bars represent 100μM. 
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6.3.2 BMMSC Expansion on SF/G Blended Films 
SF/G substrate blends provided a surface that facilitated expansion of BMMSCs 
over 72 h. Higher ratios of SF within the substrate blends appeared to support cell 
expansion to the greatest degree, with SF at 50% and 25% causing a significant 
reduction in cell expansion after 48 h, compared to BMMSCs cultured on plastic. 
After 72 h in culture, expansion of cells on 75SF/25G was not different compared to 
cells cultured on plastic (Figure 6.2). 
 
 
Figure 6.2 - Expansion of BMMSCs on SF/G substrate blends. Expansion of BMMSCs 
cultured on SF/G at a blend ratio of 75:25 was not changed, compared to cells cultured on 
plastic, after 72 h. Error bars represent ±SD (n=3). * = P<0.05, **=p<0.01, ***=p<0.001. 
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6.3.3 BMMSC Morphology on SF/G/DDM Films 
BMMSCs seeded onto substrate blends of SF/G demonstrate cellular attachment to 
all blend ratios tested in addition to fibroblast-like morphology (Figure 6.3), akin to 
BMMSCs seeded onto plastic (Figure 6.1). 
 
Figure 6.3 - Morphological appearance of BMMSCs on 75% SF/25% gelatin, loaded with 
DDM at concentrations of 0-20µg/mL, 48 h post-seeding. BMMSCs demonstrate fibroblast-
like morphology on substrates at all DDM concentrations tested. White bars represent 
100μM. 
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6.3.4 BMMSC expansion on SF/G/DDM Films 
DDM-loaded SF/G substrates supported cell expansion over 72 h. After 24 h, 
BMMSCs cultured on SF/G loaded with DDM at 10g/mL underwent significantly 
greater expansion, compared to cells cultured on un-loaded SF/G substrates 
(P<0.05). After 72 h, BMMSCs cultured on SF/G loaded with DDM at 20g/mL had 
expanded significantly more compared to cells cultured on un-loaded SF/G (P<0.05) 
(Figure 6.4). 
 
 
 
Figure 6.4 - Expansion of BMMSCs on DDM-loaded SF/G substrates. Loading of DDM at 
20µg/mL enhanced BMMSC expansion, the greatest compared to un-loaded constructs 
after 72 h. Error bars represent ±SD (n=3). * = P<0.05. 
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6.3.5 RunX2 Gene Expression of BMMSCs on SF/G/DDM Films 
RunX2 expression of BMMSCs cultured on SF/G films was not changed after 5 days 
in culture; and was comparable to the expression level of RunX2 in cells cultured on 
plastic. No differences in RunX2 expression level between BMMSCs cultured on 
SF/G films loaded with varying DDM concentrations were observed (Figure 6.5). 
 
 
Figure 6.5 – RunX2 expression of BMMSCs cultured on DDM-loaded SF/G substrates after 5 
days. No differences for RunX2 expression were observed during the culture period. Error 
bars represent ±SD (n=3). 
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6.3.6 Mineral Deposition Analysis of BMMSCs Cultured on SF/G/DDM Films 
Alizarin red staining of BMMSCs cultured on SF/G substrates did not reveal any 
distinct nodules. However, faint staining is visible for cells cultured on SF/G 
substrates loaded with the various concentrations of DDM (black arrows). No 
staining was visible for BMMSCs cultured on un-loaded SF/G (Figure 6.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 - Micrograph images for BMMSCs cultured on SF/G substrates stained with 
Alizarin red after 28 days in culture. No prominent mineralised nodules were 
apparent for any group tested, however, faint staining is present for cells cultured in 
substrates loaded with DDM. White bars represent 100µM. 
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6.4 Discussion 
Preliminary data obtained in this Chapter demonstrated that SF/G blended films 
supported expansion of BMMSCs, which was enhanced by additional blending with 
DDM, thus indicating the successful incorporation of DDM into SF/G films. 
Furthermore, osteogenic potential of DDM-loaded SF/G films was demonstrated, 
indicating their potential as a substrate carrier for DDM. 
Numerous methods have been developed to prepare SF based constructs, including 
electrospinning (Park et al, 2010; Liu et al, 2013), freeze drying (Zhang et al, 2010; 
Mandal et al, 2013); and salt-leaching (Marolt et al, 2006; Bhumiratana et al, 2011). 
Methods in this Thesis utilised the generation of SF/G films via casting, which has 
also been demonstrated as a preparation method for silk-based biomaterials 
(Mieszawska et al, 2010; Yao et al, 2012). This method was chosen so that direct 
comparisons could be made between BMMSCs seeded onto SF/G constructs and on 
to tissue culture plastic. SF films also demonstrate good mechanical strength when 
wet, in addition to excellent permeability of small molecules (Yang et al, 2015). 
BMMSCs seeded onto SF/G films at respective blend ratios of 75:25, 50:50 and 
25:75 all demonstrated cell attachment coupled with fibroblast-like morphology of 
cells, comparable to culture on tissue culture plastic. Blending of SF and gelatin has 
previously been demonstrated to generate constructs that have successfully 
promote adhesion of hepatic (Yang et al, 2012) and fibroblastic (Yang et al, 2015) 
cell lines. Regarding cellular expansion, after 72 h in culture, a trend of a decrease 
in cell expansion was observed with increasing gelatin concentration, compared to 
cells cultured on plastic. Film constructs consisting of pure SF have demonstrated 
viability of human MG63 osteoblast-like cells equivalent to that of cells cultured on 
tissue culture surfaces, thereby indicating very high biocompatibility (Varkey et al, 
2015; Yoo et al, 2016). Blending of gelatin at concentrations of 10-20% with SF has 
been shown to provide superior proliferation of fibroblasts, compared to pure 
gelatin; and was postulated that SF can enhance the mechanical integrity of gelatin 
films to provide an optimal surface to permit cell growth (Yang et al, 2015). 
Concurrent with Yang et al (2015), the SF/G blend of 75SF/25G in this Thesis 
constituted a substrate for permitting expansion of BMMSCs. Therefore, this blend 
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ratio was further tested to analyse the effects of DDM-incorporation into SF/G films 
for directing osteogenesis of BMMSCs. 
Incorporation of DDM into SF/G films in this Thesis did not alter BMMSC 
morphology, however, loading of SF/G films with 20g/mL of DDM resulted in 
significant enhancement of BMMSC expansion after 72 h, compared to un-loaded 
SF/G films. Studies analysing loading of SF based matrices with bioactive factors 
have additionally demonstrated positive results regarding modulating cellular 
behaviours. Incorporation of VEGF in SF/calcium phosphate enhances proliferation 
of human osteoblasts, compared to un-loaded constructs (Farokhi et al, 2014). Also, 
addition of transforming growth factor-β1 (TGF-β1) to SF/chitosan 3D scaffolds 
increases cell adhesion and proliferative activity of human osteoblasts (Tong et al, 
2016). The presence of identified growth factors in DDM (Sections 4.3.2 and 4.3.3) 
that are reported to encourage BMMSC expansion, such as TGF-β1 and fibroblast 
growth factor-2 (FGF-2), suggests that these factors have been successfully 
incorporated into the SF/G substrates and are being released and/or presented to 
cells. 
To further determine the bioactive potential of SF/G/DDM films, osteogenic 
induction ability was investigated.  After 5 days in culture, culture of BMMSCs on 
un-loaded SF/G films did not promote a detectable change in RunX2 gene 
expression compared with cells cultured on tissue culture plastic. Incorporation of 
DDM at concentrations of up to 20µg/mL of scaffold additionally did not detect a 
change in RunX2 expression of BMMSCs after 5 days. However, Alizarin red staining 
was used as a further measure to identify the osteogenic potential of SF/G 
constructs in longer-term culture. Whilst no staining for mineralisation was evident 
for cells cultured on un-loaded SF/G films, staining was evident for SF/G films 
loaded with DDM. The presence of mineralised matrix in DDM loaded SF/G films, 
although a lack of observed change in RunX2 gene expression after 5 days, may be 
as a result of slow release of DDM from the scaffold. Therefore, any increased 
expression may have been delayed and not detected in at the time point tested. 
The identification of mineralised nodules, however, suggests that loading of SF/G 
with DDM may constitute a mildly osteoinductive matrix for BMMSCs 
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Whilst research into the bone forming potential of un-loaded SF constructs has 
yielded varying results, additional articles have investigated the potential of SF 
constructs loaded with bioactive factors to promote an appropriate fabrication for 
enhancement of bone repair. Encapsulation of BMP-2 into SF micro-particles 
increases mineralisation of C2C12 cells, compared to treatment of soluble BMP-2 in 
vitro, in addition to enhancing bone formation in a rat ectopic model 2 weeks after 
implantation in vivo (Bessa et al, 2010). Incorporation of BMP-2 and VEGF into SF 
hydrogels additively augment bone repair in rabbit sinus floor elevation surgeries 
12-weeks post implantation, whereas un-loaded SF hydrogels did not promote 
sufficient bone regeneration (Zhang et al, 2011b). The use of gelatin as a delivery 
vehicle for growth factors in bone repair has also been investigated by Furuya et al 
(2015), who reported that loading of gelatin hydrogels with FGF-2 enhances repair 
of bone in murine femur fractures, compared to FGF-2 free in solution. Currently, 
studies investigating the efficacy of growth factor loading in SF/G composite 
constructs are scarce. 
In this Thesis, the chosen blend ratio of 75SF/25G, although permitted the highest 
level of cell expansion, may not be suitable for promoting optimal release of 
entrapped bioactive factors. The reduced cell expansion observed for SF/G films 
with a greater proportion of gelatin may be related to a switch in fate between cell 
expansion and differentiation (Stein and Lian, 1993). A major consideration of the 
design of supportive matrices for tissue engineering is the rate of degradation. The 
rate of degradation of SF-based matrices is reliant on several factors, including 
method of fabrication, β-sheet crystallinity, matrix morphology and the degrading 
enzymes (reviewed in You et al, 2013). Dependent on processing methods, 3D silk 
scaffolds implanted in vivo in sub-cutaneous pockets of rats degrade fully over 
periods of weeks for aqueous-cast with low β-sheet conformation, to over a year 
for constructs prepared with solvent casting and high β-sheet conformation (Horan 
et al, 2005). In vitro, treatment of SF films with methanol to induce formation of β-
sheet structure results in reduced degradation rate, compared to un-treated films 
(Jin et al, 2005). Furthermore, composites of SF/G have been shown to degrade 
more rapidly in vivo with increasing ratios of gelatin to SF (Yang et al, 2012). 
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Compared with the previously characterised osteogenic potential of soluble DDM in 
culture in this Thesis, the low osteoinductive potential for DDM-loaded SF/G films 
demonstrated in this Chapter may, therefore, result from insufficient release of 
bioactive factors and thus, resulting in hindered osteoinductive potential. 
Concurrent with the visually observed degradation of SF/G films composed of 
25SF/75G, increasing the proportion of gelatin relative to silk-fibroin in DDM-loaded 
films would likely result in increased construct degradation and subsequent release 
of bioactive DDM. Experimentation of DDM loading to SF/G films with a higher 
proportion of gelatin would be beneficial in testing this hypothesis. The rate of 
degradation in vitro, however, is likely to vary largely from that of in vivo, as 
macrophages and other large, multi-nucleated cells have been reported to 
concentrate around SF scaffold and tissue interfaces when implanted in vivo (Wang 
et al, 2008). 
Concentrations of factors loaded into SF based constructs are also a pivotal 
consideration. Although DDM at 10μg/mL has previously been demonstrated in this 
Thesis to induce osteogenic responses of BMMSCs, the release of biologically active 
concentrations of DDM from SF/G films is likely to not have been achieved.  
Although SF based constructs loaded with growth factors have been successful for 
promoting osteogenesis, the concentrations of these factors are up to the range of 
mg/mL of scaffold material (Li et al, 2006; Zhang et al, 2011b). Therefore, the rate 
of a degradation of SF/G films, in conjunction with low concentrations of loaded 
DDM, may be responsible for the lack of any observed osteogenic potential. 
Collectively, modification of SF fabrications may be necessary to induce sufficient 
osteogenic potential and thus, further experimentation is required to fully examine 
the potential of SF/G constructs for driving osteogenesis of BMMSCs. 
To date, various studies have investigated the potential for SF constructs in 
directing bone repair in vivo, with varying results reported. Critical-sized calvarial 
defects in mice filled with porous, 3D SF scaffolds either un-loaded or loaded with 
MSCs, demonstrated no considerable bone formation as determined by no 
observed mineralisation and lack of osteocalcin (OC) expression after 5 weeks 
(Meinel et al, 2005). Conversely, almost complete bone regeneration has been 
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achieved by filling of rabbit calvarial defects with SF nanofibrous meshes for 12 
weeks (Kim et al, 2005). Studies investigating the effects of gene expression of SF 
constructs are more limited, however, scaffolds of SF modified with hydroxyapatite 
induce up-regulation of gene expression of RunX2, collagen type I and osteopontin 
(OPN) of rabbit BMMSCs after 2 weeks, compared to unmodified SF scaffolds (Jiang 
et al, 2013). Even though mineralisation of BMMSCs cultured on SF/G/DDM films 
analysed in this Thesis was low, SF possesses high potential for promoting 
mineralisation. Whilst debated, it is postulated that the β-sheet structure of SF is 
anionic and may present nucleation sites for the deposition of hydroxyapatite (HAp) 
nanocrystals (Marelli et al¸2012), or potentially that β-sheet crystals of SF act as 
sites of nucleation for HAp deposition (Vetsch et al, 2015). SF films have also 
demonstrated the ability to support extensive mineralised matrix deposition by 
human osteoblasts (Jin et al, 2015). 
Overall, this Chapter has preliminarily identified that SF/G blends can support cell 
attachment and expansion. Loading of this SF/G blend with DDM at a range of 
concentrations tested provoked an osteogenic response of BMMSCs, evidenced by 
the identification of sparse and weakly stained nodules. Further testing of modified 
SF/G/DDM constructs is needed to fully determine the potential for loading of SF/G 
based matrices with bioactive factors for use in tissue engineering of bone. 
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Chapter 7 - General Discussion 
The overall aim of this Thesis was to assess the bioactive effects of demineralised 
dentine matrix (DDM) for directing osteogenesis of bone marrow-derived, 
mesenchymal stem cells (BMMSCs) and to identify the key components of DDM 
that elicits these responses. It was demonstrated that DDM elicited concentration-
dependent responses of BMMSCs with regards to reducing cell expansion (0.1-
10μg/mL), attenuating apoptosis (10μg/mL) and encouraging cell migration 
(0.1μg/mL). Pertinently, DDM at 10μg/mL directed osteogenic differentiation of 
BMMSCs, as determined by increases in osteogenic gene expression of RunX2 and 
collagen type I, in addition to stimulating matrix mineralisation. Analyses of DDM 
identified a plethora of growth factors related to osteogenesis, including 
transforming growth factor-β1 (TGF-β1), bone morphogenetic protein-2 (BMP-2) and 
vascular epidermal growth factor (VEGF). However, fractionation of these growth 
factors from DDM resulted in highly attenuated osteogenic potency, as evaluated 
by diminished RunX2 expression by BMMSCs, in addition to attenuated mineral 
deposition. Furthermore, biglycan and decorin, present with DDM, were identified 
to possess differential roles for directing the osteogenesis of BMMSCs; decorin-
depletion not affecting osteogenic potency, however, biglycan-depletion resulted in 
diminished osteogenic potency of DDM. Overall therefore, the matrix of DDM is 
considered to be highly complex and contains a multitude of constituents required 
for directing osteogenic differentiation of BMMSCs. 
The heterogeneity of mesenchymal stem cells (MSCs) as a result in variations of 
tissue source, method of acquisition and in vitro culture protocols is well 
acknowledged; and is regarded as responsible for discrepancies between literature 
reports regarding MSC behaviours (reviewed in Wagner et al, 2006). In this Thesis, 
the isolation of fibronectin-adherent cells from a commercially available batch of 
BMMSCs (acquired from Lonza, UK), resulted in a more primitive population of cells 
with enhanced expansive capacity in vitro, as previously demonstrated 
(Dowthwaite et al, 2004; Waddington et al, 2009), thereby increasing homogeneity 
and providing an additional level of standardisation of the MSCs utilised in 
experimental procedures. 
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This study identified that DDM elicited a variety of effects on BMMSCs, such as 
reducing cell expansion, reducing apoptosis and providing a migration gradient. 
Most importantly, DDM stimulated the differentiation of BMMSCs towards an 
osteoblast lineage and resulted in matrix mineralisation. For successful bone 
regeneration to be achieved, there is a widely regarded consensus relating to 
appropriate differentiation of endogenous MSCs to sufficiently migrate to the site 
of injury, expand and differentiate into osteoblasts, which are responsible for the 
formation of reparative bone tissue (Knight and Hankenson, 2013; Wang et al, 
2013; Açil et al, 2014). Collectively, the responses of BMMSCs to DDM further 
validate previous reports that DDM can induce reparative bone formation in vivo 
(Gomes et al, 2008; deOlivera et al, 2013). 
Analyses of DDM identified the presence and elucidated the concentrations of a 
wide array of growth factors implicated in directing osteogenesis of mesenchymal 
stem cells (MSCs). Notably, TGF-β1 and BMP-2 were present at relatively high 
concentrations (ng/mg), whereas other factors associated with osteogenic 
differentiation of MSCs such as BMP-4 and BMP-7, were identified at much lower 
concentrations (pg/mg). Critically, the concentrations of these factors in DDM that 
resulted in osteogenic responses of MSCs were much lower than concentrations of 
factors used in clinical practice, where concentrations of growth factors are used at 
μg levels. BMP-2 and BMP-7 are commercially available for clinical intervention of 
bone repair, however, their effectiveness is regarded as limited due to a lack of 
clinical trials demonstrating results for these growth factors in providing significant 
enhancement of clinical outcome, in addition to a caveat of cost-effectiveness, 
resulting from supra-physiological doses required for effect (Garrison et al, 2007; 
Gautschi et al, 2007). The combination of growth factors in DDM suggests that 
these factors may be working in co-operatively with each other, as several studies 
have determined that growth factor-driven, differentiation of MSCs towards an 
osteoblast phenotype can be synergistically enhanced using combinations two or 
more growth factors (Kugimiya et al, 2005; Yuan et al, 2013; Açil et al, 2014). The 
range of growth factors present in DDM may, therefore, be more beneficial for 
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enhancing bone repair than single growth factors that are currently in clinical 
practice. 
A key finding in this Thesis was that fractionation of DDM in an attempt to isolate 
growth factors, resulted in diminished bioactivity towards BMMSCs, compared to 
unfractionated matrix. Increasing reports are highlighting the interactions of growth 
factors with other extracellular matrix (ECM) components, which are proposed to 
maintain a reservoir of growth factors; and these require proteolytic activation to 
release these factors into the local environment for bioactivity to be conferred 
(Schönherr and Hausser, 2000; Wilgus, 2012). Mounting evidence is also becoming 
available that demonstrate the importance of the ECM in conferring bioactivity of 
growth factors (Martino et al, 2011; 2014). In this Thesis, the requirement for 
biglycan and decorin in the osteogenic potency of DDM was elucidated, with 
differential roles identified for each of these proteins. Notably, the absence of 
biglycan from DDM resulted in attenuated osteogenic potency towards BMMSCs, 
which was not rescued following treatment of cells with enriched biglycan fraction 
of DDM, therefore suggesting a requirement for synergistic interactions between 
both growth factors and matrix components to provide bioactivity. 
Successful tissue engineering for bone requires the emulation of an environment 
that closely mimics the tissue in question to replicate the in vivo cell and matrix 
interactions; and is considered one of the biggest hurdles to overcome (Geckil et al, 
2010). Reports are available that demonstrate growth factor efficacy can be 
enhanced by additional ECM constituents. Martino et al, (2011) demonstrated that 
a fibrin matrix cross-linked to fibronectin resulted in promiscuous binding of BMP-2 
and platelet-derived growth factor-BB (PDGF-BB) to the fibrin matrix. When placed 
into a sub-cutaneous implant model, fibronectin-bound growth factors resulted in 
the formation of organised bone tissue, whereas negligible bone tissue was 
observed for growth factors that were administered, but not bound to fibronectin. 
Furthermore, blocking of integrin α5β1 significantly reduced fibronectin-bound 
growth factor induced morphogenesis, compared to freely administered growth 
factors, thus suggesting that growth factor signalling may be mediated through 
integrin binding. A later study identified that modification of BMP-2 and PDGF-BB 
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with a domain from placental growth factor-2 (PlGF-2), induced exceptional affinity 
towards ECM proteins, such as fibronectin, fibrinogen and heparan sulphate. 
Interestingly, the delivery of these PlGF-2 modified growth factors resulted in 
markedly greater deposition of bone tissue in a rat calvarial defect model, 
compared to unmodified growth factors. Critically, the responses elicited for PlGF-
2-modified growth factors were observed at a dose 5-fold smaller than for topically 
applied growth factors (Martino et al, 2014). Previous proteomic analyses dentine 
revealed the presence of fibronectin, fibronigen and heparin sulphate (Park et 
al¸2009; Jágr et al, 2012); and therefore may be critical ECM components required 
for the optimal osteogenic potential for DDM. 
Incorporation of DDM in silk-fibroin/gelatin (SF/G) films resulted in a mild, yet 
positive, osteogenic response of BMMSCs, as determined by the onset of 
mineralisation. Intriguingly, mineralisation was achieved with a single dose of DDM 
incorporated into the films, compared to previous Chapters where repeated doses 
were administered. Several previous reports indicate numerous benefits for silk-
based materials in bone tissue engineering (reviewed in Midha et al, 2016); and 
incorporation of bioactive factors have demonstrated bone forming ability in vivo, 
however, using concentrations of growth factors in the range of mg/mL (Zhang et 
al, 2011). An important consideration for loading of bioactive factors into scaffolds 
is the rate of release. It has been demonstrated that sustained release of BMP-2 
over 4 weeks in vivo resulted in significantly greater bone formation, compared to 
short release over 3 days (Jeon et al, 2008). As such, the low concentrations of DDM 
incorporated in SF/G films that resulted in osteogenic responses of BMMSCs 
suggests entrapment of DDM within the substrate and steady, sustained release of 
bioactive factors that stimulated cellular responses. The degradability of SF/G 
matrices in vitro, however, is likely to differ largely to those that would occur in 
vivo, due to the presence of marcophages and other degrading cells that have been 
shown to concentrate around implanted silk-fibroin matrices (Wang et al, 2008). 
A further critical consideration of mimicking the environment for bone tissue 
engineering is the promotion of vascularisation, which is required to allow the 
introduction of oxygen and nutrients to the centre of implanted grafts, without 
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which graft necrosis may occur (Lascheke et al, 2006). At the fracture sites of bone, 
VEGF is regarded as the most important contributor to vascularisation (Keramaris et 
al, 2008). Whilst it has been demonstrated that human DDM can accelerate the 
healing of rat tooth sockets, this observation was accompanied by enhanced VEGF 
synthesis and blood vessel formation; and is postulated that osteogenic potential of 
DDM was attributable to the stimulation of angiogenesis (Reis-Filho et al, 2012). 
Vascularisation of bone defects induced by VEGF on collagen sponges has been 
promoted in rabbits, also suggesting that osteogenesis and angiogenesis are 
dependent processes (Geiger et al, 2005). Investigations into the potential for VEGF 
in DDM to promote vascularisation in bone defects in vivo may be beneficial for 
determining the extent of VEGF signalling in DDM-induced bone repair. 
The potential for autologous dentine implantation for bone augmentation in 
implant sockets have previously been described in humans, with positive results for 
bone healing recognised. This healing was achieved even despite extensive 
processing and sterilisation procedures (Kim et al, 2010; Pang et al, 2016), however, 
the small volume attainable from autologous dentine restricts the potential for 
grafting to larger defect sites. In this Thesis, DDM pooled from different donors 
demonstrated positive osteogenic effects on BMMSCs from a single donor, thus 
suggesting DDM may be beneficial as an allogenic grafting material. Allogenic 
dentine has also been successfully utilised in rabbit models, to enhance bone 
formation in surgically induced bone defects accompanied with an apparent lack of 
inflammation (Bakhshalian et al, 2013). Furthermore, the potential for xenogenic 
dentine grafting from humans into rabbits for bone augmentation has also been 
investigated; and demonstrated enhanced bone formation with minor associated 
inflammation (Al-Asfour et al, 2013). Compositional comparisons between human- 
and animal-derived, dentine have determined that bovine dentine demonstrate the 
highest similarities compared to other species, such as porcine and ovine (Teruel et 
al, 2015). Collectively, the use of xenogenic dentine for investigations into the 
potential for bone augmentation may be an alternative option to alleviate the 
shortcomings of using autologous dentine. However, current research into the use 
of xenogenic dentine on human-derived, cells is scarce. Therefore, trials 
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investigating the biocompatibility of xenogenic dentine on human cells are required 
to determine the potential for consideration of dentine from alternative sources to 
be used clinically for bone repair interventions. 
The bioactivity and osteogenic induction ability of dentine has been studied within 
previous literature reports, in addition to within this Thesis. Whilst the osteogenic 
potential of dentine was investigated in this Thesis, further evidence is presented 
for the osteogenic potential of constituents present within the enamel of teeth. The 
principle protein component of enamel is amelogenin, which is secreted by 
ameleoblasts and represents around 90% enamel proteins, amongst much less 
abundant proteins, such as enamelin and ameloblastin (Fincham and Simmer, 1997; 
Robinson et al, 1998). Amelogenin is not expressed in primary odontoblasts, 
however, it is present in secondary odontoblasts 4 weeks-post after the 
introduction of a cavity within teeth. In vitro, amelogenin is present in dental pulp-
derived, mesenchymal stem cells (DPSCs) induced to differentiate into odontoblasts 
at sites of mineralisation (Mitsiadis et al, 2014). Furthermore, exogenous 
application of amelogenin to BMMSCs induced to differentiate into osteoblasts 
amplifies mRNA expression of type I collagen, osteopontin (OPN) and bone 
sialoprotein (BSP), in addition to increased mineralised matrix deposition (Tanimoto 
et al, 2012). Consequently, additional proteins derived from dental tissues may be 
of interest for investigation into their osteogenic properties. 
Overall, within this Thesis, it was determined that a multitude of components of 
DDM including both growth factors and matrix proteins are essential for 
orchestrating osteogenic responses of BMMSCs. However, the precise composition 
of components present within the vast proteome of DDM required for bioactivity is 
yet to be elucidated, although increasing it is becoming acknowledged that growth 
factor interactions with other ECM proteins are key mediators in inducing repair of 
bone. The use of a scaffold for DDM may also be of great benefit for aiding in 
release kinetics of bioactive factors for optimal effect. Whilst current research has 
largely focussed on the use of autologous and allogenic dentine for bone 
augmentation, there is potential for xenogenic substitutes to overcome the 
shortcomings associated with autologous/allogenic dentine for grafting. Further 
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work investigating the influence of additional constituents of DDM required for 
osteogenesis would be beneficial for determining defined combinations of 
components required for optimal osteogenic potency and therefore, would assist in 
the development of successful tissue engineered interventions for enhanced bone 
repair. 
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Chapter 8 - Future work 
 
Various efforts have been made to provide clinically available interventions to assist 
in the augmentation of bone, including bone grafts (Black et al, 2015), growth 
factors (Katayama et al, 2009), and biocompatible scaffolds (Bose et al, 2012; Oryan 
et al, 2014). However, currently available treatments are largely ineffective or are 
fought with further complications, which negate their efficacy. The results obtained 
and discussed within this Thesis support a growing body of evidence for the use of 
demineralised dentine matrix (DDM) as an alternative solution to bone grafting 
(Gomes et al, 2008; Reis-Filho et al, 2012; de Oliveira et al, 2013). As also identified, 
DDM constitutes a complex matrix consisting of a variety of components that elicit 
bioactive effect, which was shown not to be recapitulated by isolating selected 
components. In conjunction with existing data relating to the limited efficacy of 
single growth factors for augmenting bone repair clinically (Calori et al, 2008; 
Katayama et al, 2009), it is becoming increasingly evident that successful bone 
repair strategies require mimicking of complex biological matrices.  
Although osteogenic gene expression and mineralisation of bone marrow-derived, 
mesenchymal stem cells (BMMSCs) as a result of culturing with DDM was identified 
in this Thesis, there is currently a lack of knowledge relating to cellular signalling 
events that are induced to elicit such responses. There are a wide range of 
intracellular signalling cascades associated with the differentiation of mesenchymal 
stem cells (MSCs) down the osteogenic lineage, including Smad (Song et al, 2010), 
Wnt (Gaur et al, 2005) p38 and extracellular regulated kinases (ERK) (Artigas et al, 
2014). As there is a large degree of cross-talk between these pathways (reviewed in 
Rodríguez-Carballo et al, 2016), determining the extent of DDM to induce these 
pathways will provide further evidence for bioactivity and osteogenic potency. In 
particular, comparisons of pathway activations by DDM compared to bone matrix, 
and by individual matrix components (i.e. growth factors) would assist in 
determining comparative efficacy of each potential treatment, and may provide 
evidence to drive further research into using DDM-based treatment modalities for 
clinical bone repair. 
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Although dentine preparations have shown to provide efficacious induction of 
reparative bone, a caveat of limited dentine harvestable from human teeth largely 
restricts clinical potential to that in dental applications, accompanied with very 
limited translation to orthopaedic applications. As has been researched within the 
relevant literature, scaffolds loaded with bioactive components elicit enhanced 
bone repair responses compared to un-loaded matrices and individually applied 
growth factors (Bessa et al, 2010; Zhang et al, 2011b). As discussed in Chapter 6, 
incorporation of DDM into a biocompatible scaffold may maximise the potential for 
efficacy and could also provide a route for translating DDM-based interventions for 
bone repair clinically. Additional investigations into the potential for DDM loaded 
into silk-fibroin/gelatin (SF/G) matrices in vitro will be able to further determine the 
potential for stimulating biological responses to aid in the bone repair process, in 
addition to elucidating characteristics including degradation and release of 
incorporated bioactive constituents. Successful optimisation of DDM-loaded SF/G 
substrates, for directing bone repair responses in vitro, could lead in to preliminary 
in vivo investigations in rodent models to test the potential for clinically translatable 
DDM-based interventions for augmenting bone. The use of such a substrate carrier 
to deliver optimal controlled doses of biologically active signalling components 
could also reduce the amount of DDM required, and subsequently would encourage 
translation into orthopaedics, where volumes of bone required for augmentation 
are typically larger than those in applications in dentistry. 
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